cluster	Name	VH_nuc	VH_AA	VL_nuc	VL_AA	Heavy_V_gene	Heavy_J_gene	Heavy_D_gene	Light_V_gene	Light_J_gene	CDRL1_AA	CDRL2_AA	CDRL3_AA	CDRH1_AA	CDRH2_AA	CDRH3_AA	VH Genbank ID	VL Genbank ID	PMID	Reference	Specificity	Binds to	Donor ID	Donor Status	PDB	clonotype
1	4A10	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAGCTTTAGTAGCTATTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGCCAACATAAAGCAATATGGAAGTGAGAAATACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTTTATCTACAAATGAACAGCCTAAGAGACGACGACACGGCCGTTTATTACTGTGCGAGAATGGGGAGTTATCTAGATACTTACTACTACCACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCC	EVQLVESGGGLVQPGGSLRLSCAASGFSFSSYWMTWVRQAPGKGLEWVANIKQYGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRDDDTAVYYCARMGSYLDTYYYHYGMDVWGQGTTVTVS	ATGGCCTGGATGATGCTTCTCCTCACTCTCCTCGCTCACTGCACAGGGTCCTGGGCCCAGTCTGTGCTGACGCAGCCGCCCTCACTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCTGCACGGGGAGCAGCTCCAACATCGGGGCAGATTATGATGTATATTGGTATCAGCACCTTCCAGGAACAGCCCCCAAACTCCTCATGTATGGTGACGGCTATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGTCTGAGTCGTCGTGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTTGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGATGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATAG	QSVLTQPPSLSGAPGQRVTISCTGSSSNIGADYDVYWYQHLPGTAPKLLMYGDGYRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSRRVVFGGGTKLTVL	IGHV3-7*03	IGHJ6*02	IGHD3-16*02	IGLV1-40*01	IGLJ2*01,IGLJ3*01	SSNIGADYD	GDG	QSYDSSLSRRVV	GFSFSSYW	IKQYGSEK	ARMGSYLDTYYYHYGMDV	JF806288.1	JF806289.1	21880983	Krause et al. J Immunol 187:3704-3711 (2011)	Group 1	HA:Head	Crowe_donor_47	a healthy 47-year-old human subject	nan	3.0
1	2K11	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGTAGCCTCCACGTTCAGCCTTATTAACTATTGGATGACCTGGGTCCGCCAGGCTCCTGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAGGATGGATTTGAGAAATACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAATTCACTGTATCTGCAAATGAACAGCCTGAGAGTCGAGGACACGGCTGTGTATTACTGTGCGAGACAGGGATCCTACGCTGACACGTACTTCTACCACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCC	EVQLVESGGGLVQPGGSLRLSCVASTFSLINYWMTWVRQAPGKGLEWVANIKQDGFEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARQGSYADTYFYHYGMDVWGQGTTVTVS	ATGGCCTGGATGATGCTTCTCCTCACTCTCCTCGCTCACTGCACAGGGTCCTGGGCCCAGTCTGCGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGCATACTGGTACCAGCAACTTCCAGGAACAGCCCCCAAACTCCTCATCTACGGTAACAGCAATCGACTCTCAGGGGTCCCTGACCGATTCTCTGCCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGTCGATTTTCGGCGGAGGGACCAAGCTGACCGTCCTACGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATAG	QSALTQPPSVSGAPGQRVTISCTGSSSNIGAGYDAYWYQQLPGTAPKLLIYGNSNRLSGVPDRFSASKSGTSASLAITGLQAEDEADYYCQSYDSSLSIFGGGTKLTVL	IGHV3-7*01	IGHJ6*02	IGHD4-17*01	IGLV1-40*01	IGLJ2*01,IGLJ3*01,IGLJ3*02	SSNIGAGYD	GNS	QSYDSSLSI	TFSLINYW	IKQDGFEK	ARQGSYADTYFYHYGMDV	JF806284.1	JF806285.1	21880983	Krause et al. J Immunol 187:3704-3711 (2011)	Group 1	HA:Head	Crowe_donor_47	a healthy 47-year-old human subject	nan	3.0
1	T1-8A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSDLKVVF	nan	nan	ARQDSFANTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-5B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSVSGLDVVF	nan	nan	ARQGSFADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T3-7B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*02	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYALDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-1D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-5C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*02	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLGVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-7B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-7C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDNSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-9C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSRSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-10A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-11C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-5C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDNSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-8A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T3-7A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-1C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDNSLSGLNVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-5C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLKVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-7B	nan	nan	nan	nan	IGHV3-7*03	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDNSLSGLNVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-9A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLKVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-10A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-11D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-2A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-2C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-6A	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCACCTGTGCAACCTCTGGATTCAGCTTTAATAGCTATTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCAAGTTGGAAGTGAGATATATTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGACGACACGGCTGTGTATTACTGTGCGAGACAGGGGAGTTTTGCAGACACTTACTTCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGLVQPGGSLRLTCATSGFSFNSYWMTWVRQAPGKGLEWVANINQVGSEIYYVDSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYYCARQGSFADTYFYYYAMDVWGQGTTVTVSS	CAGTCTGTGCTGACTCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTTCACTGGTACCAGCTTCTTCCAGGAACAGCCCCCAAACTCCTCATCTATGCTTTCAGCGATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTGAGGATGAGGGTGATTATTACTGCCAGTCCTATGACACCGGCCTGAGTGGTTTAGAAGTCGTATTCGGCGGAGGGACCAAGTTGACCGTCCTAG	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQLLPGTAPKLLIYAFSDRPSGVPDRFSGSKSGTSASLAITGLQAEDEGDYYCQSYDTGLSGLEVVFGGGTKLTVL	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01,IGLJ3*01	SSNIGAGYD	AFS	QSYDTGLSGLEVV	GFSFNSYW	INQVGSEI	ARQGSFADTYFYYYAMDV	KP231611.1	KP231632.1	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-6D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-12C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-2B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLNNLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-3A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-4D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLKVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-9B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-9C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*02	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-10B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-11A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-2A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QPYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-2B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-3B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-5B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	RSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-6B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-9B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T3-11A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLNVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T3-12C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGKV2-28*01or2D-28*01	IGKJ2*01	nan	nan	MQTLETPQTF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	nan
1	mbc_T3-2B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T3-3C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T3-4A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-11D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-12A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLNVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-12C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLNVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-1A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-2B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-51*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	nan
1	T1-3C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLSGLNVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-4B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-6D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDNNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-7C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLNVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-9C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLSGLNVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-10C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QTYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-1C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-9A	GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAACCTCTGGATTCAGCTTTAGTAATTATTGGATGACATGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGAAGGAAGTGAGGAGTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAATTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGACAAGGGAGTTTTGCAGACACCTACTATTACTACTACGCCATGGACGTCTGGGGCCAGGGGACCACGGTCACCGTCTCCTCA	EVQLLESGGGLVQPGGSLRLSCATSGFSFSNYWMTWVRQAPGKGLEWVANIKQEGSEEYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQGSFADTYYYYYAMDVWGQGTTVTVSS	CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGGCAGAGGGTCACCATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTTCACTGGTACCAACTTCTTCCAGGAACAGGCCCCAAACTCCTCATCTATGCTTACAGTGATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGACTCCAGCCTGAGGATGAGGGTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGTTTAGATGTGGTATTCGGCGGTGGGACCAAGCTGACCGTCCTAG	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQLLPGTGPKLLIYAYSDRPSGVPDRFSGSKSGTSASLAITGLQPEDEGDYYCQSYDSSLSGLDVVFGGGTKLTVL	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01,IGLJ3*01	SSNIGAGYD	AYS	QSYDSSLSGLDVV	GFSFSNYW	IKQEGSEE	ARQGSFADTYYYYYAMDV	KP231609.1	KP231630.1	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-3D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLNVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-5B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLSGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-8C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-8A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLSGLEVVF	nan	nan	ARQGSFANTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-7D	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCTCTGAGACTCTCCTGTGTAGACTCTGGATTCACTTTTAGAAGTTACTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAATCAAGATGGAAGTGAGAAATACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTATATTATTGTGCGAGACAAGGGAGTTTTGGAGACACTTACTTCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGLVQPGGSLRLSCVDSGFTFRSYWMTWVRQAPGKGLEWVANINQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQGSFGDTYFYYYAMDVWGQGTTVTVSS	CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGGGGCCCCAGGACAGAGGGTCACCATCTCCTGCACTGGGAGCAGCTCCAACATCGGGGCAGATTTTGATGTACACTGGTACCAGCAACTTCCAGGAACAGCCCCCAAACTCCTCATCTATGCTAACAGCGATCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCATCACTGGGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCCAGTCCTATGACAGCAGCCTGAGTGGGTTAGATGTGGTATTCGGCGGAGGGACCAAGTTGACCGTCCTAG	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGADFDVHWYQQLPGTAPKLLIYANSDRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGLDVVFGGGTKLTVL	IGHV3-7*01	IGHJ6*02	IGHD3-3*01,IGHD3-3*02	IGLV1-40*01	IGLJ2*01,IGLJ3*01	SSNIGADFD	ANS	QSYDSSLSGLDVV	GFTFRSYW	INQDGSEK	ARQGSFGDTYFYYYAMDV	KP231610.1	KP231631.1	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-12D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTGLNNLEVVF	nan	nan	ARQGSYADTYFYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-7A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*03	IGLJ2*01or3*01	nan	nan	QSYDTTLSGLDVVF	nan	nan	ARQGSYANTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-9A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSFADTYYHYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-7B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLDVVF	nan	nan	ARQGSFADTYYYDYGMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-8D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSMSGSVVVF	nan	nan	ARQGSFGDTYYHDYGMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-10D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGSVVVF	nan	nan	ARQGSFGDTYYYDYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-2C	nan	nan	nan	nan	IGHV3-7*03	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDNSLSGLNVVF	nan	nan	ARQGSYADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-3B	nan	nan	nan	nan	IGHV3-7*03	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDNSLSGLDVVF	nan	nan	ARQGSYADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-1D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDRSLSGLDVVF	nan	nan	VRQGSFADTYYYYYAMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-10D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSMSGSVVVF	nan	nan	ARQGSFGDTYFYDYGMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-10D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLHVVF	nan	nan	ARQGSFGDTYFYYYALDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-11B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLHVVF	nan	nan	ARQGSFGDTYFYYYALDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-2D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGSVVVF	nan	nan	ARQGSFGDTYYSDYGMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-10D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGSVVVF	nan	nan	ARQGSFGDTYYSDYGMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-2D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSSLSGSVVVF	nan	nan	ARQGSFGDTYYSDYGMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T2-7A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-3*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGSVVVF	nan	nan	ARQGSFGDTYYYDYGMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-10C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDISLSRSDVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-5D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDTTLSGLDVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-8A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDISLSRSDVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T1-8C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDISLSRSDVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	mbc_T3-5D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDTALSGLDVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-11A	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDNTPSGLHVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T1-11C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLHVIF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-11D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01or1-40*02	IGLJ2*01or3*01	nan	nan	QSYDTTLGDLNVIF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-6C	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSNLNGLDVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-9D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*01	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDISLSRTDVVF	nan	nan	ARQGSYADTYFYYYAIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T3-6D	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYDSSLSGLHVIF	nan	nan	ARQGSYADTYFYYYGIDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	T2-5B	nan	nan	nan	nan	IGHV3-7*01	IGHJ6*02	IGHD3-16*01	IGLV1-40*01	IGLJ2*01or3*01	nan	nan	QSYGSTLSGSVVIF	nan	nan	ARQGSYGDTYYYDYAVDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	H1	HA:Head	Donor_H	B-cells;Influenza Human Vaccinee	nan	3.0
1	6D9	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCATTTTTGAAAGTTACTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAAAACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGACCTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCATGTATTACTGTGCGAGATCGGGCAGCAACTGGGACACATATTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCC	EVQLVESGGGLVQPGGSLRLSCAASGFIFESYWMTWVRQAPGKGLEWVANIKQDGSEKNYVDSVKGRFTISRDNAKTSLYLQMNSLRAEDTAMYYCARSGSNWDTYYYYYGMDVWGQGTTVTVS	nan	nan	IGHV3-7*03	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFIFESYW	IKQDGSEK	ARSGSNWDTYYYYYGMDV	JF806292.1	nan	21880983	Krause et al. J Immunol 187:3704-3711 (2011)	Group 1	HA:Head	Crowe_donor_47	a healthy 47-year-old human subject	nan	nan
1	4K8	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCGGGGGGGTCCCTACGACTCTCCTGTGCAGCCTCTGAATTCAACTTTAAGAGTTATTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCAAGATGGAAGTGAGAAAAACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGATAATGCCAAGAACTCGCTGCATCTGCAAATGAGCAGCCTGAGAGTCGACGACACGGCTGTATATTACTGTGCGCGAACGGGCAGCAGTTGGGACACATACTACTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCC	EVQLVESGGGLVQPGGSLRLSCAASEFNFKSYWMTWVRQAPGKGLEWVANINQDGSEKNYVDSVKGRFTISRDNAKNSLHLQMSSLRVDDTAVYYCARTGSSWDTYYYYYAMDVWGQGTTVTVS	GACATCCAGTTGACCCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTGGTCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCCCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCGCGAAGATTTTGCAGTGTATTATTGTCAGCAGTATGGTAGGTCTTTTGGCCAGGGGACCAAGGTGGAGATCAAACGTACG	DIQLTQSPVSLSLSPGERATLSCRASQSVSSSYLVWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEREDFAVYYCQQYGRSFGQGTKVEIK	IGHV3-7*01	IGHJ6*02	IGHD6-13*01	IGKV3-20*01	IGKJ2*01,IGKJ2*02,IGKJ2*03	QSVSSSY	GAS	QQYGRS	EFNFKSYW	INQDGSEK	ARTGSSWDTYYYYYAMDV	JF806290.1	JF806291.1	21880983	Krause et al. J Immunol 187:3704-3711 (2011)	Group 1	HA:Head	Crowe_donor_47	a healthy 47-year-old human subject	nan	nan
2	315-53-06_1C05	CAGGTGCAGCTGCAGCAGTCCGGTCCGGGACTGGTGAAGCCCTCGCAGACCCTCTCAGTCACCTGTGTCATCTCCGGTGACAGTGTCTCTAGCAACAATGCTGTTTGGAACTGGGTCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTTCAGGTCCAAGTGGTATAATGATTATGCAGACTCTGTGAGGAGTCGAATAACGATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGACCTCTGTGACTCCCGACGACACGGCTGTATATTACTGTGCGAGAGCGGGGATTATGATTTTTGGACTGATTGTTGGCGGCTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSVTCVISGDSVSSNNAVWNWVRQSPSRGLEWLGRTYFRSKWYNDYADSVRSRITINPDTSKNQFSLQLTSVTPDDTAVYYCARAGIMIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*02	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSSNNAV	TYFRSKWYN	ARAGIMIFGLIVGGLDV	MN009540.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1C06	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAGGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCGAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGATTCTGTGAAAAGTCGACTAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGACGACACGGGTGTTTATTATTGTGCAAGAGCGGGGATTATGATTTTTGGAGTGATTGTTGGCGGTTTGGACGTGTGGGGCCAAGGGGCCATGGTCACCGTCTCCTCAG	QVQLQQSGPGLVRPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYADSVKSRLTINPDTSKNQFSLQLNSVTPDDTGVYYCARAGIMIFGVIVGGLDVWGQGAMVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGIMIFGVIVGGLDV	MN009525.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-05M_1F04	CAGGTGCAGCTACAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACGTGTGTCATCTCCGGGGACAGTGTCTCTAGTAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGTCTGGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGATTCTGTGAAAAGTCGACTAATAATCAACCCAGACACATCCAGAAACCAGTTCTCCCTGCAGTTGAAGTCTGTGACTCCCGACGACACGGCTGTTTATTTCTGTGCGAGAGCGGGAATTATGATTTTTGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCAGGGGACCACGGTCATCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYADSVKSRLIINPDTSRNQFSLQLKSVTPDDTAVYFCARAGIMIFGVIVGGLDVWGQGTTVIVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGIMIFGVIVGGLDV	MN009533.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1A06	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTCTCATCTCCGGTGACAGTGTCTCTAGCAACAGCGCCGCTTGGAATTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTTCTATAATGATTATGCAGATTCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCCAGAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGCGGGGATTATGATTTTTGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCLISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKFYNDYADSVKSRITINPDTSQNQFSLQLNSVTPEDTAVYYCARAGIMIFGVIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKFYN	ARAGIMIFGVIVGGLDV	MN009541.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1D11	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGTCTGGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGATTCTGTGAAAAGTCGAGTAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAAGTCTGTGACTCCCGAGGACACGGCTGTTTATTTCTGTGCGAGAGCGGGAATTATGATTTTTGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCATGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYADSVKSRVTINPDTSKNQFSLQLKSVTPEDTAVYFCARAGIMIFGVIVGGLDVWGQGTMVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGIMIFGVIVGGLDV	MN009542.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1E11	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCAACAGCGCTACTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATACTGATTATGCGGATTCTGTGAAAAGTCGAGTAACCATCAACCCAGACACATCCAAGAACCAGTTTTCCCTGCAGCTGAACTCTATGACTCCCGAGGACACGGCTATTTATTACTGTGCAAGAGCGGGGATTATGATTTTCGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCGAGGGACCATGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSATWNWIRQSPSRGLEWLGRTYYRSKWYTDYADSVKSRVTINPDTSKNQFSLQLNSMTPEDTAIYYCARAGIMIFGVIVGGLDVWGRGTMVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAT	TYYRSKWYT	ARAGIMIFGVIVGGLDV	MN009543.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1B04	CAGGTGCAGCTGCAGCAGTCAGGTCCGGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACGTGTGTCATCTCCGGGGACAGTGTCTCGAGCAACAGCGCTACTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATTATGATTATGGAGAATCTGTGAAAAGTCGATTAACCATCAACGCAGACACATCCAAGAACCAGCTCTCCCTGCAACTGAAGTCTGTGACTCCCGAGGACACGGCTGTTTATTACTGTGCAAGAGCGGGAATTATGATTTTTGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCGAGGGACCATGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSATWNWIRQSPSRGLEWLGRTYYRSKWYYDYGESVKSRLTINADTSKNQLSLQLKSVTPEDTAVYYCARAGIMIFGVIVGGLDVWGRGTMVTVSS	nan	nan	IGHV6-1*02	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAT	TYYRSKWYY	ARAGIMIFGVIVGGLDV	MN009555.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1B10	CTGTCCCAGGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGTCTGGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGATTCTGTGAAAAGTCGACTAATAATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAAGTCTGTGACTCCCGAGGACACGGCTGTTTATTTCTGTGCGAGAGCGGGAATTATGATTTTTGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	LSQVQQSGPGLVKPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYADSVKSRLIINPDTSKNQFSLQLKSVTPEDTAVYFCARAGIMIFGVIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGIMIFGVIVGGLDV	MN009553.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1C04	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGTCTGGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGATACTGTGAAAAGTCGAGTAATAATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAAGTCTGTGACTCCCGAGGACACGGCTGTTTATTTCTGTGCGAGAGCGGGAATTATGATTTTTGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYADTVKSRVIINPDTSKNQFSLQLKSVTPEDTAVYFCARAGIMIFGVIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGIMIFGVIVGGLDV	MN009554.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1F10	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCGTCTCCGGGGACACTGTCTCTAGCGACAGCGCTACTTGGAACTGGATGAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATTATGATTATGGAGACTCTATGAAAAGTCGGATAACCATCAGTCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAGGTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTCGACGCCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVVSGDTVSSDSATWNWMRQSPSRGLEWLGRTYYRSKWYYDYGDSMKSRITISPDTSNNQFSLHLRSVTPEDTAVYYCARAGIRIFGLIVGGFDAWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSDSAT	TYYRSKWYY	ARAGIRIFGLIVGGFDA	MN009544.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	20A-678-41_1F06	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGAACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009565.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	20A-678-41_2C06	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009566.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	20A-678-41_2C08	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009567.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-05M_1A07	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009534.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-05M_1D09	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009535.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-05M_1D12	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCGACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSDSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSDSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009536.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1A04	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCTCTCACCTGTGTCATCTCCGAGGACACTGTCTCTTCCAACAGCGCTACTTGGAACTGGATCAGGCAGTCCCCCTCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATTTTGATTATGGAGACTCTGTGAAAGGTCGCATAAGTGGCAGTGCAGACACATCCAACAACCAGTTTTCCCTGCACCTGAAATCTGTGACTCCCGAGGACACGGCTGTATATTACTGTGCCAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISEDTVSSNSATWNWIRQSPSRGLEWLGRTYYRSKWYFDYGDSVKGRISGSADTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	EDTVSSNSAT	TYYRSKWYF	ARAGIRIFGLIVGGLDV	MN009545.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1B10	CCAGTGCAGGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCTACCAACAGCGCTACTTGGAACTGGATCAGACAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTTCAGGTCCAAGTGGTATAGTGATTATGGAGACTCTCTCAAGAGTCGCCTGACCATAAGCCCGGACACATCCAAGAACCAGATCTCCCTGCACCTGCAGTCTGTGACTCCCGACGACACGGGTGTCTATTACTGTGCCAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGATTGGACGTCTGGGGCCAGGGGACCACGGTCACCGTCTCATCAG	PVQVQQSGPGLVKPSQTLSLTCVISGDSVSTNSATWNWIRQSPSRGLEWLGRTYFRSKWYSDYGDSLKSRLTISPDTSKNQISLHLQSVTPDDTGVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSTNSAT	TYFRSKWYS	ARAGIRIFGLIVGGLDV	MN009546.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1A09	CAGGTGCAGGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTACCAACAGCGCTACTTGGAACTGGATCAGACAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAGTGATTATGGAGACTCTCTGAAAAGTCGGATGAGCATTAGTCCAGACACATCCAAGAACCAGATCTCCCTGCACCTGAAGTCTGTGACTCCCGACGACACGGGTGTCTATTACTGTGCCAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGGTTGGACGTCTGGGGCCAGGGCACCACGGTCACCGTCTCATCAG	QVQVQQSGPGLVKPSQTLSLTCVISGDTVSTNSATWNWIRQSPSRGLEWLGRTYYRSKWYSDYGDSLKSRMSISPDTSKNQISLHLKSVTPDDTGVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSTNSAT	TYYRSKWYS	ARAGIRIFGLIVGGLDV	MN009556.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1B07	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009557.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1G02	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGTTCTCCCTGCACCTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCATTAGGATTTTTGGACTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRITISPDTSNNQFSLHLKSVTPEDTAVYYCARAGIRIFGLIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNSAA	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MN009558.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-1F12	CAGGTACAGCTGCAGCAGTCAGGTCCGGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCGTCTCCGGGGACACTGTCTCTAGTAACACCGCTACTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGGCGACTCTGTGAAAAGTCGGATAAGCATCAGCCCAGACACATCCAACAACCACTTCTCCCTGCACCTGAAGTCTGTGACACCCGAGGACGCTGCTGTGTATTTCTGTGCAAGAGCGGGCATTAGGATTTTTGGTCTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAGCGTCG	QVQLQQSGPGLVKPSQTLSLTCVVSGDTVSSNTATWNWIRQSPSRGLEWLGRTYYRSKWYNDYGDSVKSRISISPDTSNNHFSLHLKSVTPEDAAVYFCARAGIRIFGLIVGGLDVWGQGTMVTVSS	GACATCCAGATGACACAGAGCCCTAGCTCCCTGAGCGCCTCCGTGGGCGATCGGGTGACCATCACATGCAGAACCTCTCAGAGCGTGTCTAGCTACCTGCACTGGTATCAGCAGAAGCCCGGCAAGGCCCCTGAGCTGCTGATCTACGCCACATCCAACCTGCACTCTGGAGTGCCAAGCAGGTTCTCCGGATCTGGAAGCGGAACCGACTTTTCCCTGACAATCTCTAACCTGCAGCCAGACGATTTCGCCACCTACTTTTGTCAGCAGTCCTCTACCAATCCCGGCTATACATTCGGCCGGGGCACCAAGCTGGAGATCAAG	DIQMTQSPSSLSASVGDRVTITCRTSQSVSSYLHWYQQKPGKAPELLIYATSNLHSGVPSRFSGSGSGTDFSLTISNLQPDDFATYFCQQSSTNPGYTFGRGTKLEI	IGHV6-1*02	IGHJ3*01	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV1-39*01,IGKV1D-39*01	IGKJ2*01,IGKJ2*02,IGKJ2*03	QSVSSY	ATS	nan	GDTVSSNTAT	TYYRSKWYN	ARAGIRIFGLIVGGLDV	MF289006.1	MF289031.1	28783708	Andrews et al. Sci Immunol 2:eaan2676 (2017)	Group 1,2	HA:Stem	VRC_315-53	H7N9 Human Vaccinee	nan	72.0
2	315-53-08_1E04	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCGACAGCGCTACTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAATTGGTATCATGATTATGGAGACTCTGTGAAAAGTCGGATAACCATCAGCCCAGACACATCCAACAACCAGCTGTCCCTGCACCTGAGGTCTGTGACTCCCGAGGACACGGCTGTTTATTACTGTGCAAGAGCGGGCATTAGGGTTTTTGGAGTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSDSATWNWIRQSPSRGLEWLGRTYYRSNWYHDYGDSVKSRITISPDTSNNQLSLHLRSVTPEDTAVYYCARAGIRVFGVIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01,IGHD3-3*02	nan	nan	nan	nan	nan	GDTVSSDSAT	TYYRSNWYH	ARAGIRVFGVIVGGLDV	MN009559.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-05M_1G04	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGATTCTGTGAAAGGTCGAATAAGTATCAACCCAGACACATCCAAGAACCACTTTTCCCTGCACCTGAACTTTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGGATTTCGATTTTTGGAGTGATTGTTGGCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYADSVKGRISINPDTSKNHFSLHLNFVTPEDTAVYYCARAGISIFGVIVGGMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGISIFGVIVGGMDV	MN009537.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1E07	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGATTCTGTGAAAGGTCGAATAAGTATCAACCCAGACACATCCAAGAACCACTTTTCCCTGCACCTGAACTTTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGGATTTCGATTTTTGGAGTGATTGTTGGCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYADSVKGRISINPDTSKNHFSLHLNFVTPEDTAVYYCARAGISIFGVIVGGMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGISIFGVIVGGMDV	MN009547.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	20A-678-41_2D11	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGACCTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGAATCTGTGAAAAGTCGAATAATTATCAATCCAGACACATCCAAGAACCAGTTCTCCCTGCACCTGAACTTTGTGACTCCCGAGGACACGGCTGTTTATTTCTGTGCAAGAGCGGGGATTACGATTTTTGGATTGAATGTTGGCGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWTWIRQSPSRGLEWLGRTYYRSKWYNDYAESVKSRIIINPDTSKNQFSLHLNFVTPEDTAVYFCARAGITIFGLNVGGMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGITIFGLNVGGMDV	MN009568.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1G04	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCTCCTGTGTCATCTCCGGGGACAGTGTCTCTAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGAATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGTTGAACTCGGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCGGGCAAAATGATTTTCGGACTGATTGTTGGCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCGCCTCAG	QVQLQQSGPGLVKPSQTLSLSCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAESVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAGKMIFGLIVGGMDVWGQGTTVTVAS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARAGKMIFGLIVGGMDV	MN009548.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1C05	CAGGTGCAGCTACAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACGTGTGTCATCTCCGGGGACAGTGTCTCTAGTAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGTCTGGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATTATGATTATGCAGATTCTGTGAAAAGTCGACTAATAATCAACTCAGACACATCGAAGAACCAGTTCTCCCTGCAGTTGAAGTCTGTGACTCCCGACGACACGGCTGTTTATTTCTGTGCGAGAGCGGGAACTATGATTTTTGGGGTGATTGTTGGCGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCVISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYYDYADSVKSRLIINSDTSKNQFSLQLKSVTPDDTAVYFCARAGTMIFGVIVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYY	ARAGTMIFGVIVGGLDV	MN009526.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1A10	CAGGTCGAACTGAAGGAATCAGGTCCGGGACTGGTGAAGCCCTCGCAGACCCTCTCAGTCACCTGCGTCATCTCCGGGGACAGTGTCTCAAGCAACAGTGTTGCTTGGGACTGGATCAGGCAGTCCCCGTCGAGAGGCCTTGAGTGGCTGGGGCGGACATACTTCAGGTCGAGATGGTATACTGATTATGCAGAGTCCGTAAAAAGTCGAATAACCATCAACGCAGATTCATCTAACAACCAGTTCTCCCTGCACTTGAAGTCCGTGACTCCCGAGGACACGGCTGTATATTATTGTGCAAGAGCGGTGATTACAGTTTTTGGACTGATTGTTGGCGGTCTGGACGTCTGGGGCCACGGGACCGCGGTCGCCGTCTCCTTC	QVELKESGPGLVKPSQTLSVTCVISGDSVSSNSVAWDWIRQSPSRGLEWLGRTYFRSRWYTDYAESVKSRITINADSSNNQFSLHLKSVTPEDTAVYYCARAVITVFGLIVGGLDVWGHGTAVAVS	nan	nan	IGHV6-1*02	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSSNSVA	TYFRSRWYT	ARAVITVFGLIVGGLDV	MN009531.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1C10	CAGGTGCAGGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCCTCTCCGGGGACAGTGTCGCTACTAATACTGCTGCTTGGAACTGGATCAGGCAGTCCCCGTCGAGAGGCCTAGAGTGGCTGGGAAGGACATACTTCAGGTCCAAGTGGTTTACTGATTATGCAGAATCTGTGAAAGGTCGAATAACCATCAATCCAGACACATCCAAGAACCAGTTCTCCCTGCAGTTGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGGGCGGGGATCACGATTTTTGGAGTCATTGTTGGCGCTATGGATGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQVQQSGPGLVKPSQTLSLTCALSGDSVATNTAAWNWIRQSPSRGLEWLGRTYFRSKWFTDYAESVKGRITINPDTSKNQFSLQLKSVTPEDTAVYYCARAGITIFGVIVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVATNTAA	TYFRSKWFT	ARAGITIFGVIVGAMDV	MN009562.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-05M_1E02	CAGGTGCAGGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCCTCTCCGGGGACACTGTCTCTACTGACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCGTCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTTCAGGTCCAAGTGGTTTACTGATTATGCAGAATCTGTGAAAAGTCGAATAACCATCAATCCAGACACATCCAAGAACCAGTTCTCCCTGCAGTTGCGCTCTGTGACTCCCGAAGACACGGGTGTGTATTATTGTGCAAGAGCGGGAATTACAATTTTTGGAGTGCTTGTTGGCGGTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCA	QVQVQQSGPGLVKPSQTLSLTCALSGDTVSTDSAAWNWIRQSPSRGLEWLGRTYFRSKWFTDYAESVKSRITINPDTSKNQFSLQLRSVTPEDTGVYYCARAGITIFGVLVGGMDVWGQGTAVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDTVSTDSAA	TYFRSKWFT	ARAGITIFGVLVGGMDV	MN009538.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1E09	CAGGTGCAGGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCCTCTCCGGGGACAGTGTCTCTACTAATAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCGTCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTTCAGGTCCAAGTGGTTTACTGATTATGCAGAATCTGTGAAAAGTCGAATAACCATCAATCCAGACACATCCAAGAACCAGTTCTCCCTGCAGTTGAACTCTGTGACTCCCGAGGACACGGGTGTGTATTATTGTGCAAGAGCGGGGATTACGATTTTTGGAGTGGTTGTTGGCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQVQQSGPGLVKPSQTLSLTCALSGDSVSTNSAAWNWIRQSPSRGLEWLGRTYFRSKWFTDYAESVKSRITINPDTSKNQFSLQLNSVTPEDTGVYYCARAGITIFGVVVGGMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSTNSAA	TYFRSKWFT	ARAGITIFGVVVGGMDV	MN009527.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-05M_1G11	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCCTCTCCGGGGACAGTGTCTCTACTAATAGTGGTGCTTGGAACTGGATCAGGCAGTCCCCGTCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTTTAGTGATTATGCAGAATCTGTGAAAAGTCGAATAACCATCAATCCAGACACATCCAAGAACCAGTTCTCCCTGCAGTTGAACTCTGTGACTCCCGAGGACACGGCTGTGTACTATTGTGCAAGAGCGGGGATTACGATTTTTGGAGTGGTTGTTGGCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCALSGDSVSTNSGAWNWIRQSPSRGLEWLGRTYYRSKWFSDYAESVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARAGITIFGVVVGGMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSTNSGA	TYYRSKWFS	ARAGITIFGVVVGGMDV	MN009539.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1C08	CTGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAGCAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGAATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCACCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTTTTACTGTGCAAGAGCGGGGATTACGGTTTTTGGAGTGATTACTGGCGCTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCAG	LVQLQQSGPGLVKPSQTLSLTCAISGDSVSSSSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAESVKSRITINPDTSKNQFSLHLSSVTPEDTAVFYCARAGITVFGVITGAMDVWGQGTAVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSSSAA	TYYRSKWYN	ARAGITVFGVITGAMDV	MN009560.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1G05	CTGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAGCAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGAATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTTTTACTGTGCAAGAGCGGGGATTACGGTTTTTGGAGTGATTACTGGCGCTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCAG	LVQLQQSGPGLVKPSQTLSLTCAISGDSVSSSSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAESVKSRITINPDTSKNQFSLQLSSVTPEDTAVFYCARAGITVFGVITGAMDVWGQGTAVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSSSAA	TYYRSKWYN	ARAGITVFGVITGAMDV	MN009561.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	20A-678-41_1C12	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MN009569.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1D03	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MN009528.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1E03	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MN009529.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1F09	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MN009530.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1A05	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MN009552.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1A04	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MN009563.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-08_1B12	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MN009564.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-1B06	CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGGAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACAATGGTCACCGTCTCT	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAGVTVFGVVVGAMDVWGQGTMVTVS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCGTTAGCAGCTATTTACATTGGTATCAGCAGAAACCAGGGAAAGCCCCAAAGCTCCTGATCTATGCTGCATCCAGTTTGCAGAGTGGGGTCCCATCAAGATTCAGTGGCAGTAGATCTGGGACAGATTTCACTCTGACCATCAGCAGTCTACAACCCGAAGATTTTGCAACCTACTACTGTCAACTGAGTTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	DIQMTQSPSSLSASVGDRVTITCRASQSVSSYLHWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQLSYTFGQGTKLEIK	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	IGKV1-39*01,IGKV1D-39*01	IGKJ2*01,IGKJ2*02	QSVSSY	AAS	QLSYT	GDSVSSNSGA	TYYRSKWYN	ARAGVTVFGVVVGAMDV	MF289011.1	MF289035.1	28783708	Andrews et al. Sci Immunol 2:eaan2676 (2017)	Group 1,2	HA:Stem	VRC_315-53	H7N9 Human Vaccinee	nan	72.0
2	315-53-06_1D02	CCAGTGCAAGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGGCCCTTTCACTCACCTGTGCCCTCTCCGGGGACAGTGTCTCTTCTGATAGTGGTACTTGGAACTGGATCAGGCAGTCCCCGTCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTTTACTGATTATGCAGAATTTGTGAAAGGTCGAATAACCGTCGATGCAGATACATCCAAGAACCAGTTCTCCCTCCGGTTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGCGGGGACTAAGGTTTTTGGAGTGGTTGTTGGCGGTCTTGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCGG	PVQVQQSGPGLVKPSQALSLTCALSGDSVSSDSGTWNWIRQSPSRGLEWLGRTYYRSKWFTDYAEFVKGRITVDADTSKNQFSLRLSSVTPEDTAVYYCARAGTKVFGVVVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01,IGHD3-3*02	nan	nan	nan	nan	nan	GDSVSSDSGT	TYYRSKWFT	ARAGTKVFGVVVGGLDV	MN009549.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1G02	CTGTCCCAGGTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTTTCAGCCATCTGTGCCCACTCCGGGGACAGTGTCGCTTCTGATAGTGGTACTTGGAACTGGATCAGGCAGTCCCCGTCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTTTACTGATTATGCAGAATTTGTGAAAGGTCGAATAACCGTCAATGCAGATACATCCAAGAACCAGTTCTCCCTTCGGTTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGCGGGGACTAAGGTTTTTGGAGTGGTTGTTGGCGGTCTTGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCGG	LSQVQQSGPGLVKPSQTLSAICAHSGDSVASDSGTWNWIRQSPSRGLEWLGRTYYRSKWFTDYAEFVKGRITVNADTSKNQFSLRLSSVTPEDTAVYYCARAGTKVFGVVVGGLDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01,IGHD3-3*02	nan	nan	nan	nan	nan	GDSVASDSGT	TYYRSKWFT	ARAGTKVFGVVVGGLDV	MN009550.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-54-05M_1H01	CAGGTGCAGCTGAAGCAGTCAGGTCCAGGACTGGTGAGGACCTCCCAGAGTCTCTCACTCACCTGTGACATTTCCGGGGATAGTGTCTCCTCCAACAGTGGAGCCTGGACCTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGGCTGACATACTACAGGTCTAAGTGGTATGACGATTATGCACTGTCTGTGAAAGGTCGAATCACCATCAAGGCCGACACATCCAGGAACCAGCTCTCCCTGCATCTGAACTCTGTGACTCCCGAAGACTCGGCTGTCTATTTCTGTGCAAGAGCGGGTGTTTCCGTTTTTGGAATTACTGTTATGGCTATGGACGTCTGGGGCCAAGGGACCACGGTCATCGTCTCGTCCG	QVQLKQSGPGLVRTSQSLSLTCDISGDSVSSNSGAWTWIRQSPSRGLEWLGLTYYRSKWYDDYALSVKGRITIKADTSRNQLSLHLNSVTPEDSAVYFCARAGVSVFGITVMAMDVWGQGTTVIVS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01,IGHD3-3*02,IGHD3/OR15-3a*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYD	ARAGVSVFGITVMAMDV	MN009928.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
2	315-53-06_1D12	CCATGTGAAGTGCAGCAGTCGGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCAATTAATTGTGACATCTCCGGGGACAGTGTCTCTAGGACCAGCGGCGCTTGGGACTGGATCAGGCAGTCCCCTTCGAGAGGCCTTCAGTGGCTGGGGAGGACATACTACAGGTCCAGGTGGTATACTGATTATGCAGATTTTGTGAAAAGTCGCATAACCATCACTGCGGACACATCTAAGAACCAATTCTCCCTACAATTGACCTCTGTGACTCCCGACGACACGGCTGTCTATTTCTGTGCAAGAGCGGGAGTTTCGGTCTTTGGACTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTTTCCTCAG	PCEVQQSGPGLVKPSQTLSINCDISGDSVSRTSGAWDWIRQSPSRGLQWLGRTYYRSRWYTDYADFVKSRITITADTSKNQFSLQLTSVTPDDTAVYFCARAGVSVFGLVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSRTSGA	TYYRSRWYT	ARAGVSVFGLVVGAMDV	MN009551.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	20A-678-41_2A12	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACATTGCTGTATATTTCTGTGCAAGAGCGGTAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDIAVYFCARAVVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAVVTVFGVVVGAMDV	MN009570.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
2	315-53-04_1B09	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGGTGCTTGGGACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATAATTATGCAGATTTTGTGAAAAGTCGAATAACCATCAATCCGGACACATCCAAGAACCAGTTTTCCCTGCAACTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGTGCAAGAGCGGTAGTTACGGTCTTTGGAGTGGTTGTTGGCGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSGAWDWIRQSPSRGLEWLGRTYYRSKWYNNYADFVKSRITINPDTSKNQFSLQLSSVTPEDTAVYFCARAVVTVFGVVVGAMDVWGQGTTVTVSS	nan	nan	IGHV6-1*01	IGHJ6*02	IGHD3-3*01	nan	nan	nan	nan	nan	GDSVSSNSGA	TYYRSKWYN	ARAVVTVFGVVVGAMDV	MN009532.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
3	56.a.11_Heavy	CAGGTGCAGCTGCAACAGTCAGGCCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTACTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATATTACAGGTCCAGGTGGTATAATGACTATGCAGTTTCTGTGAAAAGTCGAGTAACGATCAACCCAGACACTTCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGCCTCGGCGATGATTTTTGGAATTGTTATTATACTTGAGTCCTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSATWNWIRQSPSRGLEWLGRTYYRSRWYNDYAVSVKSRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARASAMIFGIVIILESWGQGALVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGTAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAT	TYYRSRWYN	ARASAMIFGIVIILES	KX387173.1	KX386545.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.12_Heavy	CAGGTGCAGCTGCAACAGTCAGGCCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTACTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATATTACAGGTCCAGGTGGTATAATGACTATGCAGTTTCTGTGAAAAGTCGAGTAACGATCAACCCAGACACTTCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGCCTCGGCGATGATTTTTGGAATTGTTATTATACTTGAGTCCTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSATWNWIRQSPSRGLEWLGRTYYRSRWYNDYAVSVKSRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARASAMIFGIVIILESWGQGALVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGTAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAT	TYYRSRWYN	ARASAMIFGIVIILES	KX387174.1	KX386546.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.ND.01_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACCGTGCTGCTTGGAACTGGATCAGACAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATACTGATTATGCCGTATCTGTGAAAAGTCGAATAACCATCACCCCAGACACATCCAAGAACCAGTTCTCCCTGCAGATGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGGCTCGGCTATGATTTTTGGAATAGTTATTATATTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNRAAWNWIRQSPSRGLEWLGRTYYRSKWYTDYAVSVKSRITITPDTSKNQFSLQMKSVTPEDTAVYYCARGSAMIFGIVIIFESWGQGTLVTVSS	nan	nan	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNRAA	TYYRSKWYT	ARGSAMIFGIVIIFES	KX387216.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
3	56.a.05_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCCGTCTCTGTGAAAAGTCGAATAACCATCACCCCCGACACATCCAAGAACCAGTTCTCCCTGCAGATGAACTCTGTGACTCCCGACGACACGGCTGTGTATTATTGTGCAAGAGGCTCGGCGATGATTTTTGGAATAGTTATTATACTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITITPDTSKNQFSLQMNSVTPDDTAVYYCARGSAMIFGIVIILESWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGAGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCATTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGATGGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASNRATGVPDRFSGSGSGTDFILTISRLEPEDFAVYYCQQYDGSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVASSY	GAS	QQYDGSQYT	GDTVSSNSAA	TYYRSKWYN	ARGSAMIFGIVIILES	KX387167.1	KX386539.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.06_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCCGTCTCTGTGAAAAGTCGAATAACCATCACCCCCGACACATCCAAGAACCAGTTCTCCCTGCAGATGAACTCTGTGACTCCCGACGACACGGCTGTGTATTATTGTGCAAGAGGCTCGGCGATGATTTTTGGAATAGTTATTATACTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITITPDTSKNQFSLQMNSVTPDDTAVYYCARGSAMIFGIVIILESWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGAGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCATTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGCATGATGGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASNRATGVPDRFSGSGSGTDFILTISRLEPEDFAVYYCQQHDGSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVASSY	GAS	QQHDGSQYT	GDTVSSNSAA	TYYRSKWYN	ARGSAMIFGIVIILES	KX387168.1	KX386540.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.09_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACCGTGCTGCTTGGAACTGGATCAGACAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATACTGATTATGCCGTATCTGTGAAAAGTCGAATAACCATCACCCCAGACACATCCAAGAACCAGTTCTCCCTGCAGATGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGGCTCGGCTATGATTTTTGGAATAGTTATTATACTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNRAAWNWIRQSPSRGLEWLGRTYYRSKWYTDYAVSVKSRITITPDTSKNQFSLQMKSVTPEDTAVYYCARGSAMIFGIVIILESWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGAGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCATTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGATGGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASSRATGVPDRFSGSGSGTDFILTISRLEPEDFAVYYCQQYDGSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVASSY	GAS	QQYDGSQYT	GDTVSSNRAA	TYYRSKWYT	ARGSAMIFGIVIILES	KX387171.1	KX386543.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Stem	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	5K9J, 5K9K	6.0
3	56.a.02_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGAATCTGTGAAAAGTCGAGTAACGATCAACCCAGACACTTCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGGCTCGGCGATGATCTTTGGAATTGTTATTGTACTTGAATCCTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAESVKSRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARGSAMIFGIVIVLESWGQGALVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCGGAGTGTTGGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASRSVGSSYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	RSVGSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSKWYN	ARGSAMIFGIVIVLES	KX387164.1	KX386536.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.21_Heavy	CAGGTGCAGTTGCAGGAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCGCCATTGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAGTGATTATGCCGTGTCTGTAAAAAGTCGAATAACGATCACTCCAGACACATCCAAGAACCAGTTGTCCCTGCAGTTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGGCTCGGCGATGATTTTTGGAATAGTTATTGTACTGGAGTCCTGGGGCCAGGGAATCCCGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPLRGLEWLGRTYYRSKWYSDYAVSVKSRITITPDTSKNQLSLQLNSVTPEDTAVYYCARGSAMIFGIVIVLESWGQGIPVTVSS	GAAATTGTGTTGACGCAGCCTCCAGTCTCCCTGTCTTTGTCTCCAGGAGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCCAGTAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCATTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGATGGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQPPVSLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASSRATGVPDRFSGSGSGTDFILTISRLEPEDFAVYYCQQYDGSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ5*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVASSY	GAS	QQYDGSQYT	GDTVSSNSAA	TYYRSKWYS	ARGSAMIFGIVIVLES	KX387183.1	KX386555.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.23_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGGCTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATTATGATTTTGCCGTCTCTGTGAAAAGTCGAATAACCATCACCCCCGACACATCCAAGAACCAGTTCTCCCTTCAGATGAACTCTGTGACTCCCGACGACACGGCTGTGTATTTTTGCGCAAGAGGCTCGGCGATGATTTTTGGAATAGTTATTGTACTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPSRGLEWLGRTYYRSRWYYDFAVSVKSRITITPDTSKNQFSLQMNSVTPDDTAVYFCARGSAMIFGIVIVLESWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGAGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGTATCCAACAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCATTCTCACCATCAGCAGACTGGAGCCTGGAGATTTTGCAGTGTATTACTGTCAGCAGTATGATGGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGVSNRATGVPDRFSGSGSGTDFILTISRLEPGDFAVYYCQQYDGSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVASSY	GVS	QQYDGSQYT	GDTVSSNSAA	TYYRSRWYY	ARGSAMIFGIVIVLES	KX387185.1	KX386557.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.24_Heavy	CAGGTGCAGTTGCAGGAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCGCCATTGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTTTGGTGATTATGCCGTGTCTGTAAAAAGTCGAATAACGATCACTCCAGACACATCCAAGAACCAGTTCTCCCTGCATCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGGCTCGGCGATGATTTTTGGAATAGTTATTGTACTGGAGTCCTGGGGCCAGGGAATCCCGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCVISGDTVSSNSAAWNWIRQSPLRGLEWLGRTYYRSKWFGDYAVSVKSRITITPDTSKNQFSLHLNSVTPEDTAVYYCARGSAMIFGIVIVLESWGQGIPVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGAGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAAAGTGTTGCCAGTAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCTTCAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCATTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASFRATGVPDRFSGSGSGTDFILTISRLEPEDFAVYYCQQFDGSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ5*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVASSY	GAS	QQFDGSQYT	GDTVSSNSAA	TYYRSKWFG	ARGSAMIFGIVIVLES	KX387186.1	KX386558.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.ND.05_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGAATCTGTGAAAAGTCGAGTAACGATCAACCCAGACACTTCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGGCTCGGCGATGATCTTTGGAATTGTTATTGTACTTGAATCCTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAESVKSRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARGSAMIFGIVIVLESWGQGALVTVSS	nan	nan	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSKWYN	ARGSAMIFGIVIVLES	KX387220.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
3	56.ND.02_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAGGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACCGTGCTGCTTGGAACTGGATCAGACAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATACTGATTATGCCGTATCTGTGAAAAGTCGAATAACCATCACCCCAGACACATCCAAGAACCAGTTCTCCCTGCAGATGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGGCTCGCCTATGATTTTTGGAATTGTTATTATACTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVRPSQTLSLTCVISGDTVSSNRAAWNWIRQSPSRGLEWLGRTYYRSKWYTDYAVSVKSRITITPDTSKNQFSLQMKSVTPEDTAVYYCARGSPMIFGIVIILESWGQGTLVTVSS	nan	nan	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSNRAA	TYYRSKWYT	ARGSPMIFGIVIILES	KX387217.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
3	56.ND.04_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCGACCGTGCTACTTGGAACTGGATCAGACAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATACTGATTATGCCGTATCTGTGAAAAGTCGAATCACCATCACCCCAGACACATCCAAGAACCAGTTCTCCCTGCAGATGAAGTCTGTGACTCCCGAGGACACGGCTGTTTATTATTGTGCAAGAGGCTCGCCTATGATTTTTGGAATAGTTATTATACTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSDRATWNWIRQSPSRGLEWLGRTYYRSRWYTDYAVSVKSRITITPDTSKNQFSLQMKSVTPEDTAVYYCARGSPMIFGIVIILESWGQGTLVTVSS	nan	nan	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDTVSSDRAT	TYYRSRWYT	ARGSPMIFGIVIILES	KX387219.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
3	56.a.10_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACCGTGCTGCTTGGAACTGGATCAGACAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATACTGATTATGCCGTATCTGTGAAAAGTCGAATAACCATCACCCCAGACACATCCAAGAACCAGTTCTCCCTGCAGATGAAGTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGGCTCGCCTATGATTTTTGGAATAGTTGTTATACTTGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNRAAWNWIRQSPSRGLEWLGRTYYRSKWYTDYAVSVKSRITITPDTSKNQFSLQMKSVTPEDTAVYYCARGSPMIFGIVVILESWGQGTLVTVSS	GAAATTGTGTTGACGCAGGCTCCAGTCACCCTGTCTTTGTCTCCAGGAGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTGCCAGCAGCTATTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGCGTCTGGGACAGACTTCATTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGATGGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATTAAA	EIVLTQAPVTLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASSRATGVPDRFSGSASGTDFILTISRLEPEDFAVYYCQQYDGSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVASSY	GAS	QQYDGSQYT	GDTVSSNRAA	TYYRSKWYT	ARGSPMIFGIVVILES	KX387172.1	KX386544.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.08_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCACGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATGTCCGGGGACAGTGTCTCCAGCAACAGCGCTGCTTGGAACTGGATCAGGCAGTCCCCAGCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCTAAGTGGTATAATGATTATGCAGTATCTGTGAAAAGTCGAATAATCATCAACGCAGACACATCCAAGAACCAGGTCTCCCTGCAGTTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGGCTCGGCGATGTTTTTTGGAGTGGTTATTATACTTGACTTCTGGGGCCAGGGATCCCTGGTCACCGTCTCCTCA	QVQLQQSGPRLVKPSQTLSLTCAMSGDSVSSNSAAWNWIRQSPARGLEWLGRTYYRSKWYNDYAVSVKSRIIINADTSKNQVSLQLSSVTPEDTAVYYCARGSAMFFGVVIILDFWGQGSLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGGGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAGGATTTTGCAGTGTATTATTGTCAGCAGTTTGGTGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01,IGHD3-3*02	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFGGSHYT	GDSVSSNSAA	TYYRSKWYN	ARGSAMFFGVVIILDF	KX387170.1	KX386542.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.01_Heavy	CAGGTGCAGTTGCAGCAGTCAGGTCCAGGATTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCTACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGTATCTGTGAGAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTATTGTGCAAGAGGCTCGGCGATGATTTTTGGAGTGGTTATTATACTTGACCTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSYSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVRSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARGSAMIFGVVIILDLWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCTACAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAACCTGAAGATTTTGCAGTGTATTACTGTCAACAGTTTGGTAGCTCACAGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSYRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSQYTFGQGTKLEIK	IGHV6-1*01	IGHJ5*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GTS	QQFGSSQYT	GDSVSSYSAA	TYYRSKWYN	ARGSAMIFGVVIILDL	KX387163.1	KX386535.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.13_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCAATTACATGTGTCATCTCCGGGGACGGTGTCTCTAGTAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATTATGATTATGCAGTCTCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAAGACACGGCTATTTATTACTGTGCAAGAGGCTCGGCGATGATTTTTGGAGTGGTTATTATACTTGACCAATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSITCVISGDGVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYYDYAVSVKSRITINPDTSKNQFSLQLSSVTPEDTAIYYCARGSAMIFGVVIILDQWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAATGTATTACTGTCAGCAGTTTGGTGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAMYYCQQFGGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFGGSHYT	GDGVSSNSAA	TYYRSKWYY	ARGSAMIFGVVIILDQ	KX387175.1	KX386547.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.07_Heavy	CAGGTGCAGCTGCAACAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCAGTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGTAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGTATCTGTGAAAAGTCGAATAAGGATCAATTCAGACCCATCCAGGAACCAGCTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGGCTCGGCGATGATTTTTGGAGTGGTTATTGTACTTGACTGCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSVTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRIRINSDPSRNQLSLQLSSVTPEDTAVYYCARGSAMIFGVVIVLDCWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAACCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCTCTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLTWYQQKPGQAPRLLIFGASSRASGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSKWYN	ARGSAMIFGVVIVLDC	KX387169.1	KX386541.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.18_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGGCTGGTGAAGCCCTCGCAGACCCTCTCAGTCACCTGTGCCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTTCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATAGTGATTACGCAGTTTCTGTGAAAAGTCGCTTAACCATCAGCCCAGACACATCCAAGAACCAGCTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTATATATTACTGTGCAAGAGGGTCGGCGATGATTTTTGGAGTGGTTATTGTCCTTGACTTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSVTCAISGDTVSSNSASWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVKSRLTISPDTSKNQLSLQLSSVTPEDTAIYYCARGSAMIFGVVIVLDLWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCCCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIFGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDTVSSNSAS	TYYRSRWYS	ARGSAMIFGVVIVLDL	KX387180.1	KX386552.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.19_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGGCTGGTGAAGCCCTCGCAGACCCTCTCAGTCACCTGTGCCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTTCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATAGTGATTACGCAGTTTCTGTGAAAAGTCGCTTAACCATCAGCCCAGACACATCCAAGAACCAGCTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTATATATTACTGTGCAAGAGGGTCGGCGATGATTTTTGGAGTGGTTATTGTCCTTGACTTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSVTCAISGDTVSSNSASWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVKSRLTISPDTSKNQLSLQLSSVTPEDTAIYYCARGSAMIFGVVIVLDLWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCCCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPGSLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIFGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDTVSSNSAS	TYYRSRWYS	ARGSAMIFGVVIVLDL	KX387181.1	KX386553.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.20_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGGCTGGTGAAGCCCTCGCAGACCCTCTCAGTCACCTGTGCCATCTCCGGGGACACTGTCTCTAGCAACAGTGCTTCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATAGTGATTACGCAGTTTCTGTGAAAAGTCGCTTAACCATCAGCCCAGACACATCCAAGAACCAGCTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTATATATTACTGTGCAAGAGGGTCGGCGATGATTTTTGGAGTGGTTATTGTCCTTGACTTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSVTCAISGDTVSSNSASWNWIRQSPSRGLEWLGRTYYRSRWYSDYAVSVKSRLTISPDTSKNQLSLQLSSVTPEDTAIYYCARGSAMIFGVVIVLDLWGQGTLVTVSS	GAAATTGTGTTGACGCAGCCCCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCCCTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQPPVSLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIFGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDTVSSNSAS	TYYRSRWYS	ARGSAMIFGVVIVLDL	KX387182.1	KX386554.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.15_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCAGTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGTAATAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATACTGATTATGCAGTTTCTGTGAAAAGTCGCTTAACCATCAACCCAGACACATCCAAGAACCAGCTCTCCCTGCACCTGAGCTCTGTGACTCCCGACGACACGGCTGTATATTACTGTGCAAGAGGGTCGGCGATGATTTTTGGAGTGGTTGTTGTCCTTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSVTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSRWYTDYAVSVKSRLTINPDTSKNQLSLHLSSVTPDDTAVYYCARGSAMIFGVVVVLDFWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACAGTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVTLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSQYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSQYT	GDSVSSNSAA	TYYRSRWYT	ARGSAMIFGVVVVLDF	KX387177.1	KX386549.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.25_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAAGATTGGTGAAGCCCTCGCAGACCCTTTCAGTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGTGATAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATACTGATTATGCAGTTTCTGTGAAAAGTCGCTTAACCATCAACCCAGACACATCCAAGAACCAGCTCTCCCTGCACCTGAGTTCTGTAACTCCCGACGACACGGCTATATATTACTGTGCAAGAGGGTCGGCGATGATTTTTGGAGTGGTTGTTGTCCTTGACTTCTGGGGCCCGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPRLVKPSQTLSVTCAISGDSVSSDSAAWNWIRQSPSRGLEWLGRTYYRSRWYTDYAVSVKSRLTINPDTSKNQLSLHLSSVTPDDTAIYYCARGSAMIFGVVVVLDFWGPGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACGTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCCGAAGATTTTGCAGTGTATTACTGTCAGCGGTTTGATGGCTCACAGTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYVAWYQQRPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQRFDGSQYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QRFDGSQYT	GDSVSSDSAA	TYYRSRWYT	ARGSAMIFGVVVVLDF	KX387187.1	KX386559.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	31.g.01_Heavy	CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGTCATCTCCGGGGACACTGTCTCTAGCAACAGTGATGCATGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATTATGATTTTGCCGTCTCTGTGAAAAGTCGAATAACCATCACCCCCGACACATCCAAGAACCAGTTCTCCCTTCAGATGAACTCTGTGACTCCCGACGACACGGCAGTCTATTTTTGCGCAAGAGGATCGGCGATGATTTTTGGAATAGATATTGAAATGGAGTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNSDAWNWIRQSPSRGLEWLGRTYYRSRWYYDFAVSVKSRITITPDTSKNQFSLQMNSVTPDDTAVYFCARGSAMIFGIDIEMESWGQGTLVTVSS	GAAATTGTGATGACCCAGTCTTCAAACACCCTGTCTTTGTCTCCGGGAGAAAGAACCGGCATCTCCTGCAGGGTCAGTCAGAGTGTTGTGAGAGTATATTTAGACTGGTACCGGAAGGAACCTGGCCTGGCTACCGGGTTCTTCATTAAAGGTGTATCCAACAGGGCCAGTGACGTCCCAGACAGGTTCAGTGGCAGGGGGTTTGGGACAGAATACATTTTCACCATCAGCAGAGTGGAGCAAGGAGATTTTGCAGTGTATTACTGTCAGCAGTATGATGTCTCACGGTACACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA	EIVMTQSSNTLSLSPGERTGISCRVSQSVVRVYLDWYRKEPGLATGFFIKGVSNRASDVPDRFSGRGFGTEYIFTISRVEQGDFAVYYCQQYDVSRYTFGQGTKVEIK	IGHV6-1*01	IGHJ5*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVVRVY	GVS	QQYDVSRYT	GDTVSSNSDA	TYYRSRWYY	ARGSAMIFGIDIEMES	KX387041.1	KX386435.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Unknown	HA:Unk	VRC_310_cohort_donor_31	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.03_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATATTACAGGTCCAAGTGGTATAATGATTATGCAGAATCTGTGAAAAGACGACTCACCATCAAACCAGACACTTCCAAGAACCAGTTCTCCCTGCAGCTGACCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGGCTCGCCGATGATTTTTGGAATTGTTATTATATTTGACTCCTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAESVKRRLTIKPDTSKNQFSLQLTSVTPEDTAVYYCARGSPMIFGIVIIFDSWGQGALVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCACCAGGGCCAATGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGASTRANGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSKWYN	ARGSPMIFGIVIIFDS	KX387165.1	KX386537.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.14_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGTAGGACATATTATAGGTCCAGGTGGTATAATGATTATGCAGTTTCTGTGAAAGGTCGAGTGACGATCAACCCAGACACTTCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGGCTCGCCGATGATTTTTGGAATTGTTATTGTACTTGACTCGTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSRWYNDYAVSVKGRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARGSPMIFGIVIVLDSWGQGALVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCACCCTGTCTTTGTCTCCAGGGGAGAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGTAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTCTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSRWYN	ARGSPMIFGIVIVLDS	KX387176.1	KX386548.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.17_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGTTGGGTCGGACATACTACAGGTCCAGGTGGTATAATGATTATGCAGTTTCTGTGAAAGGTCGAGTGACGATCAATCCAGACACTTCCAAGAATCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGGCTCGCCGATGATTTTTGGAATTGTTATTGTTCTTGACTCGTGGGGCCCGGGAGCCCTGGTCACCGTCTCCTCC	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSRWYNDYAVSVKGRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARGSPMIFGIVIVLDSWGPGALVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGTAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSRWYN	ARGSPMIFGIVIVLDS	KX387179.1	KX386551.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.22_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGGTCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGTCGGACATACTACAGGTCCAGGTGGTATAACGATTATGCAGTTTCTGTGAGAGGTCGAGTGACGATCAACCCAGACACTTCCAAGAATCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTTCTGTGCAAGAGGCTCGCCGATGATTTTTGGAATTGTTATTGTTCTTGACTCGTGGGGCCCGGGAGCCCTGGTCACCGTCTCCTCG	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWVRQSPSRGLEWLGRTYYRSRWYNDYAVSVRGRVTINPDTSKNQFSLQLSSVTPEDTAVYFCARGSPMIFGIVIVLDSWGPGALVTVSS	GAAATTGTGATGACCCAAAGTTCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGTAGCTACTTAGCCTGGTACCAGCAAAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVMTQSSVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSRWYN	ARGSPMIFGIVIVLDS	KX387184.1	KX386556.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.ND.03_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGTAGGACATATTATAGGTCCAGGTGGTATAATGATTATGCAGTTTCTGTGAAAGGTCGAGTGACGATCAACCCAGACACTTCCAAGAACCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGACGACACGGCTGTCTATTACTGTGCAAGAGGCTCGCCGATGATTTTTGGAATTGTTATTGTACTTGACTCGTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSRWYNDYAVSVKGRVTINPDTSKNQFSLQLSSVTPDDTAVYYCARGSPMIFGIVIVLDSWGQGALVTVSS	nan	nan	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	nan	nan	nan	nan	nan	GDSVSSNSAA	TYYRSRWYN	ARGSPMIFGIVIVLDS	KX387218.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
3	56.a.16_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGTCGGACATATTACAGGTCCAGGTGGTATAATGATTATGCAGTTTCTGTGAAAGGTCGAGTGACGATCAACCCAGACACTTCCAAGAATCAGTTCTCCCTGCAGCTGAGCTCTGTGACTCCCGAGGACACGGCTGTCTATTACTGTGCAAGAGGCTCGCCGATGGTTTTTGGAATTGTTATTGTTCTTGACTCGTGGGGCCCGGGAGCCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSRWYNDYAVSVKGRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARGSPMVFGIVIVLDSWGPGALVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGTAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSRWYN	ARGSPMVFGIVIVLDS	KX387178.1	KX386550.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
3	56.a.04_Heavy	CAGGTGCAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTTTCAGTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAGGTGGTATACTGATTATGCAGTTTCTGTGAAAAGTCGCTTAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAACTGAACTCTGTGACTCCCGAGGACACGGCTGTATATTACTGTGCAAGAGGGTCGCCGATGATTTTTGGAGTGGTTGTTGTCCTTGACTTTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	QVQLQQSGPGLVKPSQTLSVTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSRWYTDYAVSVKSRLTINPDTSKNQFSLQLNSVTPEDTAVYYCARGSPMIFGVVVVLDFWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAGACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAACAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGGAGATTTTGCAGTGTATTACTGTCAGCAGTTTGATGGCTCACACTACACTTTTGGCCGGGGGACCAAGCTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIFGASNRATGIPDRFSGSGSGTDFTLTISRLEPGDFAVYYCQQFDGSHYTFGRGTKLEIK	IGHV6-1*01	IGHJ4*02	IGHD3-3*01	IGKV3-20*01	IGKJ2*01	QSVSSSY	GAS	QQFDGSHYT	GDSVSSNSAA	TYYRSRWYT	ARGSPMIFGVVVVLDF	KX387166.1	KX386538.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_56	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	6.0
4	315-09-05M_1A09	CAGGTTCAGTTGGTGCAGTCTGGAGTTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACAGTTTTGTCAACTATGGCATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGGTTACACTGGTAATACAAACCATGCACAGAGATTCCAGGGCAGAGTCTCCATGACCATAGACACATCCACGAACACGGCCTACCTGGACCTGAGGAGTCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGATCCTTCAGGGCGCTGTTATCGTCGACTCCCTCTATTACACTATGGACGTCTGGGGCCAGGGGACCGCGGTCACCGTCTCATCA	QVQLVQSGVEVKKPGASVKVSCKASGYSFVNYGISWVRQAPGQGLEWMGWISGYTGNTNHAQRFQGRVSMTIDTSTNTAYLDLRSLRSDDTAVYYCARGILQGAVIVDSLYYTMDVWGQGTAVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-16*02	nan	nan	nan	nan	nan	GYSFVNYG	ISGYTGNT	ARGILQGAVIVDSLYYTMDV	MN008702.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-08_1B03	CAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCACCTATGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAATCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTACTACTGTGCGAGAGGGATCCTTCAGGGAGTTGTTATCTTCGACTCCTACTACTACACTATGGACGTCTGGGGCCAGGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYGISWVRQAPGQGLEWMGWISAYTGNTNYAQNLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGILQGVVIFDSYYYTMDVWGQGTTVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTTYG	ISAYTGNT	ARGILQGVVIFDSYYYTMDV	MN008736.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-04_1A09	CAGGTGCAGTTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTGCCAACTATGGCATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACCATGCACAGAAGTTCCAGGGCAGAGTCAGCATGACCATAGACACATCCACGAACACGGCCTACCTGGACCTGAGGAGTCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGATCCTTCAGGGCGTTGTTATCGTCGACTCCTACTATTACACTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCATCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFANYGISWVRQAPGQGLEWMGWISAYTGNTNHAQKFQGRVSMTIDTSTNTAYLDLRSLRSDDTAVYYCARGILQGVVIVDSYYYTMDVWGQGTTVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-16*02	nan	nan	nan	nan	nan	GYTFANYG	ISAYTGNT	ARGILQGVVIVDSYYYTMDV	MN008696.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_4B05	CAGGTTCAGTTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTGCCAACTATGGCATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACCATGCACAGAAGTTCCAGGGCAGAGTCAGCATGACCATAGACACATCCACGAACACGGCCTACCTGGACCTGAGGAGTCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGATCCTTCAGGGCGTTGTTATCGTCGACTCCTACTATTACACTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCATCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFANYGISWVRQAPGQGLEWMGWISAYTGNTNHAQKFQGRVSMTIDTSTNTAYLDLRSLRSDDTAVYYCARGILQGVVIVDSYYYTMDVWGQGTTVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-16*02	nan	nan	nan	nan	nan	GYTFANYG	ISAYTGNT	ARGILQGVVIVDSYYYTMDV	MN008712.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_1C08	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008715.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_1F01	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008716.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_4B06	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008717.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_4C07	CAGGTNCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008718.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5A03	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008719.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5A07	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008720.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5B03	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008721.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5B05	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008722.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5C03	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008723.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5C07	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008724.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5D12	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008725.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5F09	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008726.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5F10	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008727.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5G08	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008728.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5H05	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYAMDV	MN008729.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5C10	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGTACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACACTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYVQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYTMDVWGQGTTVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYTMDV	MN008730.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5E07	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATTAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACACTGGTAACACAAACTATGTACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACACTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNYVQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYTMDVWGQGTTVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDSYYYTMDV	MN008731.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-1B12-UCA	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTTGTTATCCTCGACTCCTACTACTACACTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGVVILDSYYYTMDVWGQGTTVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCGGTGGACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRWTFGQGTKLEIK	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	IGKV3-20*01	IGKJ2*02	QSVSSSY	GAS	QQYGSSPRWT	GYTFTSYG	ISAYNGNT	ARGLLQGVVILDSYYYTMDV	MH997404.1	MH997405.1	30808695	Corbett et al. mBio 10:e02810-18 (2019)	Group 2	HA:Stem	VRC_315-09	B-cells;H7N9 Human Vaccinee	nan	52.0
4	36.g.01_Heavy	CAGGTTCAATTGGTGCAGTCTGAAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACACCTTTACCAGTTATGGGATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCATACACTGGTAACACAAACTCTGCACAGAAACTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGACCTGACGACACGGCCGTGTATTACTGTGCGAGAGGGCTCCTTCAGGGAGTAGTTATCCTCGACTACTCCTACTACACTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSEAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYTGNTNSAQKLQGRVTMTTDTSTSTAYMELRSLRPDDTAVYYCARGLLQGVVILDYSYYTMDVWGQGTTVTVSS	GAAATTGTGTTGACGCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGATTCAGAGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTTTTACTGTCAGCTGTATGGTTCCACACCTCGGTGGACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA	EIVLTQSPVSLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFRGSGSGTDFTLTISRLEPEDFAVFYCQLYGSTPRWTFGQGTKVEIK	IGHV1-18*01	IGHJ6*02	IGHD3-3*01,IGHD3-3*02	IGKV3-20*01	IGKJ2*02	QSVSSNY	GAS	QLYGSTPRWT	GYTFTSYG	ISAYTGNT	ARGLLQGVVILDYSYYTMDV	KX387057.1	KX386438.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	52.0
4	36.g.02_Heavy	CAGGTTCAGTTGGTGCAGTCTGGAGCTGAGGTGAAGAGGCCTGGGGCCTTAGTGAAGGTCTCCTGCAAGGCGTCTGGTTACAACTTTGCCAGCCATGGCATTAGCTGGGTGCGACAGGCCCCTGGACAGGGGCTTGAGTGGATGGCTTGGATCAGCGTTTACACCGGTGACACGAGTTTCGCACAGAAGTTCAAGGGCAGAGTCACCGTGACCACAGACCCATCGACGAACACAGCGTTTATGGAAATGCGGAGCCTGAGATCCGACGACACGGCCGTCTATTTCTGTGCGAGAGGGCTCCTTCAGGGAGCTGTTATGGTCGACTCCTTATACTACGCTCTGGACGTCTGGGGCCAAGGGACCACGGTCATCGTCACCTCA	QVQLVQSGAEVKRPGALVKVSCKASGYNFASHGISWVRQAPGQGLEWMAWISVYTGDTSFAQKFKGRVTVTTDPSTNTAFMEMRSLRSDDTAVYFCARGLLQGAVMVDSLYYALDVWGQGTTVIVTS	GAAATTGTGTTGACGCAGGTTCCAGTCTCCCTGTCTTTGTCTCCCGGGGATAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAATGTTAACAACAGGTTCATAGCCTGGTACCAACATAAACCTGGCCAGTCTCCCAGACTCCTCATCTATGGTGCATCCAACAAGGCCACTGGCATCCCAGACAGGTTCAGAGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAATGTATTATTGTCAGCTGTTTGATAGTTCACCTCGGTGGACTTTTGGCCAGGGGACCAAACTGGAGATCAAG	EIVLTQVPVSLSLSPGDRATLSCRASQNVNNRFIAWYQHKPGQSPRLLIYGASNKATGIPDRFRGSGSGTDFTLTISRLEPEDFAMYYCQLFDSSPRWTFGQGTKLEI	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	IGKV3-20*01	IGKJ2*02	QNVNNRF	GAS	QLFDSSPRWT	GYNFASHG	ISVYTGDT	ARGLLQGAVMVDSLYYALDV	KX387058.1	KX386439.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	52.0
4	315-09-05M_1E01	CAGGTCCAGTTGGTCCAGTCGGGATCTGAAGTGAAGAACCCTGGGGCTTCAGTGAAGGTTTCCTGCAAGGCGTCTGGTTACACCTTTGCCAGTCATGGTGTTAACTGGGTGCGACAGACCCCTGGGCAGGGGCTTGAGTGGATGGGCTGGATCAGCGCTTACACTGGTACCACAAACTTTGCACAGAAGTTCCAGGGCAGAGTCACCATGACCACAGACACTTCCACGAGCACAGCCTACATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTCTATTACTGTGCGAGAGGGCTCCTTCAGGGAGCTGTAATGGTCGACTCCTACTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGSEVKNPGASVKVSCKASGYTFASHGVNWVRQTPGQGLEWMGWISAYTGTTNFAQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGLLQGAVMVDSYYYAMDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD1-26*01,IGHD2-8*01	nan	nan	nan	nan	nan	GYTFASHG	ISAYTGTT	ARGLLQGAVMVDSYYYAMDV	MN008704.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5E09	CAGGTTCACTTGGTGCAGTCTGGACCTGAGATGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTGCCAACTATGGCATCAGCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGCTGGGATGGATCAGCGCTTACACTGGTAACACAAAGAATGCACAGAAGTTCCAGGGTAGAGTCTCTATGACCACAGACACATCCACCAACACGGCCTACCTGGACCTGAGGACTCTGACATCCGACGACACTGCCGTATATTACTGTGCGAGAGGGATCCTTCAGGGCGCTGTTATGGTCGACTCCTACCATTACACTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCATCA	QVHLVQSGPEMKKPGASVKVSCKASGYTFANYGISWVRQAPGQGLEWLGWISAYTGNTKNAQKFQGRVSMTTDTSTNTAYLDLRTLTSDDTAVYYCARGILQGAVMVDSYHYTLDVWGQGTTVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD5-12*01,IGHD5-24*01,IGHD5/OR15-5a*01	nan	nan	nan	nan	nan	GYTFANYG	ISAYTGNT	ARGILQGAVMVDSYHYTLDV	MN008710.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-06_5F04	CAGGTTCACTTGGTGCAGTCTGGACCTGAGATGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTGCCAACTATGGCATCAGCTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGCTGGGATGGATCAGCGCTTACACTGGTAACACAAAGAATGCACAGAAGTTCCAGGGTAGAGTCTCTATGACCACAGACACATCCACCAACACGGCCTACCTGGACCTGAGGACTCTGACATCCGACGACACTGCCGTATATTACTGTGCGAGAGGGATCCTTCAGGGCGCTGTTATGGTCGACTCCTACCATTACACTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCATCA	QVHLVQSGPEMKKPGASVKVSCKASGYTFANYGISWVRQAPGQGLEWLGWISAYTGNTKNAQKFQGRVSMTTDTSTNTAYLDLRTLTSDDTAVYYCARGILQGAVMVDSYHYTLDVWGQGTTVTVSS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD5-12*01,IGHD5-24*01,IGHD5/OR15-5a*01	nan	nan	nan	nan	nan	GYTFANYG	ISAYTGNT	ARGILQGAVMVDSYHYTLDV	MN008711.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
4	315-09-08_1C10	CAGGTGCAGCTGGTGCAATCTGGTAGTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAAGTCTCCTGCAAGGCGTCTGGTTACACCTTTCGCAATTATGGTGTTAGTTGGGTGCGGCAGGCCCCTGGACAAGGGCCTGAGTGGATGGGATGGATCAGCGCTTACACCGGCAACATAAAATATGCACAGAAGTTCCAGGGCAGGGTCACCGTGACTACAGACACATCCACGAGCACAGCCTCTATGGAACTGAGGAGCCTAACATCTGACGACACGGCCGTTTATTACTGTGCGAGAGGGCTCCTTCAGGGAGCTGTTATGGTCGACTCCAACCACTATGCCTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCACCTCA	QVQLVQSGSEVKKPGASVKVSCKASGYTFRNYGVSWVRQAPGQGPEWMGWISAYTGNIKYAQKFQGRVTVTTDTSTSTASMELRSLTSDDTAVYYCARGLLQGAVMVDSNHYALDVWGQGTTVTVTS	nan	nan	IGHV1-18*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GYTFRNYG	ISAYTGNI	ARGLLQGAVMVDSNHYALDV	MN008737.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-06_5F11	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGCCTCCGTCAGCAATGGTGATTTCTACTGGAGTTGGATCCGCCAGCCCCCAGGGAGGGGCCTGGAGTGGATTGCATACACATATTACACTGGGAGCACCTACTACAGCCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCCAAGAACCACCTCTCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTGTATTACTGTGCCAGGATCCCCCGAGATATTGTACTGGTACCAGGTGCTAGTCGCTGGGCAGCAGCCATTGACTATTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCTVSGASVSNGDFYWSWIRQPPGRGLEWIAYTYYTGSTYYSPSLKSRVTISVDTSKNHLSLKLTSVTAADTAVYYCARIPRDIVLVPGASRWAAAIDYWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GASVSNGDFY	TYYTGST	ARIPRDIVLVPGASRWAAAIDY	MN008503.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-04_1B04	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCAAAGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATTTCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAACTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGCCAGGGTCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATTGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCKVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCARVPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	ARVPRDIVLVPGGSRWAATIDD	MN008500.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-05M_1H03	CAGGTGCAGCTGCCGGGGTTGGGCCCAGGATTGTTGAACCTTTACCAGACCTTGTCCTTACCTTGCATGGTTTCTGGGGGTTCCTTCAGCAGTGGTGATTACTTCGGGAGTGGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLPGLGPGLLNLYQTLSLPCMVSGGSFSSGDYFGSGIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSFSSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	MN008501.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-06_4A02	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	MN008504.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-06_5D01	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	MN008505.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-06_5E11	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	MN008506.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-06_5F02	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	MN008507.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	315-09-06_5G05	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	MN008508.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
5	36.a.01_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387048.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.a.02_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTCAGTCTGCAGGAGAAAGGGCCAGAGGCAACCGCAGGGTCAGGACGAGTGGTGACAGTAGCAAGGGAGCGCGGTACCAGCGGAAATATCACGGGAAGCCCTGTCTCCTCATTTCCGGTGTGTCCACCAGGGCCACCGGCATGCCAGACAGGTTCAGTGGCAGTGGGTGTGGGACAGACTTCACTCTCACCATTGGCAGACTGGAGCCTGAAGATTGGCAGAGTATTACTGTCAACAGTATGGTAGCTCACTGTTCACTTTTGGCCAGGGGAACAAGTTGGAAATCAAAA	EIVLTQSPGTLSQSAGERARGNRRVRTSGDSSKGARYQRKYHGKPCLLISGVSTRATGMPDRFSGSGCGTDFTLTIGRLEPEDWQSITVNSMVAHCSLLARGTSWKS	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	IGKV3-20*01	IGKJ2*01	TSGDSSK	GVS	NSMVAHCSL	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387049.1	KX386436.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.b.01_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387050.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.c.01_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387051.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.d.01_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387052.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.d.02_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	GAAATTGTGATGACCCAGTCTCCAGTCTCCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCCGGCTCCTCATCTATGGTGCATCTAACAGGGCCACTGACATCCCAGCCAGGTTCCGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGTAGCCTAGACCCTGAGGATTTTGCAGTTTATTACTGTCAGCAGTATACCAACTGGCCTCGAACGTTCGGCCAAGGGACCAAGGTGGAAACCAAA	EIVMTQSPVSLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASNRATDIPARFRGSGSGTDFTLTISSLDPEDFAVYYCQQYTNWPRTFGQGTKVETK	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	IGKV3-11*01	IGKJ1*01	QSVSSY	GAS	QQYTNWPRT	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387053.1	KX386437.1	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.d.03_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387054.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.e.01_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387055.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.f.02_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387056.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.ND.01_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387059.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	36.ND.02_Heavy	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCATTGTCTCTGGTGGCTCCATCAGCAGTGGTGATTACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATGTATTACACTGGGAGCACCTACTACAACCCCTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCCAAGAACCACCTCGCCCTGAAGCTGACCTCTGTGACTGCCGCAGACACGGCCGTTTATTACTGTGGCAGGATCCCCCGAGATATTGTTCTAGTTCCAGGTGGTAGTCGCTGGGCGGCAACTATAGACGACTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCIVSGGSISSGDYFWSWIRQPPGKGLEWIAYMYYTGSTYYNPSLKSRVAISVDTSKNHLALKLTSVTAADTAVYYCGRIPRDIVLVPGGSRWAATIDDWGQGILVTVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*01,IGHD2-2*02,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSGDYF	MYYTGST	GRIPRDIVLVPGGSRWAATIDD	KX387060.1	nan	27453470	Joyce et al. Cell 166:609-623 (2016)	Group 1,2	HA:Unk	VRC_310_cohort_donor_36	Individual received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine	nan	nan
5	315-09-06_5A02	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCCTTGTCTCTGGTGACTCCATCAGCAGTGGTCAATACTTCTGGAGTTGGATCCGCCAGCCCCCAGGGAAGGGCCTGGAGTGGATTGCCTACATCTATTACACTGGGAGCACCTACCAGAATCCCTCCCTCAAGAGTCGAATTGGCATATCAATAGACACGTCCAAGAACCAGGTTTCCCTAAAGCTGACCTCTGTGACTGCAGCAGACACGGCCGTCTATTACTGTGGCAGAGTCCCCCGAGATGTTGTTCTAGTTCCAGGTGGGACTCGCTGGGCGGCAACTATACCCGACTGGGGCCAGGGAGTCCCGGTCATTGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCLVSGDSISSGQYFWSWIRQPPGKGLEWIAYIYYTGSTYQNPSLKSRIGISIDTSKNQVSLKLTSVTAADTAVYYCGRVPRDVVLVPGGTRWAATIPDWGQGVPVIVSS	nan	nan	IGHV4-30-4*01	IGHJ4*02	IGHD2-2*02,IGHD2-8*01,IGHD2-8*02	nan	nan	nan	nan	nan	GDSISSGQYF	IYYTGST	GRVPRDVVLVPGGTRWAATIPD	MN008509.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
6	20A-609-30_1A03	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCATGGGACGTCCCTGAGACTCTCCTGTGCGGCGTCTGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGACTGGGTGGCAGTTATATGGTATGATGGAAGTCATAAATACTATGCAGACTCCGTGACGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGTCTATTACTGTGCGAGAGCGACAGCAGGAGCTGATAGTTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTTCCTCAG	EVQLVESGGGVVQHGTSLRLSCAASGFTFSSFGMHWVRQAPGKGLDWVAVIWYDGSHKYYADSVTGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARATAGADSYYYYGMDVWGQGTTVTV	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGSHK	ARATAGADSYYYYGMDV	MN008296.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
6	315-06-08_1G01	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTTCAAGAACACGCTGTCTCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGATGTATAGCAGGAGCTGGTTCTTACTATTACTACGGAATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNFKNTLSLQMNSLRAEDTAVYYCARCIAGAGSYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGSNK	ARCIAGAGSYYYYGMDV	MN008285.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
6	315-24-08_1G09	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCGAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGCCTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAATACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAATAATAGCAGGAGCTGGTAGTTATTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCCCA	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGEGLEWVAVIWYDGSNKYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIIAGAGSYYYYGMDVWGQGTTVTVS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGSNK	ARIIAGAGSYYYYGMDV	MN009358.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	20A-623-30_1G06	CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCATGTTCAGTAGCTTTGGCATGCAGTGGGTCCGCCAGGCCCCAGACAAGGGGCTGGAGTGGGTGGCTGTTATATGGTATGATGGAAGTAATAAATATTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACCCTGTATCTGCAAATGAACAGCCTGAGAGTCGACGACACGGCTCTGTATTACTGTGCGAGAGTAACTGCAGGAGCTGGCGACTACTATTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCATCGTCTCGTCA	QVQLVESGGGVVQPGRSLRLSCAASGFMFSSFGMQWVRQAPDKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRVDDTALYYCARVTAGAGDYYYYGMDVWGQGTTVIVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFMFSSFG	IWYDGSNK	ARVTAGAGDYYYYGMDV	MN009418.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	20A-623-30_1G11	CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGACTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCGCCTTCAGCAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTAGAGTGGGTGGCAGTTATTTGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAGGGGCCGATTCGTCATCTCCAGAGACAATTCCAAGGACACTCTGTATTTGCAAATGAACAGCCTGAGAGTCGAGGACACGGGTGTCTATTATTGTGCGAGATGTATAGCAGGAGCTGGCGACCACTACTACTACGGAATGGACGTCTGGGGCCGAGGGACCACGGTCATCGTCTCCTCA	QVQLVESGGGVVQTGRSLRLSCAASGFAFSSFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFVISRDNSKDTLYLQMNSLRVEDTGVYYCARCIAGAGDHYYYGMDVWGRGTTVIVSS	nan	nan	IGHV3-33*01,IGHV3-33*04	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFAFSSFG	IWYDGSNK	ARCIAGAGDHYYYGMDV	MN009264.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	20A-623-30_1D12	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTTAGTAGTTTTGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTTATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATGTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTTTATTACTGTGCGAGGTGTATAGCCGGAGCTGGATCCCACTCTTATTATGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWVAVIWYDGSYKYYADSVKGRFTISRDNSKNTLYVQMNSLRAEDTAVYYCARCIAGAGSHSYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFA	IWYDGSYK	ARCIAGAGSHSYYGMDV	MN009265.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	20A-609-30_2D09	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCTCTGAGACTCTCCTGTGCTGCGTCTGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTTTGATGGAAGTGAGAAGTACTATGGAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTCTATATTACTGTGCGAGATTTATAGCGGGAGCTGGAGACTACTACTACTACGGTATGGACGTCTGGGGCCGAGGGACCACGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVIWFDGSEKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARFIAGAGDYYYYGMDVWGRGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD1-26*01	nan	nan	nan	nan	nan	GFTFSSFG	IWFDGSEK	ARFIAGAGDYYYYGMDV	MN008297.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
6	315-21-08_1C02	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAATAGTCTGAGAGCCGAAGACACGGCTCTGTACTACTGTGCGAGACATATAGCAGGAGCTGGGGACAACTATTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARHIAGAGDNYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGSNK	ARHIAGAGDNYYYGMDV	MN008991.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
6	20A-618-30_1D06	GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCATGTTCAGCAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGAGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGCCCGATTCACCATCTCCAGAGACAATTCGAAGAACACGATGTATCTGCAAATGAGCAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGACATATAGCAGGAGCTGGTGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGVVQPGRSLRLSCAASGFMFSSFGMHWVRQAPGKELEWVAVIWYDGSNKYYADSVKARFTISRDNSKNTMYLQMSSLRAEDTAVYYCARHIAGAGDYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFMFSSFG	IWYDGSNK	ARHIAGAGDYYYYGMDV	MN007839.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
6	20A-609-30_2B08	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCTAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCGTCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGACATATAGCAGGAGCTGGTGGTTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQALGKGLEWVAVIWYDGSNKYYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTAVYYCARHIAGAGGYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGSNK	ARHIAGAGGYYYYGMDV	MN008298.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
6	20A-618-30_1F12	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCCCCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTACAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATCTCTGTGCGAGACATATAGCAGGAGCTGGTTACTACTATTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCAASGFPFSSFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYLCARHIAGAGYYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFPFSSFG	IWYDGSNK	ARHIAGAGYYYYYGMDV	MN007840.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
6	315-24-08_1D06	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGTTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAATAATATCAGGAGCTGGTTCCTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIISGAGSYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGSNK	ARIISGAGSYYYYGMDV	MN009359.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	315-21-08_1E12	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTTAGTAGCTTTGCCATGCAGTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGTGACTAGTGGTTCGGGGAGCTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFAMQWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVTSGSGSYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GFTFSSFA	IWYDGSNK	ARVTSGSGSYYYYGMDV	MN008993.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
6	20A-623-30_1F09	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCAGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAACTAATAAATATTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTCTCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGTGTATTCCTGTGCGAGAAACATAGCAGCAGCTGGTGACTACTACTACTACGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVIWYDGTNKYYADSVKGRFTISRDNSKNTLSLQMNSLRDEDTAVYSCARNIAAAGDYYYYGLDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGTNK	ARNIAAAGDYYYYGLDV	MN009366.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	315-24-08_1H06	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGAATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATTTGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGACGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGATATATAGCAGCAGCTGGTTACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGVVQPGRSLRLSCAASEFTFSSFGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYIAAAGYYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	EFTFSSFG	IWYDGSNK	ARYIAAAGYYYYYGMDV	MN009424.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	20A-620-30_2E02	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCACTGAGACTCTCCTGTGTAGCGTCTGGATTCACCTTCAGCAGTTTTGGCATGCAGTGGTTCCGCCAGGCTCCAGGCACGGGGCTGGAGTGGGTGGCAGTTATATCGTTTGATGGAAGTAATAAATACTATGCAGACTCCCTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATTTGCAATTGAGCAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGTTACTGCAGGAGCTGGGGGCGATTATTACTACGGTATGGACGTCTGGGGCCCAGGGACCATGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCVASGFTFSSFGMQWFRQAPGTGLEWVAVISFDGSNKYYADSLKGRFTISRDNSKNTLYLQLSSLRAEDTAVYYCARVTAGAGGDYYYGMDVWGPGTMVTVSS	nan	nan	IGHV3-33*01,IGHV3-33*05	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	ISFDGSNK	ARVTAGAGGDYYYGMDV	MN008980.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
6	315-24-08_1B08	GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTTTGATGGAAGTAATAAATATTATACGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGTTGTATCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGTGTATTACTGTGCGAGAGTTACAGCATCAGCTGGTAGTTACCACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTTA	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVIWFDGSNKYYTDSVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARVTASAGSYHYYGMDVWGQGTTVTVS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWFDGSNK	ARVTASAGSYHYYGMDV	MN009419.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
6	315-24-08_1C12	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGTTCCACCTTGGAAGGTCCTGGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGTTTTGGCATGCACGGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGAGAATTCCAAGAATACGCTGTATCTCCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTTCGAGACATATAGCAGCAGCTGGCGGATACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCA	QVQLVESGGGVFHLGRSWRLSCAASGFTFSSFGMHGVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRENSKNTLYLQMNSLRAEDTAVYYCSRHIAAAGGYYYYGMDVWGQGTAVTVSS	nan	nan	IGHV3-33*01	IGHJ6*02	IGHD6-13*01	nan	nan	nan	nan	nan	GFTFSSFG	IWYDGSNK	SRHIAAAGGYYYYGMDV	MN009439.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
7	K77-1A06	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCGGCCTCTGGATTCACCTTCAGTAGTTATGGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATTTCAGACATCAGTAGTGATAGAAGTACCATATACTACACGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAAACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGTCGACGACACGGCTGTGTATTACTGTGCGAGAGACTTTATGTCCTATTTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMNWVRQAPGKGLEWISDISSDRSTIYYTDSVKGRFTISRNNAKNSLYLQMNSLRVDDTAVYYCARDFMSYFFDYWGQGTLVTVSS	AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCCGCAGCAGTGGCAGCATTGCCAGCAACTATGTGCAGTGGTACCAGAAGCGCCCGGGCAGTTCCCCCACCACTGTGATCTATGAGGATGACCAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCCTCCCTCACCATCTCTGGACTGAAGACTGAGGACGGGGCTGACTACTACTGTCAGTCTTTTGATAGCAGCAATCATAGGGTATTCGGCGGAGGGACCTAAGCTGCCTGTCCTA	NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQKRPGSSPTTVIYEDDQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDGADYYCQSFDSSNHRVFGGGT*AACP	IGHV3-48*04	IGHJ4*02	IGHD2-21*01,IGHD2-21*02,IGHD3-10*02	IGLV6-57*01	IGLJ2*01,IGLJ3*01	SGSIASNY	EDD	QSFDSSNHRV	GFTFSSYG	ISSDRSTI	ARDFMSYFFDY	MK311448.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	nan
7	K77-1F01	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCGGCCTCTGGATTCACCTTCAGTAGCTATGGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATTTCAGACATCAGTAGTGATAGAAGTACCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAGATGAACAGCCTGAGAGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTTTATGTCCTATTTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMNWVRQAPGKGLEWISDISSDRSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARDFMSYFFDYWGQGTLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGCTTATAACTATGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCTTGATTTATGATGTCAATAATCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAACTCATATACAAGCATCAGCACTGGGGTATTCGGCGGAGGGACCAATGTGACCGGTTTAG	QSALTQPASVSGSPGQSITISCTGTSSDVGAYNYVSWYQQHPGKAPKLLIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSISTGVFGGGTNVT	IGHV3-48*04	IGHJ4*02	IGHD2-21*01,IGHD2-21*02,IGHD3-10*02	IGLV2-14*03	IGLJ2*01,IGLJ3*01	SSDVGAYNY	DVN	NSYTSISTGV	GFTFSSYG	ISSDRSTI	ARDFMSYFFDY	MK311449.1	MK312034.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	nan
7	R95-1H08	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTAAGACTCTCCTGTGTAGCCTCTGGGTTCACCTTCGGGAGCTATGGTCTGCACTGGGTCCGCCAGACTCCAGGCAAGGGACTCGAGTGGGTGGCATTTATATCATATGATGGATATGATAAAACCTATGCCGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACACTTCCAAGAACACTCTCTATCTACAAATGAACAGCCTGAGAGTTGAAGACACGGCTCTCTACTACTGTGCGAGAGTATTCGAATCCTACTTCTTTGACTACTGGGGCCAGGGAACCCTGGTCGCCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCVASGFTFGSYGLHWVRQTPGKGLEWVAFISYDGYDKTYADSVKGRFTISRDTSKNTLYLQMNSLRVEDTALYYCARVFESYFFDYWGQGTLVAVSS	CAGTTTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATTACCATCTCCTGCACTGGAACCAGCAGTGATGTTGCGAAGTATAACCTTGTCGCCTGGTACCAACAACACCCAGGCAGAGCCCCCAAACTCCTTATTTATGAGGACAGTGAGCGGCCCTCAGCGATTTCTCATCGCTTCTCTGGCTCCAAGTCAGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTATTGCTGTTCATTTGCAGGTAGTGACACCTGGGTGTTCGGCACAGGGACGAAACTGACCGTCCTGG	QFALTQPASESGSPGQSITISCTGTSSDVAKYNLVAWYQQHPGRAPKLLIYEDSERPSAISHRFSGSKSGNTASLTISGLQAEDEADYYCCSFAGSDTWVFGTGTKLTVL	IGHV3-30*03	IGHJ4*02	IGHD2-21*01,IGHD2-21*02	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ3*02	SSDVAKYNL	EDS	CSFAGSDTWV	GFTFGSYG	ISYDGYDK	ARVFESYFFDY	MK311790.1	MK312124.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Head	Melbourne_donor_R95	2015 IIV3 vaccination	nan	16.0
7	R95-2H01	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTAAGACTCTCCTGTGTAGCCTCTGGGTTCACCTTCGGGAGCTATGGTCTGCACTGGGTCCGCCAGACTCCAGGCAAGGGACTCGAGTGGGTGGCATTTATATCATATGATGGATATGACAAAACCTATGCCGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACACTTCCAAGAGCACTCTCTATCTGCAAATGAACAGCCTGAGAGTTGAAGACACGGCTCTCTACTACTGTGCGAGAGTATTCGAATCCTACTTCTTTGACTACTGGGGCCAGGGAACCCTGGTCGCCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCVASGFTFGSYGLHWVRQTPGKGLEWVAFISYDGYDKTYADSVKGRFTISRDTSKSTLYLQMNSLRVEDTALYYCARVFESYFFDYWGQGTLVAVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATTACCATCTCCTGCACTGGAACCAGCAGTGATGTTGCGAAGTATAACCTTGTCGCCTGGTACCAACAACACCCAGGCAGAGCCCCCAAACTCCTGATTTATGAGGACAGTGAGCGGCCCTCAGGGATTTCTCATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTATTGCTGTTCATTTGCAGGTAGTGACACCTGGGTGTTCGGCACAGGGACGAAACTGACTGTCACTG	QSALTQPASESGSPGQSITISCTGTSSDVAKYNLVAWYQQHPGRAPKLLIYEDSERPSGISHRFSGSKSGNTASLTISGLQAEDEADYYCCSFAGSDTWVFGTGTKLTV	IGHV3-30*03	IGHJ4*02	IGHD2-21*01,IGHD2-21*02	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ3*02	SSDVAKYNL	EDS	CSFAGSDTWV	GFTFGSYG	ISYDGYDK	ARVFESYFFDY	MK311791.1	MK312125.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	16.0
7	R95-1G11	GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCGGTAGCTATGATATGCTCTGGGTCCGCCAGGCTCCAGGCAAGGGGCTAGAGTGGGTGGCATTTATATCATATGATGGCAGTGATAGAAACTACGCAGACTCCGTGAAGGGCCGATTTACCATCTCCGGAGCCAATTCCAAAAACACACTGTATCTGCAAATGAACAGCCTGGGAGCTGAGGACACGGCTGTGTATTATTGTGCGAGAACTTATGAATCGTACTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAVSGFTFGSYDMLWVRQAPGKGLEWVAFISYDGSDRNYADSVKGRFTISGANSKNTLYLQMNSLGAEDTAVYYCARTYESYSFDYWGQGTLVTVSS	nan	nan	IGHV3-30*01	IGHJ4*02	IGHD2/OR15-2a*01,IGHD2/OR15-2b*01	nan	nan	nan	nan	nan	GFTFGSYD	ISYDGSDR	ARTYESYSFDY	MK311778.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
7	R95-1C10	GAGGTGCAGCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCGTGTGCAACGTCTGGATTCACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTTTGTCATATGATGGAGTTGATAAATACGCAGACTCCGTGAAGGGCCGCTTCACCATCTCCAGAGAGAGGCCCAAGAACACCCTGTTTTTGCAAATGAAAAGCCTGAAACCTGAGGACACGGCTGTCTATTTCTGTGCGAGAGTTCTTGAGTCGTACTCCTTTGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAC	EVQLVESGGDVVQPGGSLRLSCATSGFTFSSYGMHWVRQAPGKGLEWVAFLSYDGVDKYADSVKGRFTISRERPKNTLFLQMKSLKPEDTAVYFCARVLESYSFDYWGQGTLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGCGATGTTGGGAGATATAACCTTGTCTCCTGGTTTCAACAACACCCAGGCAAAGCCCCCAAACTCATGATTTATGAGGACAATGAGCGGCCCTCAGGGGTTTCTAGTCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTATTGCTGCTCATATGCAGGTAGTGACACTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG	QSALTQPASESGSPGQSITISCTGTSSDVGRYNLVSWFQQHPGKAPKLMIYEDNERPSGVSSRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSDTWVFGGGTKLTVL	IGHV3-30*19	IGHJ4*02	nan	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ3*02	SSDVGRYNL	EDN	CSYAGSDTWV	GFTFSSYG	LSYDGVDK	ARVLESYSFDY	MK311794.1	MK312128.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	16.0
7	R95-1A06	GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGTAGCCTCTGGATTCACCTTCGGTAGTTATGGTTTCCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTAGAGTGGGTGGCATTTATATCATATGATGGAAGTGAGAAAAACTACGCAGAGTCCGTGAAGGGCCGCTTCTCCATCTCCAGAGACAATTCCAAGAAAACGTTGTATTTGCAAATGAACAGCCTGAGACCTGAGGACACGGCTGTCTATTACTGTGCGAGAATCTACGTTTCGTATTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCVASGFTFGSYGFHWVRQAPGKGLEWVAFISYDGSEKNYAESVKGRFSISRDNSKKTLYLQMNSLRPEDTAVYYCARIYVSYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*01	IGHJ4*02	IGHD3-16*01,IGHD3-16*02	nan	nan	nan	nan	nan	GFTFGSYG	ISYDGSEK	ARIYVSYYFDY	MK311777.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
7	K77-1F08	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCCTGAGACTCTCCTGTGCAACCTCTGGATTCACCTTCGGTAGTTATGGTATCCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCTTTTATATCATATGATGGAGATAATAAATACTACGCAGACTCCGTGAAGGGCCGCTTCATCATCTCCAGAGACACTTCCAAGAACACACTGTTTCTGCAAATGAACAGCCTGAGAACTGAAGACACGGCTGTGTATTATTGTGCGAGAACATATCTCTCCTACTACTTTGACTACTGGGGCCAGGGAACCCTGCTCATCGTCTTCTCAG	EVQLVESGGGVVQPGKSLRLSCATSGFTFGSYGIHWVRQAPGKGLEWVAFISYDGDNKYYADSVKGRFIISRDTSKNTLFLQMNSLRTEDTAVYYCARTYLSYYFDYWGQGTLLIVFS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAGCCAGCAGTGATATTGGGACTTATGACCTTGTCTCCTGGTACCAATACCACCCAGGCAAAGCCCCCAAACTCATCATTTTTGAGGTCACTGAGCGGCCCTCAGGGATTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAGTACGGCGTCCCTGACTATCTCTGGGCTCCAGGTTGAGGACGAGGCTGATTATTACTGCTGCTCATATGCACCTGGTAGCACTTCCTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAC	QSALTQPASVSGSPGQSITISCTGASSDIGTYDLVSWYQYHPGKAPKLIIFEVTERPSGISNRFSGSKSGSTASLTISGLQVEDEADYYCCSYAPGSTSWVFGGGTKLTVL	IGHV3-30*04,IGHV3-30-3*03	IGHJ4*02	IGHD2-21*01,IGHD2-21*02	IGLV2-23*02	IGLJ3*02	SSDIGTYDL	EVT	CSYAPGSTSWV	GFTFGSYG	ISYDGDNK	ARTYLSYYFDY	MK311423.1	MK312027.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-2H10	GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTCAGACTCTCCTGTGCAGCGTCTGGCTTCACCTTCAGTAGTTATGGCTTCCACTGGGTCCGCCAGGCTCCCGGCAGGGGGCTGGAGTGGGTGGCTTTTATATCATATGATGGGAGTGAGAAATTATACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAAATCCAAGAACACCCTGTATCTGCAAATGAACAGCCTGAGACCTGCGGACACGGCTGTATATTACTGTGCGAGAACATATGTCTCCTATTACATTGATTATTGGGGCCAGGGAAGTCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGFHWVRQAPGRGLEWVAFISYDGSEKLYADSVKGRFTISRDKSKNTLYLQMNSLRPADTAVYYCARTYVSYYIDYWGQGSLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTAATGTTGGGAATTATAACCTTGTCTCCTGGTACCAACAGCTCCCAGGCAAGGCCCCCAAACTCGTGATTTATGAGGTTACTGAGCGGCCCTCAGGGATTTCTCATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGCTTATTACTGCTGCTCATATGTTCCTGAACCCACTTCCTGGGTCTTCGGCGGAGGGACCAAATTGACCGTCCTAA	QSALTQPASVSGSPGQSITISCTGTSSNVGNYNLVSWYQQLPGKAPKLVIYEVTERPSGISHRFSGSKSGNTASLTISGLQAEDEAAYYCCSYVPEPTSWVFGGGTKLTVL	IGHV3-30*19	IGHJ4*02	IGHD2-21*01,IGHD2-21*02,IGHD3-10*02	IGLV2-23*02	IGLJ3*02	SSNVGNYNL	EVT	CSYVPEPTSWV	GFTFSSYG	ISYDGSEK	ARTYVSYYIDY	MK311424.1	MK312028.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-1H05	CAGGTGCACCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGATGTCCCTTAGACTCTCCTGTGCAACCTCCGGATTCACCTTCAGAAGCTACTCTATGCACTGGGTCCGCCAGGCTCCCGGCAAGGGGCTGGAGTGGGTGGCATTTATATCAGATGATGGACGTGATACATACTACGCAGACTCCGTGAAGGGCCGATTCACCCTCTCCAGAGACACTTCCAGGAGCACCCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTCTTTATTACTGTGCGAGAACACATCTCTCCTACAACTTTGACTACTGGGGCCAGGGAACCCTGGTCATTGTCTCCTCAG	QVHLVESGGGVVQPGMSLRLSCATSGFTFRSYSMHWVRQAPGKGLEWVAFISDDGRDTYYADSVKGRFTLSRDTSRSTLYLQMNSLRAEDTALYYCARTHLSYNFDYWGQGTLVIVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGTTCTGGAACCCATAGTGATGTTGGGAATTATCACCTTGTCTCCTGGTACCAACAACACCCCGGCAAAGCCCCCAAACTCATTATTTATGAAGTCACTGAGCGGCCCTCAGGCGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGCCTCCAGACTGAGGACGAGGCTGATTATTACTGCTGCTCCTATGCACCTACTAGGAACTCCTGGGTGTTCGGCGGAGGGACCGAGTTGACCGTCCTAG	QSALTQPASVSGSPGQSITISCSGTHSDVGNYHLVSWYQQHPGKAPKLIIYEVTERPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAPTRNSWVFGGGTELTVL	IGHV3-30*04,IGHV3-30-3*03	IGHJ4*02	IGHD4-11*01,IGHD4-4*01,IGHD5-24*01	IGLV2-23*02	IGLJ3*02	HSDVGNYHL	EVT	CSYAPTRNSWV	GFTFRSYS	ISDDGRDT	ARTHLSYNFDY	MK311422.1	MK312026.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Head	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-2B04	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTCGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCTTTTATTTCATATGATGGAAGTGATAAAAACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCAAGAGACAAGTCCAAGAACACACTGCATCTACAAATGGACATCCTGAGAACTGAGGACACGGCTGTGTATTTCTGTGCGAGAGGCTTCGACTCATACTACTTTGACTACTGGGGCCAGGGAACGTTGGTCACCGTCTCATCTG	EVQLVESGGGVVQPRRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFISYDGSDKNYADSVKGRFTISRDKSKNTLHLQMDILRTEDTAVYFCARGFDSYYFDYWGQGTLVTVS	nan	nan	IGHV3-30*03,IGHV3-30*19	IGHJ4*02	nan	nan	nan	nan	nan	nan	GFTFSSYG	ISYDGSDK	ARGFDSYYFDY	MK311417.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	nan
7	K77-1A02	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTTTCCTGTGGAGCCTCTGGATTCACCTTCAGTAGCTATGGTCTGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTCGCATTTATATCATATGATGGAAGTGATAAGGTCTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAAATCCAAGAACACACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTTCTGTGCGAGAGGATTTCAATCGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCGASGFTFSSYGLHWVRQAPGKGLEWVAFISYDGSDKVYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYFCARGFQSYYFDYWGQGTLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCGCTGGAACCGACAGTGATGTTGGGCGTTATGACCTTGTCTCCTACTACCAACAGCGCCCAGGCAAAGCCCCCAAACTCATCATTTATGAGGTCACTGAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCTGCTCATATGCAGGTGACAACACTTGGGTGTTCGGCGGAGGGACCAGGGTGACCGTCCTAG	QSALTQPASVSGSPGQSITISCAGTDSDVGRYDLVSYYQQRPGKAPKLIIYEVTERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDNTWVFGGGTRVTVL	IGHV3-30*04,IGHV3-30-3*03	IGHJ4*02	IGHD3-16*02,IGHD3-3*01,IGHD3/OR15-3a*01	IGLV2-23*02	IGLJ3*02	DSDVGRYDL	EVT	CSYAGDNTWV	GFTFSSYG	ISYDGSDK	ARGFQSYYFDY	MK311418.1	MK312023.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-2G07	GAGGTGCAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCGGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATGACAGAAGTGATAAAACCTACGGAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACTCCAAGAACACGTTGTATCTACAGATGAATAGCCTGAGATCTGAGGACACGGCTGTTTATTACTGTGCGAGAACGTTCGATTCGTACTACATTGACTACTGGGGCCGGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGTSLRLSCAASGFTFGSYGMHWVRQAPGKGLEWVAFISYDRSDKTYGDSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARTFDSYYIDYWGRGTLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGATCCAGCAATGATGTTGGGCGTTATGACCTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATTTATGAGGTCAGTGAGCGGCCCTCGGGGGTTTCTAATCGCTTCTCTGCCTCCAAGTCTGACAACACGGCCTCCCTGAGAATCTCTGGGCTCCAGGCTGAGGACGAGTCTGAATATTACTGCTGCTCATATGCAGGTAGCGACACTTGGGTGTTCGGCGGAGGGACCAAACTGACTGCCATAG	QSALTQPASVSGSPGQSITISCTGSSNDVGRYDLVSWYQQHPGKAPKLMIYEVSERPSGVSNRFSASKSDNTASLRISGLQAEDESEYYCCSYAGSDTWVFGGGTKLT	IGHV3-30*19	IGHJ4*02	IGHD3-10*01,IGHD3-10*02,IGHD3-16*01	IGLV2-23*02	IGLJ3*02	SNDVGRYDL	EVS	CSYAGSDTWV	GFTFGSYG	ISYDRSDK	ARTFDSYYIDY	MK311419.1	MK312024.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-1F02	CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGCAGCTATGGTTTGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATGATGGAAGTGAGAAGAATTATGCAGACTCCGTGAAGGGCCGATTCACCGTCTCCCGAGACAAGTCCAAGAACACACTGTATCTGCAACTGGACAGCCTGAGAACTGACGACACGGCTGTTTATTACTGTGCGAGAGTTATGGACTCGTACTACTTTGACTACTGGGGCCAGGGAACCTTGGTCACCGTCTCCTCAG	QVHLVESGGGVVQPGRSLRLSCAASGFTFSSYGLHWVRQAPGKGLEWVAFISYDGSEKNYADSVKGRFTVSRDKSKNTLYLQLDSLRTDDTAVYYCARVMDSYYFDYWGQGTLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAGCCAGCAGTAATATTGGGAATTATAACCTTGTCTCCTGGTACCAACACCACCCAGGCAAAGCCCCCAAACTCATGATTTATGAGGTCAGTGAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACTATCTCTGGGCTCCAGACTGAGGACGAGGCTGATTATTACTGCTGCTCATATGCACCTACTAACACTTGGGTGTTCGGCGGAGGGACCCAGCTGACCGTCCTAG	QSALTQPASVSGSPGQSITISCTGASSNIGNYNLVSWYQHHPGKAPKLMIYEVSERPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAPTNTWVFGGGTQLTVL	IGHV3-30*03	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGLV2-23*02	IGLJ3*02	SSNIGNYNL	EVS	CSYAPTNTWV	GFTFSSYG	ISYDGSEK	ARVMDSYYFDY	MK311413.1	MK312019.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-1F05	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCTGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGGAGTTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCGGATGATGGATATGAAAAAGACTACGCAGACAGCACGAAGGGCCGATTCACCATCTCCCGAGAGGACTCCAAGAAAACGCTGTATCTGCAGATGAACAGCCTGAGACCTGAGGACACGGCGACGTATCACTGTGCGAGAGTTATGGACTCATATTACTTTGACTACTGGGGCCAGGGAACCCCGGTCATCGTCTCTTCAG	EVQLVESGGGVVLPGRSLRLSCAASGFTFRSYGMHWVRQAPGKGLEWVAFISDDGYEKDYADSTKGRFTISREDSKKTLYLQMNSLRPEDTATYHCARVMDSYYFDYWGQGTPVIVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGCTCACCATCTCCTGCACTGGAACCAGCGGTGATGTTGGACTTTATAACCTTGTCTCCTGGTACCAACACCACCCAGGCAAAGTCCCCAAACTTCTGATTTATGAGGTCACTGAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGTTCCAAGTCTGGCGACACGGCCTTCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGTTGCTCACATGCACCTCCTGACACTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG	QSALTQPASVSGSPGQSLTISCTGTSGDVGLYNLVSWYQHHPGKVPKLLIYEVTERPSGVSNRFSGSKSGDTAFLTISGLQAEDEADYYCCSHAPPDTWVFGGGTKLTVL	IGHV3-30*19	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGLV2-23*02	IGLJ3*02	SGDVGLYNL	EVT	CSHAPPDTWV	GFTFRSYG	ISDDGYEK	ARVMDSYYFDY	MK311416.1	MK312022.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-2E08	CAGGTGCACCTGGTGGAGTCTGGGGGAGCCGTGGTCCAGCCTGGGAAGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCCGCAGCTATGGTCTACACTGGGTCCGCCAGGCTCCAAACAAGGGGCTGGACTGGGTGGCATTTATTTCAGATGATGGAAATGACAAATATTTTGCAGACTCCGTGAAGGGCCGATTCAGCATCTCCAGAGACAATTCCAAGAAGACAGTGTCTCTGCACATGAACAGCCTGAGAGCTGCGGACACGGCTGTGTATTACTGTGCGAGAGTTATGAACTCGTACTATTTTGACCCTTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVHLVESGGAVVQPGKSLRLSCAASGFTFRSYGLHWVRQAPNKGLDWVAFISDDGNDKYFADSVKGRFSISRDNSKKTVSLHMNSLRAADTAVYYCARVMNSYYFDPWGQGTLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCGTCTCCTGCACTGGATCCAGCAGTGATGTTGAATTTTATAATCTTGTCTCCTGGTACCAGCAGCACCCAGGCAAAGCCCCCAAACTCATTATTTATGAGGTCACTGAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAAGACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCTGCTCATATACAGATACGAACACTTGGGTGTTCGGCGGAGGGACCAAGGTGACTGCTACTC	QSALTQPASVSGSPGQSITVSCTGSSSDVEFYNLVSWYQQHPGKAPKLIIYEVTERPSGVSNRFSGSKSGKTASLTISGLQAEDEADYYCCSYTDTNTWVFGGGTKVT	IGHV3-30*03	IGHJ5*02	IGHD2/OR15-2a*01,IGHD2/OR15-2b*01	IGLV2-23*02	IGLJ3*02	SSDVEFYNL	EVT	CSYTDTNTWV	GFTFRSYG	ISDDGNDK	ARVMNSYYFDP	MK311414.1	MK312020.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
7	K77-2C08	GAAGTGCAGTTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGAGTCTCCTGTACAGCCTCTGGATTCACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATGATGGCAGTGAGAGATATTACGCAGACTCCGTGAGGGGCCGACTCACCATCTCCAGAGACAAATCGAAGAATACATTGTATCTGGACATGAACAGCCTGAGACTTGAGGACACGGCTCTCTATTATTGTGTGAGAGTCATGGACTCCTACTACTTTGACTACTGGGGCCCGGGAACGCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRVSCTASGFTFSSYGMHWVRQAPGKGLEWVAFISYDGSERYYADSVRGRLTISRDKSKNTLYLDMNSLRLEDTALYYCVRVMDSYYFDYWGPGTLVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAGCCAACAGTAATATTGGGAATTATGACCTTGTCTCTTGGTATCAACACCACCCAGGCAAAGCCCCCAAACTCATAATTTTTGAGGTCCGTGAGCGGCCCTCAGGGGTTTCTAATCGGTTCTCTGCCTTCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCTGCTCATATGAGTATGGAGACACTTGGGTGTTCGGCGGAGGGACCAAGGTGACCGTCCTAG	QSALTQPASVSGSPGQSITISCTGANSNIGNYDLVSWYQHHPGKAPKLIIFEVRERPSGVSNRFSAFKSGNTASLTISGLQAEDEADYYCCSYEYGDTWVFGGGTKVTVL	IGHV3-30*03,IGHV3-30*19	IGHJ4*02	IGHD3/OR15-3a*01,IGHD3/OR15-3b*01	IGLV2-23*02	IGLJ3*02	NSNIGNYDL	EVR	CSYEYGDTWV	GFTFSSYG	ISYDGSER	VRVMDSYYFDY	MK311415.1	MK312021.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Head	Melbourne_donor_K77	2015 IIV3 vaccination	nan	16.0
8	315-21-04_1E09	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAGAGTCTCCTGCAAGACTTCGGGAGTCATCTTCAGTAGTTCTGTCATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTACCATTGGTTTGGTAAACTACGCACAGAGGTTCCAGGGCAGAATCGCGATTACCGCGGACAAATCCACGAGCACTGTCTACATGGAGGTGAGCAGCCTGAGACCTGAGGACACGGCCGTCTACTTCTGTGCGAGGTGTGGTTCGGGGAGTGGCTATTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCG	QVQLVQSGAEVKKPGSSVRVSCKTSGVIFSSSVISWVRQAPGQGLEWMGRIIPTIGLVNYAQRFQGRIAITADKSTSTVYMEVSSLRPEDTAVYFCARCGSGSGYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVIFSSSV	IIPTIGLV	ARCGSGSGYYGMDV	MN008903.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-04_1E10	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCGCCTGCAAGACTTCTGGAGTCACCTTCAGCAGTTATGCCATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTACTGTTGGTTTGGTAAACTACGCACAGAGGTTCCAGGGCAGAATCGCGATTACCGCGGACAAACCCACGAGCACAGCCTACATGGAGGTCAGCAGCCTGAGACCTGACGACACGGCCGTGTATTACTGTGCGAGGTGTGGTTCGGGGAGTGGCTATTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCG	QVQLVQSGAEVKKPGSSVKVACKTSGVTFSSYAISWVRQAPGQGLEWMGRIIPTVGLVNYAQRFQGRIAITADKPTSTAYMEVSSLRPDDTAVYYCARCGSGSGYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFSSYA	IIPTVGLV	ARCGSGSGYYGMDV	MN008909.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-06_1C03	CAGGTGCAGCTGGCGCAGTCTGGGGCTGAGCTAAAGAAGCCTGGGTCCTCGGTGAAGGTCGCCTGCAAGACTTCTGGAGTCATCTTCACCAGTTCTGTCATCGCCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTACCATAGATTTGAAAAACTACGCACCGCGCTTCCAGGGCAGAATCGCGATCACCGCGGACAAATCCACGAACACAGTCTACATGGAGGTGATGAGGCTGACACATGAAGACACGGCCGTGTACTTCTGTGCGAGGTGTGGTTCGGGGAGTGGCTATTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCG	QVQLAQSGAELKKPGSSVKVACKTSGVIFTSSVIAWVRQAPGQGLEWMGRIIPTIDLKNYAPRFQGRIAITADKSTNTVYMEVMRLTHEDTAVYFCARCGSGSGYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVIFTSSV	IIPTIDLK	ARCGSGSGYYGMDV	MN008893.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	20A-620-30_1F10	CAGGTGCAGCTGGTGCAGTCTGGGGTTGAGGTGAAGAAGCCGGGGTCCTCGGTGAAAGTCTCCTGCCAGACTTTCGGAGTCACCTTCTGTAGTTCGGTCATGGCCCGGGTGCGACAGGCCCCTGGACAAGGGCGTGAGGGGATGGGAAGGATCATCCCTATTGTTGACTTGGTAAAATACGCACCGAGGTTCCAGGGCAGAATCGCGATTAGCGCGGACAAGGCCACGAGCACAGTGTACATGGAGGTGAGCAGCCTGAGACCTGAGGACACGGCCGTGTATTACTGTGCGAGGTGTGGTTCGGGGAGTTCCTATTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCATCGTCTCCTCG	QVQLVQSGVEVKKPGSSVKVSCQTFGVTFCSSVMARVRQAPGQGREGMGRIIPIVDLVKYAPRFQGRIAISADKATSTVYMEVSSLRPEDTAVYYCARCGSGSSYYGMDVWGQGTTVIVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFCSSV	IIPIVDLV	ARCGSGSSYYGMDV	MN008894.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-05M_1A05	CAGGTGCAGCTGGTCCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTTTCCTGCAAGCCTTCTGGAGTCACCTTCAACAGCTTTGCTATGAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTATCGTTGGTATAGCAAACTACGCACAGAGGTTCCAGGGCAGAATCGCGATTACCGCGGACAAATCTACGAGCACAGTCTACATGGAGTTGAGCAGCCTGAGACCTGAGGACACGGCCGTGTATTACTGTGCGAGGTGCGGTTCGGGGAGTTCCTACTACGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGSSVKVSCKPSGVTFNSFAMSWVRQAPGQGLEWMGRIIPIVGIANYAQRFQGRIAITADKSTSTVYMELSSLRPEDTAVYYCARCGSGSSYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFNSFA	IIPIVGIA	ARCGSGSSYYGMDV	MN008916.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-05M_1D09	CAGGTGCAGCTGGTCCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGCCCTCGGGAGTCACCTTCAGCAGCTATGCTATGAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGCAGGATCATCCCTGTCGTTGGTTTGACAAACTACGCACAGAACTTCCAGGGCAGAATCGCGATCACCGCGGACAAATCCACGAGCACAGTCTACATGGAACTGAGCAGCCTGAGACCTGAGGACACGGCAGTGTATTACTGTGCGAGGTGCGGTTCGGGGAGTTCCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGSSVKVSCKPSGVTFSSYAMSWVRQAPGQGLEWMGRIIPVVGLTNYAQNFQGRIAITADKSTSTVYMELSSLRPEDTAVYYCARCGSGSSYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFSSYA	IIPVVGLT	ARCGSGSSYYGMDV	MN008906.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-05M_1D10	CAGGTCCTGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCGGGGTCCTCGGTGAAGGTCTCCTGCAAGGCCTCTGGATTCACCTTCACCAGTTATGCTTTCAGCTGGGTGCGACAGGTCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTATCGCTGAAATAGTGAACTATGCTCCGAGATTCCAGGGCAAAGTCGCCATTAGCGCGGACAGATCTACGAGCACAGTCTACATGGAGGTGAGCAGCCTGGAGTCTGAGGACACGGCCATGTATTACTGTGCGAGGTGCGGTTCGGGGAGCTCCTACTATGGTATGGACGTCTGGGGCCAAGGGACCACGGTCATCGTCTCCTCA	QVLLVQSGAEVKKPGSSVKVSCKASGFTFTSYAFSWVRQVPGQGLEWMGRIIPIAEIVNYAPRFQGKVAISADRSTSTVYMEVSSLESEDTAMYYCARCGSGSSYYGMDVWGQGTTVIVSS	nan	nan	IGHV1-69*04	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GFTFTSYA	IIPIAEIV	ARCGSGSSYYGMDV	MN008896.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-08_1D09	CAGGTGCAGATGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTCACCAGCTATGCCATGAGCTGGGTGCGACAAGCCCCTGGACAAGGGCTTGAGTGGATGGGGAGGGTCATCCCTATCGCTGGTATAGCAAATTACGCACCGACGTTCCAGGGCAGAATCGCGATTACCGCGGACACATCCACGAGCACAGTGTACATGGAGTTGAGCGGCCTGAGACCTGAGGACTCGGCCGTCTATTTCTGTGCGAGGTGCGGTTCGGGGAGTTCCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQMVQSGAEVKKPGSSVKVSCKASGFTFTSYAMSWVRQAPGQGLEWMGRVIPIAGIANYAPTFQGRIAITADTSTSTVYMELSGLRPEDSAVYFCARCGSGSSYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GFTFTSYA	VIPIAGIA	ARCGSGSSYYGMDV	MN008904.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-06_1G07	CAAGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGTCACCTTCAGCAGCTATGCTATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGCAGGATCATCCCTGTCGCTGACATAGTGAACTACGCACCGACCTTCCCGGGCAGAGTCGCGTTGACCGCGGACAAATCCACGAGCACAGTGTACATGGAGCTGATCGACCTGAGACCTGACGACACGGCCGTCTATTACTGTGCGAGGGGTGGTTCGGGAAGTGGATACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGSSVKVSCKASGVTFSSYAMHWVRQAPGQGLEWMGRIIPVADIVNYAPTFPGRVALTADKSTSTVYMELIDLRPDDTAVYYCARGGSGSGYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*04	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFSSYA	IIPVADIV	ARGGSGSGYYGMDV	MN008902.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-05M_1F06	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAGGACTTCTGGAGTCACCTTCACCAGTTTTGCTATACACTGGGTGCGACAGGCCCCTGGGCAAGGGCTTGAGTGGATGGGAAGGATCATCCCAACCATTGGTCTGACAAACTACGCACCGAGTTTCCAGGGCAGAATCACGATTACCGCGGACAAATCCACGAGTAGTGTCTCCTTGGAGATGACCAGCCTGAGACCTGACGACACGGCCGTGTATTACTGTGCGAGGGGCGGTTCGGGGAGCTCCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGSSVKVSCRTSGVTFTSFAIHWVRQAPGQGLEWMGRIIPTIGLTNYAPSFQGRITITADKSTSSVSLEMTSLRPDDTAVYYCARGGSGSSYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFTSFA	IIPTIGLT	ARGGSGSSYYGMDV	MN008898.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-06_1B04	CAGGCCCAACTGGGGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGCCTTCTGGAGTAACTTTCAACAACTACGCTATACACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATAATACCTGTCGCTGGTCTGACAAACTATGGACTGGGGTTCCAGGGCAGAATCGCGATTACCGCGGACAAATCCACGAACACAGTCTACATGGAGTTGGGCAGCCTGAGACCTGAAGACACGGCCGTCTATTACTGTGCGAGGGGCGGTTCGGGGAGTTCCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACAGTCACCGTCTCCCCA	QAQLGQSGAEVKKPGSSVKVSCKPSGVTFNNYAIHWVRQAPGQGLEWMGRIIPVAGLTNYGLGFQGRIAITADKSTNTVYMELGSLRPEDTAVYYCARGGSGSSYYGMDVWGQGTTVTVS	nan	nan	IGHV1-69*04	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFNNYA	IIPVAGLT	ARGGSGSSYYGMDV	MN008895.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	HMLAH15	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGACCCATGTTCAGCAGATCTGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCCACCGTTGATCTAAAAAATTACGCACAGAAGTTCCAGGGCAGGGTCACCTTTACCGCGGACAAATCTACGGCCACATCCTACATGGAACTGAGGAGTCTGAAATCTGAGGACACGGCCGTCTATTACTGTGCGAGAATGGGGTCCGGTTCGTCTTATTACGGTATGGATGTCTGGGGCCTAGGGACCGCGGTCACCGTGTCCACAG	QVQLVQSGAEVKKPGSSVKVSCKASGPMFSRSAFSWVRQAPGQGLEWMGRIIPTVDLKNYAQKFQGRVTFTADKSTATSYMELRSLKSEDTAVYYCARMGSGSSYYGMDVWGLGTAVTVS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GPMFSRSA	IIPTVDLK	ARMGSGSSYYGMDV	LC388845.1	nan	31462639	Adachi et al. Nat Commun 10:3883 (2019)	Group 2	HA:Stem	Adachi_donors	Humanized mouse with HA immunization	nan	nan
8	20A-620-30_2D06	CAGGTCCTCCTGGTTCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGACTTCTGGAGCCATCTTCACTAGTTCTGTCATCAACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGACCATCCCCACCATTGAATTGGTAAACTACGCACCGAGGTTCCAGGGCAGAATCGCGATTACCGCGGACAAATCCACGAGCACAGTCTACATGGCGGTGAGCAGCCTGAGACCTGAAGACACGGCCGTCTATTACTGTGCGAGGAGTGGTTCGGGGAGTGGCTATTTCGGTATGGACGTTTGGGGCGAAGGGACCACGGTCACCGTCTCCTCGG	QVLLVQSGAEVKKPGSSVKVSCKTSGAIFTSSVINWVRQAPGQGLEWMGRTIPTIELVNYAPRFQGRIAITADKSTSTVYMAVSSLRPEDTAVYYCARSGSGSGYFGMDVWGEGTTVTVSS	nan	nan	IGHV1-69*04	IGHJ6*02,IGHJ6*04	IGHD3-10*01	nan	nan	nan	nan	nan	GAIFTSSV	TIPTIELV	ARSGSGSGYFGMDV	MN008897.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	20A-620-30_1A11	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGACTTCTGCCGTCACCTTCAGCAGTTCTGTCATCAACTGGGTGCGACAGGCCCCTGGACAGGGGCTTGAGTGGATGGGAAGGATCATCCCTGTCGCTGGTTTGGTAAACTACGCACCGAGGTTCCAGGGCAGAATCGCGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGGTGAGCAGCCTGAGACCTGAGGACACGGCCGTGTATTACTGTGCGAGGAGTGGTTCGGGGAGTTCCTATTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCG	QVQLVQSGAEVKKPGSSVKVSCKTSAVTFSSSVINWVRQAPGQGLEWMGRIIPVAGLVNYAPRFQGRIAITADKSTSTAYMEVSSLRPEDTAVYYCARSGSGSSYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*09	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	AVTFSSSV	IIPVAGLV	ARSGSGSSYYGMDV	MN008905.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-21-05M_1D03	CAGGTCCAACTGGGCCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGACTTCGGGAGTCACTTTCAGCAGCTCTGCTTTCCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTATTGCTGGTATAACAAACTACGCGCTGAGCTTACAGGGCAGATTCGCGATTACCGCGGACAAATCCACGAGCACAGTCTACATGGACTTGAGCAGCCTGAGCCCTGAGGACACGGCCGTATATTACTGTGCGAGGAGCGGTTCGGGGAGTTCCTATTACGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLGQSGAEVKKPGSSVKVSCKTSGVTFSSSAFHWVRQAPGQGLEWMGRIIPIAGITNYALSLQGRFAITADKSTSTVYMDLSSLSPEDTAVYYCARSGSGSSYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*04	IGHJ6*02	IGHD3-10*01	nan	nan	nan	nan	nan	GVTFSSSA	IIPIAGIT	ARSGSGSSYYGMDV	MN008901.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
8	315-24-04_1E11	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTCACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACACTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGGTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAGAGGAGGGAGCGGTCGCTATTACTACGGAATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQPPGKGLEWIGYIYYTGSTNYNPSLKSRVTISVDTSKNQFSLKVSSVTAADTAVYYCARGGSGRYYYGMDVWGQGTTVTVSS	nan	nan	IGHV4-59*11	IGHJ6*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSHY	IYYTGST	ARGGSGRYYYGMDV	MN009305.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
9	W85-1H10	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAATGTGTCTGGTGGCTCCATAAGTAATAGTGGTTACTATTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGACTATCTATTATAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATTAGCAGACACGTCTAAGAACCAGTTCTCCCTGACGCTGAGCTCTGTGACCGCCGCAGACACGGCTATATATTACTGTGCGAGACGTGCAAGTAGTGGGAGTTACTACGAATACTTCCATCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQVQESGPGLVKPSETLSLTCNVSGGSISNSGYYWGWIRQPPGKGLEWIGTIYYSGSTYYNPSLKSRVTILADTSKNQFSLTLSSVTAADTAIYYCARRASSGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTGATGGATACAACTATTTGGATTGGTACCTGCAGAGGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGCTCTATTCGGGCCTCCGGGGTCTCTGATAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTATTGTATGCAAGCTCTACAAACTCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSDGYNYLDWYLQRPGQSPQLLIYLGSIRASGVSDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSDGYNY	LGS	MQALQTPFT	GGSISNSGYY	IYYSGST	ARRASSGSYYEYFHH	MK311700.1	MK311952.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-2G03	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAATGTGTCTGGTGCCTCCATCAGCAATAGTGGTTACTACTGGGGCTGGATCCGCCAGCCCCCCGGGAAGGGGCTGGAATGGATTGGGACAATCTATTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATTAGCAGACACGTCCAAGAACCAGTTCTCCCTGACGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTCTATTACTGTGCGAGACGTGCAACTAGTGGGAGTTACTACGAATACTTCCATCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQVQESGPGLVKPSETLSLTCNVSGASISNSGYYWGWIRQPPGKGLEWIGTIYYSGSTYYNPSLKSRVTILADTSKNQFSLTLSSVTAADTAVYYCARRATSGSYYEYFHHWGQGTLVTVSS	nan	nan	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	nan	nan	nan	nan	nan	GASISNSGYY	IYYSGST	ARRATSGSYYEYFHH	MK311701.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	nan
9	W85-3C10	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACGTGCAATGTCTCTGGTGGCTCCATCAGAAGTAGTAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTACGATAGTGGGAACACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATCTATGTAGACACGTCCAAGAACCAGTTCTTCCTGAACCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTATTGTGCGAGACGTCCAATTAGTGGGAGCTACTATGAATACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQVQESGPGLVKPSETLSLTCNVSGGSIRSSSYYWGWIRQPPGKGLEWIGSIYDSGNTYYNPSLKSRVTIYVDTSKNQFFLNLSSVTAADTAVYYCARRPISGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAACCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATTAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAAATCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQNPFTFGPGTKVDIK	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSNGYNY	LGS	MQALQNPFT	GGSIRSSSYY	IYDSGNT	ARRPISGSYYEYFHH	MK311702.1	MK311953.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-1D02	CAGGTGCAGCTGCAGGTGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAATGTGTCTGGTGGCTCCATCAGCAGTAGTGGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTCCAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGGCACCATATACATAGACACGTCGAAGAACCAGTTTTCACTGAAGCTGACCTCTGTGACCGCCGCAGACACGGCTGTATATTACTGTGCGAGACGTCCAAGTAGTGGGAGCTACTACGACTACTTCCATCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQLQVSGPGLVKPSETLSLTCNVSGGSISSSGYYWGWIRQPPGKGLEWIGSIYSSGSTYYNPSLKSRGTIYIDTSKNQFSLKLTSVTAADTAVYYCARRPSSGSYYDYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGTCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATATGGGTTCTAATCGGGCCTCCGGGGCCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATATTGGGGTTTATTACTGCATGCAAGCTCTAGAAACTCCATTCACTTTCGGCCCTGGGACCAAAGTGGATGTCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYMGSNRASGAPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQALETPFTFGPGTKVDVK	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSNGYNY	MGS	MQALETPFT	GGSISSSGYY	IYSSGST	ARRPSSGSYYDYFHH	MK311703.1	MK311954.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	R95-2H12	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCACTCCTCTGCAATGTCTCTGGTGCCTCCATCAGCAATAGTGGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTCTCTATCACAGTGGGAACACCTTCTACAACCCGTCCCTCAAGAGTCGGGTCACCATATCCGTGGACAGGTCCATGAATCAATTCTCCCTGAGGGTGAGGTCTGTGACCGTCGCAGACACGGCTGTGTATTACTGTGCGAGGCGCCCCTACAGTGGGAGTTACTATGAATATTTCCACCATTGGGGCCAGGGCACCCTGGTAACCGTCTCTTCAG	QVQVQESGPGLVKPSETLSLLCNVSGASISNSGYYWGWIRQPPGKGLEWIGSLYHSGNTFYNPSLKSRVTISVDRSMNQFSLRVRSVTVADTAVYYCARRPYSGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCCAGTCAGAGCCTCCTGCATAGTAATGCACACAATTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATCTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAAGTCCTCACACTTTTGGCCAGGGGACCAAGCTAGAGATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNAHNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQSPHTFGQGTKLEIK	IGHV4-39*01,IGHV4-39*02	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ2*01	QSLLHSNAHNY	LGS	MQALQSPHT	GASISNSGYY	LYHSGNT	ARRPYSGSYYEYFHH	MK311848.1	MK311996.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	13.0
9	W85-2E05	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGACCCTCACCTGCTCCGTCTCTGGTGGCTCCATTAGAAGTAGCGCTTACTTCTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGATGGAATGGATTGGGATTATTTATGATGGTGGGAGCACCTCCTACAACCCGTCCCTCAAGAGTCGAGTCTCCATATTCGTAGACACGTCCAGGAATGAGTTCGCCCTGAGGCTGAGCTCTGTGACCGCCGCAGACACGGCTATGTATTACTGTGCGAGACGTTCAAGTAGTGGGAGTTACTACGAATACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCGCCTCAC	QVQVQESGPGLVKPSETLTLTCSVSGGSIRSSAYFWGWIRQPPGKGMEWIGIIYDGGSTSYNPSLKSRVSIFVDTSRNEFALRLSSVTAADTAMYYCARRSSSGSYYEYFHHWGQGTLVTVAS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCAGAATAATGGATACAACTATTTGGATTGGTACCTGCAGAGGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTATATTGACAATCACCAGAGTGGAGGCTGAAGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCATTCACTTTCGGCCCTGGGACCAAAGTGCATATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLQNNGYNYLDWYLQRPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFILTITRVEAEDVGVYYCMQALQTPFTFGPGTKVHIK	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLQNNGYNY	LGS	MQALQTPFT	GGSIRSSAYF	IYDGGST	ARRSSSGSYYEYFHH	MK311704.1	MK311955.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-2A05	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACCGTCTCTGGTGGCTCCATCAGAAGTCCAAGTTACTTCTGGGGCTGGATCCGCCAGTCCCCAGGGAAGGGGCTGGAGTGGATTGGGATTATTTATGATGGTGGGCGCACCGATTATAACCCGTCCCTCGAGAGTCGAGTCTCCATTTACGTAGACACATCCAAGAACCAGGTCTCCCTGAGTCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGAGACGTACCAGTGGTGGAAGTTACTACGAATACTTCCACCACTGGGGCCCGGGCACACTGGTCACCGTCTCCGCAG	QVQVQESGPGLVKPSETLSLTCTVSGGSIRSPSYFWGWIRQSPGKGLEWIGIIYDGGRTDYNPSLESRVSIYVDTSKNQVSLSLSSVTAADTAVYYCARRTSGGSYYEYFHHWGPGTLVTVSA	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGCATACACCTATTTGGATTGGTACCTGCAGAAGCCAGGGCACTCTCCACAGCTCCTGATCTATCTGGGTTCTATTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGCTCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGTTTTATTACTGCATGCAAGCTCTACACACTCCATTCACTTTCGGCCCTGGGACCAAAGTGGAGATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNAYTYLDWYLQKPGHSPQLLIYLGSIRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALHTPFTFGPGTKVEIK	IGHV4-39*01	IGHJ1*01	IGHD2-15*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSNAYTY	LGS	MQALHTPFT	GGSIRSPSYF	IYDGGRT	ARRTSGGSYYEYFHH	MK311705.1	MK311956.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-1A08	CAGGTGCAGCTGCAGGCGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGTAATGTCTCTGGTGGCTCCATCAGGAGTAGTGCTTACTTCTGGGGCTGGATCCGCCAGTCCCCAGGGAAGGGGCTGCAGTGGATTGGGACGATTTATGATAGTGGGAGTACCGACTACAACCCGTCCCTCAAGAGTCGAGTCACAATCTCCGTCGACGTGTCCAAGAACCAGTTCTCCCTGAGGCTGAGGTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGCGACGCACAAGTAGTGGGAGCTACTACGAGTATTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCTG	QVQLQASGPGLVKPSETLSLTCNVSGGSIRSSAYFWGWIRQSPGKGLQWIGTIYDSGSTDYNPSLKSRVTISVDVSKNQFSLRLRSVTAADTAVYYCARRTSSGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGCCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTATCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTTTTTGGGTTCTGTTCGGGCCTCCGCGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGCAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTACTACTGCATGCAAGCTCTACAAAGTCCGTTCACTTTCGGCCCTGGGACCACACTGGATGTCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIFLGSVRASAVPDRFSGSGSGTDFTLQISRVEAEDVGVYYCMQALQSPFTFGPGTTLDVK	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSNGYNY	LGS	MQALQSPFT	GGSIRSSAYF	IYDSGST	ARRTSSGSYYEYFHH	MK311706.1	MK311957.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-2H01	CAGGTGCAGATGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGTAATGTCTCTGGTGCCTCCATCAGCAGTAGTGCTTACTTCTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTGTTTATGATAGTGGGAGCACCGACTACAACCCGTCCCTCAAGAGTCGAGTCATAATCTCCGTCGACATGTCCAAGAACCAGTTCTCCCTGAGGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGAGACGCACAAGTAGTGGGAGCTACTACGAATATTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCTG	QVQMQESGPGLVKPSETLSLTCNVSGASISSSAYFWGWIRQPPGKGLEWIGSVYDSGSTDYNPSLKSRVIISVDMSKNQFSLRLSSVTAADTAVYYCARRTSSGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGCCAGAGCCTCATGCATGAAAATGCATACAATTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTGTTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTACTACTGCATGCAAGCTCTACAAAGTCCGTTCACTTTCGGCCCTGGGACCAAAGTGCATGTCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLMHENAYNYLDWYLQKPGQSPQLLIYLGSVRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQSPFTFGPGTKVHVK	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLMHENAYNY	LGS	MQALQSPFT	GASISSSAYF	VYDSGST	ARRTSSGSYYEYFHH	MK311707.1	MK311958.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-3A12	CAGGTGCAGCTGCAGGCGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGTCATGTCTCTGGTGGCTCCATCAGCAGTAGTGCATACTTCTGGGGCTGGATCCGCCAGTCCCCAGGGAAGGGGCTGGAGTGGATTGGGACTGTTTATCATGGTGGGAGCACCGACTACAACCCGTCCCTCAAGAGTCGAGTCATAATCTCCGTCGACATGTCCAAGAACCAGTTCTCCCTGAGCCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGAGACGCACAAGTAGTGGGAGTTATTACGAATATTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCTG	QVQLQASGPGLVKPSETLSLTCHVSGGSISSSAYFWGWIRQSPGKGLEWIGTVYHGGSTDYNPSLKSRVIISVDMSKNQFSLSLSSVTAADTAVYYCARRTSSGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCCTCTCCTGCAGGTCTAGCCAGAGCCTCCTGCATAGTAATGGATACACCTTTTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTATTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTACTACTGCATGCAAGCTCTACAAAGTCCGTTCACTTTCGGCCCTGGGACCAAAGTGGATGTCAAAC	DIVMTQSPLSLPVTPGEPASLSCRSSQSLLHSNGYTFLDWYLQKPGQSPQLLIYLGSIRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQSPFTFGPGTKVDVK	IGHV4-39*01	IGHJ1*01	IGHD3-10*01,IGHD3-10*02	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSNGYTF	LGS	MQALQSPFT	GGSISSSAYF	VYHGGST	ARRTSSGSYYEYFHH	MK311708.1	MK311959.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-2D12	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAATGTCTCTGGTGGCTCCATCAGCAGTAGTGCTTACTTCTGGGGCTGGGTCCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGAAGTCTCTATTATCCTGGGAGCACCTCCTACAACCCGTCCCTCAAGAGTCGAGTAGCCATATTCGTAGACGCGTCCAAAAACCTCCTCTTCCTGAGGCTGACCTCTGTGACCGCCGCAGACACGGCTGTCTATTATTGTGCGCGACGTCCAACTACTGGGAGCTACTACGAATACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSETLSLTCNVSGGSISSSAYFWGWVRQPPGKGLEWIGSLYYPGSTSYNPSLKSRVAIFVDASKNLLFLRLTSVTAADTAVYYCARRPTTGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCACAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTCATCTATTTGGGCTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGACGATGTTGGGGTTTATTACTGCATGCATGCTCTACAAAGTCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEADDVGVYYCMHALQSPFTFGPGTKVDIK	IGHV4-39*02	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSNGYNY	LGS	MHALQSPFT	GGSISSSAYF	LYYPGST	ARRPTTGSYYEYFHH	MK311710.1	MK311961.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-2E10	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAATGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTTCTGGGGCTGGATCCGGCAGCCCCCAGGGGAGGGGCTGGAGTGGATTGGGACTATCTATAATTCCGGGAGCACTTATTACAGCCCGTCCCTCCAGAGTCGACTAGCCATATTCGTTGACACGTCGAAGAACCTCCTCTTCCTGAGGCTGACCTCTGTAACCGCCGCAGACACGGCTGTCTATTATTGTGCGCGACGTCCAACTACTGGGAGCTACTACGAATACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSETLSLTCNVSGGSISSSSYFWGWIRQPPGEGLEWIGTIYNSGSTYYSPSLQSRLAIFVDTSKNLLFLRLTSVTAADTAVYYCARRPTTGSYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGGGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAGTGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTCATCTATTTGGGCTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCACTGGATCAGGCACAGATTTTTCACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCATTCACTTTCGGCCCTGGGACCAAACTGGATATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSSGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGTGSGTDFSLKISRVEAEDVGVYYCMQALQTPFTFGPGTKLDIK	IGHV4-39*02	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSSGYNY	LGS	MQALQTPFT	GGSISSSSYF	IYNSGST	ARRPTTGSYYEYFHH	MK311711.1	MK311962.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-3G02	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAATGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTTCTGGGGCTGGATCCGGCAGTCCCCAGGGAAGGGGCTGGAGTGGATTGGGACTATCTATTATAGTGGGAGCACCCACTACAATCCGTCCCTCAGGAGTCGAGTAGGCATATTCGTAGACACGTCGAAGAACCTCCTCTTCCTGAGACTGACCTCTGTGACCGCCACAGACACGGCTGTCTATTATTGTGCGCGACGTCCAACTACTGGGAGCTACTACGAATACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSETLSLTCNVSGGSISSSSYFWGWIRQSPGKGLEWIGTIYYSGSTHYNPSLRSRVGIFVDTSKNLLFLRLTSVTATDTAVYYCARRPTTGSYYEYFHHWGQGTLVTVSS	nan	nan	IGHV4-39*02	IGHJ1*01	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSSSYF	IYYSGST	ARRPTTGSYYEYFHH	MK311712.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	nan
9	W85-3G03	CAGGTGCAGCTGCAGGTGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCCTCTGCAATGTCTCTGGAGGCTCCATCAGTAGTAGCAGTTACTTCTGGGGCTGGATCCGCCACCCCCCAGGGAAGGGGCTGGAGTGGATTGGGATTATCTATTCCAGTGGCAGCACCGATTACAACCCGTCCCTCCAGAGTCGAGTCACCATGTCCGTTGACACCTACAACAATCACTTCTCCCTGAACCTGAGGTCTGTGACCGCCGCAGACACGGCTGTCTACTACTGTGCGAGACGTACAAGTGGTGGGAACTACTACGAATACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVQLQVSGPGLVKPSETLSLLCNVSGGSISSSSYFWGWIRHPPGKGLEWIGIIYSSGSTDYNPSLQSRVTMSVDTYNNHFSLNLRSVTAADTAVYYCARRTSGGNYYEYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCGGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCTTCAATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTGTTCGGGCCTCCGGTGTCCCTGACAGGTTCAGTGGCAGCGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTCGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLFNSNGYNYLDWYLQKPGQSPQLLIYLGSVRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK	IGHV4-39*02	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLFNSNGYNY	LGS	MQALQTPFT	GGSISSSSYF	IYSSGST	ARRTSGGNYYEYFHH	MK311713.1	MK311963.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Head	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-1G11	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAATGTGTCTGGTGGCTCCATCAGCAGTAGTGCTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAATGGATTGGGACTCTCTATTACAGTGGGAGCACCCACTACAACCCGTCCCTCAAGAGTCGCGTCACCATTTTAGCAGACACGTCCAAGAACCACTTGTCCCTGACGCTGAGCTCCGTGACCGCCGCAGACACGGCTGTATATTACTGTTCGAGACGTACAGATAGTGGAAGTTACTACGATTACTTCCATCACTGGGGCCCGGGCACCCTGGTCACCGTCTCCTCAG	QVQVQESGPGLVKPSETLSLTCNVSGGSISSSAYYWGWIRQPPGKGLEWIGTLYYSGSTHYNPSLKSRVTILADTSKNHLSLTLSSVTAADTAVYYCSRRTDSGSYYDYFHHWGPGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGTAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATATGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYMGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK	IGHV4-39*02	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLHSNGYNY	MGS	MQALQTPFT	GGSISSSAYY	LYYSGST	SRRTDSGSYYDYFHH	MK311714.1	MK311964.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
9	W85-1F03	CAGGTGCAGGTGCAGGAGTCGGGCCCAGGACTGGTAAAGCCTTCGGAGACCCTGTCCCTCACCTGCACCGTCTCTGGTGCCTCCATCAGAAGTAGTGGTTACTTCTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGATTATTTATGATAGTGGGAGCACCGACTACAACCCGTCCCTCAAGAGTCGAGTCTCCATATTCGTGGACACGTCCAGGAACGAACTCGCCCTGAGCCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTACGAGACGTACAAGTAGTGGGAGTTACTACGACTACTTCCACCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAC	QVQVQESGPGLVKPSETLSLTCTVSGASIRSSGYFWGWIRQPPGKGLEWIGIIYDSGSTDYNPSLKSRVSIFVDTSRNELALSLSSVTAADTAVYYCTRRTSSGSYYDYFHHWGQGTLVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCAGAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGACAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCTTTCACTTTCGGCCCTGGGACCAAAGTGGATGTCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLLQSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLTISRVEAEDVGVYYCMQALQTPFTFGPGTKVDVK	IGHV4-39*01	IGHJ1*01	IGHD1-26*01	IGKV2-28*01,IGKV2D-28*01	IGKJ3*01	QSLLQSNGYNY	LGS	MQALQTPFT	GASIRSSGYF	IYDSGST	TRRTSSGSYYDYFHH	MK311709.1	MK311960.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	13.0
10	315-54-04_1F03	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCGCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATATTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGGATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGATTTTTACTCTGATAGTAGTGGTTATTACTACCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLDLQMNSLRAEDTAVYYCAKDFYSDSSGYYYLDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSSYG	ISYDGSNK	AKDFYSDSSGYYYLDY	MN010155.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
10	315-24-06_1C01	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGTGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTACGATGGAACTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAAAGATTTGCTTTCTGATAGTAGTGGTTATTACTACCTTGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAVSGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGTNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLLSDSSGYYYLDYWGQGTLVTVSS	nan	nan	IGHV3-33*06	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSSYG	IWYDGTNK	AKDLLSDSSGYYYLDY	MN009229.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
10	315-24-06_1G03	GAGGTGCAGCTGGTGGACTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGTGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTACGATGGAAGTATTAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAAAGATTTGCTTTCTGATAGTAGTGGTTATTACTACCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVDSGGGVVQPGRSLRLSCAVSGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLLSDSSGYYYLDYWGQGTLVTVSS	nan	nan	IGHV3-33*06	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSSYG	IWYDGSIK	AKDLLSDSSGYYYLDY	MN009230.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
10	315-54-04_1B03	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCACTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTCACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAGTAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTCTCTGCAAATGAACACCCTGAGAGCTGAGGACACGGCTGTGTATTATTGTGCGAAAGAGTTTTACCATGATAGTAGTGGTTATTATTACCTTGACCAGTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAASGFTFSHYGMHWVRQAPGKGLEWVAVISYDGSSKYYADSVKGRFTISRDNSKNTLSLQMNTLRAEDTAVYYCAKEFYHDSSGYYYLDQWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSHYG	ISYDGSSK	AKEFYHDSSGYYYLDQ	MN010151.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
10	315-54-05M_1C03	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGAAGTTATGGCGTGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCAGTAATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGGATCTGCAAATGAACAGCCTGAGAACTGAGGACACGGCTGTATATTTCTGTGCGAAGGAGTTCTACTTGGATAGTAGTGGTTATTACTTCCTAGATCACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYGVHWVRQAPGKGLEWMAVISYDGSNKYYADSVKGRFTISRDNSKNTLDLQMNSLRTEDTAVYFCAKEFYLDSSGYYFLDHWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFRSYG	ISYDGSNK	AKEFYLDSSGYYFLDH	MN010159.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
10	315-54-04_1G08	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGATTCCGTGAAGGGCCGATTCACCATCTCCCGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACACCCTGAGAGCTGAGGACACGGCTTTGTATTACTGTGCGAAAGAACTGTTCGGGGATAGTAGTGGTTACCAGTACTTTGACTACTGGGGCCAAGGAGCCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNTLRAEDTALYYCAKELFGDSSGYQYFDYWGQGALVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*01	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSSFG	ISYDGSNK	AKELFGDSSGYQYFDY	MN010152.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
10	315-21-06_1E02	CAGGTGCAGCTGGTGGACTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATCACTGTGCGAAAGAACTATTGGAAGATAGTAGTGGTTATTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVDSGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWMAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCAKELLEDSSGYYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSTYG	ISYDGSNK	AKELLEDSSGYYYFDY	MN008975.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
10	315_21Mem_1B01	CTGGTGCAGCTGGTGGACTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATCACTGTGCGAAAGAACTATTGGAAGATAGTAGTGGTTATTATTACTTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCTG	LVQLVDSGGGVVQPGRSLRLSCAVSGFTFSRYGMHWVRQAPGKGLEWMAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCAKELLEDSSGYYYFDSWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSRYG	ISYDGSNK	AKELLEDSSGYYYFDS	MN008972.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
10	315_21Mem_1B08	CAGGTGCAGCTGGTGGACTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATCACTGTGCGAAAGAACTATTGGAAGATAGTAGTGGTTATTATTACTTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCTG	QVQLVDSGGGVVQPGRSLRLSCAVSGFTFSRYGMHWVRQAPGKGLEWMAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCAKELLEDSSGYYYFDSWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSRYG	ISYDGSNK	AKELLEDSSGYYYFDS	MN008973.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
10	315-21-05M_1H01	CAGGTGCAGCTGGTGGACTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTAGATATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGATGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATCACTGTGCGAAAGAACTATTGGAAGATAGTAGTGGTTATTATTACTTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCTG	QVQLVDSGGGVVQPGRSLRLSCAVSGFTFSRYGMHWVRQAPGKGLEWMAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCAKELLEDSSGYYYFDSWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSRYG	ISYDGSNK	AKELLEDSSGYYYFDS	MN008974.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
10	315-06-08_1C12	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGTTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCCTCAGTGTCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCAAATGATGGAGATAATGAATATTATGCAGACTCCGTGAAGGGCCGATTCACCACCTCCAGAGACAATTCCAAGAACATGTTGTATCTGCAAATGAACAGCCTGAGACCTGAGGACACGGCTCTGTATTACTGTGCGAAAGAACTCTACGCCGCGAGCAGTGGCTATTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGGSLRLSCAASGFTLSVYGMHWVRQAPGKGLEWVAVISNDGDNEYYADSVKGRFTTSRDNSKNMLYLQMNSLRPEDTALYYCAKELYAASSGYYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFTLSVYG	ISNDGDNE	AKELYAASSGYYYFDY	MN008234.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
10	315-06-05M_1F03	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGTCTGTGTATTACTGTGCGAGAGATAAGTTAAGTAGAAGTAGTGGTTATTACTACCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTSVYYCARDKLSRSSGYYYLDYWGQGTLVTVSS	nan	nan	IGHV3-33*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSNYG	IWYDGSNK	ARDKLSRSSGYYYLDY	MN008227.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
11	AG11-2A01	GTGCAGCTGGTGGAGTCTGGGGGAGCCGTGGTACAGCCGGGGGGGTCCCTGACACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGTGAAGTTCCGGGGAAGGGTCTGGAGTGGGTCTCTCTTATTAGCTGGGATGCTGGTAACACATACTATGGAGACTCTGTGAAGGGTCGATTCAACATCTCCAGAGACAACAGCAAAAATTTCCTGTATCTACAAATGAACAGTCTGAGAGCTGACGACACCGCCTTGTATTACTGTGCAAAAGATATAGGCGGTGGTAATTATGATTACTACCACGGTATGGACGCCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	VQLVESGGAVVQPGGSLTLSCAASGFTFDDYAMHWVREVPGKGLEWVSLISWDAGNTYYGDSVKGRFNISRDNSKNFLYLQMNSLRADDTALYYCAKDIGGGNYDYYHGMDAWGQGTTVTVSS	GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTTACAGTTTTGGCAGCAAGTTGGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTACATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCGTACACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA	EIVMTQSPATLSVSPGERATLSCRASYSFGSKLAWYQQKPGQAPRLLIYGTSTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPYTFGQGTKVEIK	IGHV3-43D*04	IGHJ6*02	IGHD4-23*01	IGKV3-15*01	IGKJ2*01	YSFGSK	GTS	QQYNNWPYT	GFTFDDYA	ISWDAGNT	AKDIGGGNYDYYHGMDA	MH205359.1	MH205581.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Unk	PCWilson_donor_AG11	B-cells;Influenza natural infection or vaccination	nan	nan
11	R95-2B03	GAAGTGCAGCTGGTGGAATCTGGGGGAGTCGTGGGACAGCCTGGGGGGTCCCTGACAATCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCTCTCTTATTAGCTGGGATGGTGGTAACACCAACTATGCAGACTCTGTGAAGGGACGATTCAACATTTCCAGAGACAACACCAAAAGCTCCCTGTACCTGCAAATGAACGGTCTGAGAGCTGAGGACACCGCCTTCTATTACTGTGCAAAAGATGTGGGCGGGGGTAACTACGACTACTACCACTACATGGACGTCTGGGGCGCAGGGACCGCGGTCACCGTCTCCTCA	EVQLVESGGVVGQPGGSLTISCAASGFTFDDYAMHWVRQAPGKGLEWVSLISWDGGNTNYADSVKGRFNISRDNTKSSLYLQMNGLRAEDTAFYYCAKDVGGGNYDYYHYMDVWGAGTAVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGATGTTGGGATGTATGACCGTGTCTCCTGGTACCAGCATCACCCAGGCAAAGCCCCCAAACTCATCATTTATGAGAACAGTAAGCGGCCCTCAGGGATTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCCGAGGACGAGGCTGATTATTACTGCTGCTCATATGCAGGAACTATCAATTTTGTCCTCGGAACTGGGACGAAGGTCATCGTCCTAG	QSALTQPASESGSPGQSITISCTGTSSDVGMYDRVSWYQHHPGKAPKLIIYENSKRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGTINFVLGTGTKVIVL	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	SSDVGMYDR	ENS	CSYAGTINFV	GFTFDDYA	ISWDGGNT	AKDVGGGNYDYYHYMDV	MK311803.1	MK312133.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-2F04	GAGGTGCAGCTGGTGGAGTCTGGGGGAGCCGCGGTACAGCCGGGGGGGTCCCTGCGACTCTCCTGTGCAGCCTCTGGATTCAGCTTTGATGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCTCTCTTATTAGTTGGGACAGTGGAAATACCCACTATGCAGACTCTGTGAAGGGTCGATTCAACATCTCCAGAGACAACAACAAGAACTCCCTGTATCTGCAAATGAGCAGTCTGAGAGCTGAGGACACCGCCTTGTATTACTGTGCAAAAGATGTGGGCGGGGGTAACTACGACTACTATTATTACATGGACGCCTGGGGCAAAGGGGCCACGGTCACCGTCTCCTCA	EVQLVESGGAAVQPGGSLRLSCAASGFSFDDYAMHWVRQAPGKGLEWVSLISWDSGNTHYADSVKGRFNISRDNNKNSLYLQMSSLRAEDTALYYCAKDVGGGNYDYYYYMDAWGKGATVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCGGCAGTGATGTTGGGCATTATAACCGTGTCTCCTGGTACCAACAACACTCAGGCAAAGCCCCCAAACTCATGATTTTTGAGGACAATAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCTGGCTGAGGACGAGGCTGATTATTACTGCTGCTCATATGTAACTAGTACCACTTATGTCTTCGGAACTGGGACCAAGGTCACCTGTCCTA	QSALTQPASESGSPGQSITISCTGTGSDVGHYNRVSWYQQHSGKAPKLMIFEDNKRPSGVSNRFSGSKSGNTASLTISGLLAEDEADYYCCSYVTSTTYVFGTGTKVT	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	GSDVGHYNR	EDN	CSYVTSTTYV	GFSFDDYA	ISWDSGNT	AKDVGGGNYDYYYYMDA	MK311808.1	MK312137.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-2A02	GAGGTGCAGCTGGTGGAATCGGGGGGAGTCGTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAACCTCTGGATTCACCTTTGACGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCGCTCTTATCAGTTGGGATGCTGGTAACACCCACTATGCGGACTCTGCGAAGGGTCGATTCAACATCTCCAGAGACAACAGCAAAAACTCCCTGTTTCTGCAAATGCACAGCCTGAGAGTTGAGGACAGCGGCTTGTATTACTGTGCAAAAGATGTGGGCGGGGGTAACTACGACTACTACTACCACATGGACGGCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGVVVQPGGSLRLSCTTSGFTFDDYAMHWVRQAPGKGLEWVALISWDAGNTHYADSAKGRFNISRDNSKNSLFLQMHSLRVEDSGLYYCAKDVGGGNYDYYYHMDGWGKGTTVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCACCAGTGATGTTGGACATTATAGCCGTGTCTCCTGGTACCAACGACACCCAGGCAGAGCCCCCAAACTCATGATTTATGAAGACAATAAGCGGCCCTCAGGGGTTTCTGCTCGCTTCTCTGGCTCCAAGTCGGGCGACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAAGACGAGGCTGATTATTACTGCTGCTCATATGCAACTCGTGGCACTTTTGTCTTCGGAACTGGGACCGAGGTCACCGTCCTAG	QSALTQPASESGSPGQSITISCTGTTSDVGHYSRVSWYQRHPGRAPKLMIYEDNKRPSGVSARFSGSKSGDTASLTISGLQAEDEADYYCCSYATRGTFVFGTGTEVTVL	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	TSDVGHYSR	EDN	CSYATRGTFV	GFTFDDYA	ISWDAGNT	AKDVGGGNYDYYYHMDG	MK311804.1	MK312134.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-2B12	GAAGTGCAGCTGGTGGAATCGGGGGGAGTCGTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAACCTCTGGATTCACCTTTGACGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCGCTCTTATCAGTTGGGATGCTGGTAACACCCACTATGCGGACTCTGCGAAGGGTCGATTCAACATCTCCAGAGACAACAGCAAAAACTCCCTGTTTCTGCAAATGCACAGCCTGAGAGTTGAGGACAGCGGCTTGTATTTCTGTGCAAAAGATGTGGGCGGGGGTAACTACGACTACTACTACCACATGGACGGCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGVVVQPGGSLRLSCTTSGFTFDDYAMHWVRQAPGKGLEWVALISWDAGNTHYADSAKGRFNISRDNSKNSLFLQMHSLRVEDSGLYFCAKDVGGGNYDYYYHMDGWGKGTTVTVSS	nan	nan	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	nan	nan	nan	nan	nan	GFTFDDYA	ISWDAGNT	AKDVGGGNYDYYYHMDG	MK311805.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
11	R95-2C05	GAAGTGCAGCTGGTGGAGTCGGGGGGAGTCGTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAACCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCTCTCTTATCAGTTGGGATGCTGGTAACACCCACTATGCGGACTCTGTGAAGGGTCGATTCAACATCTCCAGAGACAACAGCAAAAACTCCCTGTTTCTGCAAATGCACAGCCTGAGAGCTGAGGACAGCGCCTTGTATTACTGTGCAAAAGATGTGGGCGGGGGTAACTACGACTACTACTACCACATGGACGGCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGVVVQPGGSLRLSCTTSGFTFDDYAMHWVRQAPGKGLEWVSLISWDAGNTHYADSVKGRFNISRDNSKNSLFLQMHSLRAEDSALYYCAKDVGGGNYDYYYHMDGWGKGTTVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGATGTTGGGCATTATAACCGTGTCTCCTGGTACCAACGACACCCAGGCAGAGCCCCCAAACTCATGATTTATGAGGACAATAAGCGGCCCTCAGGGGTTTCTACTCGCTTCTCTGGCTCCAAGTCTGGCGACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAAGACGAGGCTGATTATTACTGCTGCTCATATGCAACTAGTGGCACTTTTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG	QSALTQPASESGSPGQSITISCTGTSSDVGHYNRVSWYQRHPGRAPKLMIYEDNKRPSGVSTRFSGSKSGDTASLTISGLQAEDEADYYCCSYATSGTFVFGTGTKVTVL	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	SSDVGHYNR	EDN	CSYATSGTFV	GFTFDDYA	ISWDAGNT	AKDVGGGNYDYYYHMDG	MK311806.1	MK312135.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-2H03	GAAGTGCAGCTGGTGGAATCGGGGGGAGTCGTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAACCTCTGGATTCACCTTTGACGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCGCTCTTATCAGTTGGGATGCTGGTAACACCCACTATGCGGACTCTGCGAAGGGTCGATTCAACATCTCCAGAGACAACAGCAAAAACTCCCTGTTTCTGCAAATGCACAGCCTGAGAGTTGAGGACAGCGGCTTGTATTACTGTGCAAAAGATGTGGGCGGGGGTAACTACGACTACTACTACCACATGGACGGCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGVVVQPGGSLRLSCTTSGFTFDDYAMHWVRQAPGKGLEWVALISWDAGNTHYADSAKGRFNISRDNSKNSLFLQMHSLRVEDSGLYYCAKDVGGGNYDYYYHMDGWGKGTTVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCACCAGTGATGTTGGACATTATAGCCGTGTCTCCTGGTACCAACGACACCCAGGCAGAGCCCCCAAACTCATGATTTATGAAGACAATAAGCGGCCCTCAGGGGTTTCTGCTCGCTTCTCTGGCTCCAAGTCTGGCGACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAAGACGAGGCTGATTATTACTGCTGCTCATATGCAACTCGTGGCACTTTTGTCTTCGGAACTGGGACCGAGGTCACCTGTCCTA	QSALTQPASESGSPGQSITISCTGTTSDVGHYSRVSWYQRHPGRAPKLMIYEDNKRPSGVSARFSGSKSGDTASLTISGLQAEDEADYYCCSYATRGTFVFGTGTEVT	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	TSDVGHYSR	EDN	CSYATRGTFV	GFTFDDYA	ISWDAGNT	AKDVGGGNYDYYYHMDG	MK311807.1	MK312136.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-2E03	GAGGTGCAGCTGGTGGAGTCGGGGGGAGTCGTGGTCCAGCCTGGGGAGTCCCTGAGACTCTCCTGTACAACCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCTCTCTTATTAGTTGGGATGCTGGTAACACCCACTATGCGGACTCTGTGAAGGGTCGATTCAACATCTCCAGAGACAACAGCAAAAACTCCCTGTTTCTGCAAATGCACAGCCTGAGAGCTGAGGACAGCGGCTTGTATTACTGTGCAAAAGATGTGGGCGGGGGTAACTACGACTACTACTACTACATGGACGGCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGVVVQPGESLRLSCTTSGFTFDDYAMHWVRQAPGKGLEWVSLISWDAGNTHYADSVKGRFNISRDNSKNSLFLQMHSLRAEDSGLYYCAKDVGGGNYDYYYYMDGWGKGTTVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGATGTTGGGCATTATAACCGTGTCTCCTGGTACCAACGACACCCAGGCAGAGCCCCCAAACTCATGATTTATGAGGACAATAAGCGGCCCTCAGGGGTTTCTACTCGCTTCTCTGCCGCCAAGTCTGGCGACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAAGACGAGGCTGATTATTACTGCTGCTCATATGCAACTAGTGGCACTTTTGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG	QSALTQPASESGSPGQSITISCTGTSSDVGHYNRVSWYQRHPGRAPKLMIYEDNKRPSGVSTRFSAAKSGDTASLTISGLQAEDEADYYCCSYATSGTFVFGTGTKVTVL	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	SSDVGHYNR	EDN	CSYATSGTFV	GFTFDDYA	ISWDAGNT	AKDVGGGNYDYYYYMDG	MK311809.1	MK312138.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-1F01	GAAGTGCAGCTGGTGGCATCTGGGGGAGTCGTGGGACAGCCTGGGGGATCCCTGACAATCTCCTGTGCGGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGTCAAACTCCGGGGAGGGGTCTGGAGTGGGTCTCTCTCATTAGTTGGGATGGTGGAAACACCAACTATGCAGACTCCGTGAGGGGTCGATTCAACATGTCCAGAGACAACACCGAAAACTCCCTGTACCTACAAATGCACAGTCTGAGAGCTGAGGACACCGGCTTCTATTACTGTGCAAGAGATATGGGCGGGGGTAACTACGACTACTACTATCACATGGACGTCTGGGGCGCGGGGACCGCGGTCACCGTCTCCTCA	EVQLVASGGVVGQPGGSLTISCAASGFTFDDYAMHWVRQTPGRGLEWVSLISWDGGNTNYADSVRGRFNMSRDNTENSLYLQMHSLRAEDTGFYYCARDMGGGNYDYYYHMDVWGAGTAVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGACAGTCGATCAGCATCTCCTGCACTGGAACCAGCAATGATGTTGGGATGTATGACCGTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATCATTTATGAAAACAATAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCCGGCAACACGGCCTCCCTGACAATCTCTGGCCTCCAGGCCGGGGACGACGCTGACTATTATTGCTGCTCATATGCAGGGAGTATCACTTTTGTCCTCGGAACTGGGACGAAGGTCACCGTCCTCG	QSALTQPASESGSPGQSISISCTGTSNDVGMYDRVSWYQQHPGKAPKLIIYENNKRPSGVSNRFSGSKSGNTASLTISGLQAGDDADYYCCSYAGSITFVLGTGTKVTVL	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	SNDVGMYDR	ENN	CSYAGSITFV	GFTFDDYA	ISWDGGNT	ARDMGGGNYDYYYHMDV	MK311811.1	MK312140.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-2C06	GAAGTGCAGCTGGTGGACTCTGGGGGAGTCGTGGGACAGCCTGGGGGGTCCCTGACAATCTCCTGTGCAGCCTCTGGATTCAGCTTTGATGATTATGCCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCTCTCTTATTAGCTGGGATGGTGCTAACACCAATTATGCAGACTCTGTGAAGGGTCGATTCAACGTTTCGAGAGACAACATCAAAGGGTCCCTGTACCTACAAATGAACGGTCTGAGAGTTGAGGACACCGCCCTCTATTATTGTGCAAGAGATGCGGGCGGGGGTAATTACGACTACTACCGCTACATGGACGTCTGGGGCGCAGGGACCGCGGTCACCGTCTCCTCA	EVQLVDSGGVVGQPGGSLTISCAASGFSFDDYAMHWVRQAPGKGLEWVSLISWDGANTNYADSVKGRFNVSRDNIKGSLYLQMNGLRVEDTALYYCARDAGGGNYDYYRYMDVWGAGTAVTVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCCTGGCCAGTCGATCACCATTTCCTGCACTGGAAGCAACATTGATGTTGGGATGTATGACCGTGTCTCCTGGTACCAACATCACCCAGGCAGAGCCCCCAAACTCATCATTTATGAGAACAATAAGCGGCCCTCAGGAGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCCGAGGACGAGGCTGATTATTATTGCTGCTCATATGCAGCAAGTATCAACTTTGTCCTCGGAACTGGGACGAGGGTCATCGTCCTAG	QSALTQPASESGSPGQSITISCTGSNIDVGMYDRVSWYQHHPGRAPKLIIYENNKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAASINFVLGTGTRVIVL	IGHV3-43D*03	IGHJ6*03	IGHD3-10*01,IGHD3-10*02,IGHD3-16*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	NIDVGMYDR	ENN	CSYAASINFV	GFSFDDYA	ISWDGANT	ARDAGGGNYDYYRYMDV	MK311810.1	MK312139.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
11	R95-1A10	GAGATGGCCCTGGTGGAGTCTGGGGGAACCGTGGTACAGCCTGGGGGGTCCCTGACACTCTCCTGTGAAGTCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGTTCCGGGAAAGGGTCTAGAGTGGGTCTCTCTTATTAGTTGGGATGCTGGTAACACCAACTATGCAGACTCTGTGAAGGGGCGATTCAACATCTCCAGGGACAACACCAGGAGCATCCTCTACCTCCAAATGAGCAGTCTGAGACCTGAGGACACCGCCATATATTACTGTACAAAGGATGACGGCGGGGGTAACTACGACTACTACCGCTACATGGACGTCTGGGGCAGAGGGACCACGGTCACCGTCTCGTCG	EMALVESGGTVVQPGGSLTLSCEVSGFTFDDYAMHWVRQVPGKGLEWVSLISWDAGNTNYADSVKGRFNISRDNTRSILYLQMSSLRPEDTAIYYCTKDDGGGNYDYYRYMDVWGRGTTVTVS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGGTCTCTTGGGCAGTCGATCACCATCTCCTGCACTGGAACCAGCGGAGATGTTGGGGGTTATAACCGTGTCTCCTGGTATCAACAACACCCAGGCAAAGCCCCCAGACTCGTGATTTATGAGGGCAGTAAGCGACCCTCAGGAGTCTCTAGTCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACAATCACTGGGCTCCAGGCTGAGGACGAGGCTGAGTATTTCTGCTCCTCATATGCAGGCAGTATCACTTTTGTCTTCGGAACCGGGACTAAAGTCAACGTCCTCG	QSALTQPASESGSLGQSITISCTGTSGDVGGYNRVSWYQQHPGKAPRLVIYEGSKRPSGVSSRFSGSKSGNTASLTITGLQAEDEAEYFCSSYAGSITFVFGTGTKVNVL	IGHV3-43D*03	IGHJ6*03	IGHD4-23*01	IGLV2-23*01,IGLV2-23*03	IGLJ1*01	SGDVGGYNR	EGS	SSYAGSITFV	GFTFDDYA	ISWDAGNT	TKDDGGGNYDYYRYMDV	MK311812.1	MK312141.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	20.0
12	315-06-04_1D02	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGACGCCTGGGTCCTCGGTGAAGGTCTCCCGCAAGGCTTCGGGAGGCACCTTCAGCAACTATGCTATCAGCGGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTATCTTTAATACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACAATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTAAGGACACGGCCGTGTATTACTGTGCGAGAGCTAGTGGGGCCTACTCCCCAATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKTPGSSVKVSRKASGGTFSNYAISGVRQAPGQGLEWMGRIIPIFNTANYAQKFQGRVTITADKSTSTAYMELSSLRSKDTAVYYCARASGAYSPIDYWGQGTLVTVSS	nan	nan	IGHV1-69*06,IGHV1-69*18	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGTFSNYA	IIPIFNTA	ARASGAYSPIDY	MN008171.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
12	315-21-08_1G05	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACTTTCAGCAACTATGCTATCAACTGGGTGCGACAGGCCCCTGGACAAGGACTTGAATGGATGGGAACGATCATCCCTGTCCTTGGTGTACTAAAGTACGCACAGAGGTTGCAGGGCAGAGTCACAATTACCGCGGACAAATCCACGGGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTATTGTGCGCGAGCCAGTGGGAGCTACTCCCCGACAGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGTIIPVLGVLKYAQRLQGRVTITADKSTGTAYMELSSLRSEDTAVYYCARASGSYSPTDYWGQGTLVTVSS	nan	nan	IGHV1-69*09	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGTFSNYA	IIPVLGVL	ARASGSYSPTDY	MN008868.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
12	20A-609-30_1F11	CAGTTACAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCCTCTGGAGGCACGTTCAGCAACTATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGCCATGAATGGATGGGAAGGATCAACCCAATCTTGGGGAGAACAGACTACGCACAGAAGTTCCAGGGCAGAGTCACAATAAACGCGGACAAATCCACGGGCACACTCTACATGGAGATGAGAAGCCTGAGACGTGAGGACACGGCCGTCTACTACTGCGCCAGAGCTAGTGGGACGTACTCCCCAATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCATCAG	QLQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAFSWVRQAPGQGHEWMGRINPILGRTDYAQKFQGRVTINADKSTGTLYMEMRSLRREDTAVYYCARASGTYSPIDYWGQGTLVTVSS	nan	nan	IGHV1-69*04,IGHV1-69*06,IGHV1-69*09	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGTFSNYA	INPILGRT	ARASGTYSPIDY	MN008182.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
12	20A-609-30_2D12	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCGGGAGGCACCTTCAGCAACTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGAGATCATCCCTATCTTTGATACAGCAAAGTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCTCGGGCACAGCCTACATGGAAGTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGGCAGTGGTTCTTATTCGCCAATTGACTACTGGGGCCAGGGAAGCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGEIIPIFDTAKYAQKFQGRVTITADKSSGTAYMEVSSLRSEDTAVYYCARGSGSYSPIDYWGQGSLVTVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD3-3*01,IGHD3-3*02	nan	nan	nan	nan	nan	GGTFSNYA	IIPIFDTA	ARGSGSYSPIDY	MN008179.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
12	315-06-05M_1H05	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGTAACTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCCTGAGTGGATGGGAGAGATCCTCCCTATCTTTGGTACAGCAAAGTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGGGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAAGACACGGCCGTGTACTACTGTGCGAGAGGTAGTGGTTATTACTCGCCAATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGPEWMGEILPIFGTAKYAQKFQGRVTITADKSTGTAYMELSSLRSEDTAVYYCARGSGYYSPIDYWGQGTLVTVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGTFSNYA	ILPIFGTA	ARGSGYYSPIDY	MN008172.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
12	315-06-06_1E10	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGTAACTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCCTGAGTGGATGGGAGAGATCCTCCCTATCTTTGGTACAGCAAAGTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGGGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAAGACACGGCCGTGTACTACTGTGCGAGAGGTAGTGGTTATTACTCGCCAATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGPEWMGEILPIFGTAKYAQKFQGRVTITADKSTGTAYMELSSLRSEDTAVYYCARGSGYYSPIDYWGQGTLVTVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGTFSNYA	ILPIFGTA	ARGSGYYSPIDY	MN008175.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
12	20A-623-30_1H01	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCCGGGTCCTCGGTGAAGGTCTCCTGCAAGGCCTCTGGAGGCACTTTCAGCAACTATGCTATCAGATGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGACAAAACAAACTCCGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTTCATGGAGCTGAGCAGTCTGAGATATGAAGACACGGCCGTGTATTACTGTGCGAGATCGAGTGGGGCCTATTCCCCTCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAIRWVRQAPGQGLEWMGGIIPIFDKTNSAQKFQGRVTITADKSTSTAFMELSSLRYEDTAVYYCARSSGAYSPLDYWGQGTLVTVSS	nan	nan	IGHV1-69*06,IGHV1-69*17	IGHJ4*02	IGHD2-21*01,IGHD2-21*02	nan	nan	nan	nan	nan	GGTFSNYA	IIPIFDKT	ARSSGAYSPLDY	MN009401.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
12	20A-609-30_2E04	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCCGGAGGCACCTTCAGCAACTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGACCATCCCTATCTTTGGTACAGCAAACTACGCAGAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGGCCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTATATTACTGTGCGAGAAGTAGTGGTTCTTACTCGCCAATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTTCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGGTIPIFGTANYAEKFQGRVTITADKSTATAYMELSSLRSEDTAVYYCARSSGSYSPIDYWGQGTLVTVFS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGTFSNYA	TIPIFGTA	ARSSGSYSPIDY	MN008180.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
12	20A-623-30_1C10	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTAAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAGGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTAAAGCAAACTCCGCACAGAGGTTTCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGTTTACATGGAACTGAGCAGCCTGAGATATGACGACACGGCCGTGTATTTCTGTGCGAGACATAGCGGGAGCTACTCCCCCCTTGACTACTGGGGCCAGGGAACCCTAGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAFSWVRQAPGQGLEWMGGIIPIFGKANSAQRFQGRVTITADKSTSTVYMELSSLRYDDTAVYFCARHSGSYSPLDYWGQGTLVTVSS	nan	nan	IGHV1-69*06,IGHV1-69*17	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGTFSSYA	IIPIFGKA	ARHSGSYSPLDY	MN009356.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
12	315-06-05M_1G03	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGCAGGTCTCCTGCAAGGCTTCCGGAGGCTCCTTCAGCAACTATGCTATCAGCGGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGGGGCATCATCCCTCTCTTTGGTACAGCAAACTACGCACAAAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGGGCACAGCCTCCATGGAGCTGAGCCGCCTGAGATCTGAGGACACGGGCGTGTATTACTGTGCGCGCAGCAGTGGCTCGTACTCCCCCGCGGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVQVSCKASGGSFSNYAISGVRQAPGQGLEWMGGIIPLFGTANYAQKFQGRVTITADKSTGTASMELSRLRSEDTGVYYCARSSGSYSPADYWGQGTLVTVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GGSFSNYA	IIPLFGTA	ARSSGSYSPADY	MN008173.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
12	315-06-04_1B12	CTGGTGCAGCTGGTGCTGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGGGGCACCTTCAGTAACTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGAGATCATCCCTATCTTTGGCACAGCAAACTCCGCACAGAGGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGGGCACAGCCTACATGGCGCTGAGCAGCCTGACATCTGATGACACGGCCGTCTATTACTGTGCGAGAAGCAGTGGCTGGTACTCGCCGGTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	LVQLVLSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGEIIPIFGTANSAQRFQGRVTITADKSTGTAYMALSSLTSDDTAVYYCARSSGWYSPVDYWGQGTLVTVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GGTFSNYA	IIPIFGTA	ARSSGWYSPVDY	MN008170.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	20A-609-30_1E06	GAGGTGCAGCTGGTGCAGTCCGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGTCGGGGTTCTGGATACAGTTTTGCCGACTACTGGATCTGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGAGGATTGATCCTAGTGACTCTTATACCAACTACGGTCCGTCCTTCCAAGGCCACGTCACCATCTCAACTGACAAGTCCATCAGCACTGCCTACCTGCAGTGGAGGAGTCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGTGTCATTACGATGTCTTGACTGGATACCTGTACTTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCCG	EVQLVQSGAEVKKPGESLRISCRGSGYSFADYWICWVRQMPGKGLEWMGRIDPSDSYTNYGPSFQGHVTISTDKSISTAYLQWRSLKASDTAMYYCARCHYDVLTGYLYFFDYWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GYSFADYW	IDPSDSYT	ARCHYDVLTGYLYFFDY	MN008290.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	315-06-04_1B03	GAGGTGCAGCTGGTGCAGTCCGGAGCAGAGGTGAAAGAGCCCGGGAAGTCTCTGAGGATCTCCTGTCAGGGTTCTGGACACAGCTTTACCGGCTACTGGGTCAGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGAGGATTGATCCAACTGACTCTTTAGCCTACTACAGTCCGTCCTTCCAAGGCCACGTCACCATCTCAGTTGACAAGTCCATCAGCACTGCCTACCTGCAGTGGAGCAGTTTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAGGCCCTTACGATGTTTTGACTGGTTATCTGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVQSGAEVKEPGKSLRISCQGSGHSFTGYWVSWVRQMPGKGLEWMGRIDPTDSLAYYSPSFQGHVTISVDKSISTAYLQWSSLKASDTAMYYCARGPYDVLTGYLYYFDYWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GHSFTGYW	IDPTDSLA	ARGPYDVLTGYLYYFDY	MN008274.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	20A-609-30_2B10	GAGGTGCAGCTAGTACAGTCGGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGTAAGGCTTCTGAATACAGCTTTACCAGCTACTGGATCACCGGGGTGCGCCAGATGCCCGGGAAAGGCCGGGAGTGGCTGGGAAGGATTGATCCTAGAGATTCTTATACCCACTACAATCCGTCCGTCCAAGGCCACGTTAACATCTCCGCTGACAAGTCCATCAGCACTGCCTACTTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACATCACTACGATGTTTTGACTGGATACCTCTATTACTTTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVQSGAEVKKPGESLRISCKASEYSFTSYWITGVRQMPGKGREWLGRIDPRDSYTHYNPSVQGHVNISADKSISTAYLQWSSLKASDTAMYYCARHHYDVLTGYLYYFDFWGQGTLVTVSS	nan	nan	IGHV5-10-1*01,IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	EYSFTSYW	IDPRDSYT	ARHHYDVLTGYLYYFDF	MN008291.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	315-06-08_1A12	GAGGTGCAGCTGGTGCAGTCCGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAGGATCTCATGTAAGGGTTCTGGACACAGCTTTACCAGCTACTGGATCAGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGAGGATTGCTCCTAGTGACTCTTACACGTACTACAGCCCGTCCTTCCAAGGCCACGTCAACATCTCAGCTGACAAGTCCATCAGTACTGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAACCCATTACGATATTTTGACTGGTTACATATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVQSGAEVKKPGESLRISCKGSGHSFTSYWISWVRQMPGKGLEWMGRIAPSDSYTYYSPSFQGHVNISADKSISTAYLQWSSLKASDTAMYYCARTHYDILTGYIYYFDYWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GHSFTSYW	IAPSDSYT	ARTHYDILTGYIYYFDY	MN008284.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	20A-609-30_1F04	GAGGTGCAGCTGGTGCAGTCCGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGTAAGGGTTCTGGATACAGTTTTACCAGCTACTGGATCAGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGAGGATTGATCCTGCTGGCTCTTATTCCTACTACAGCCCGTCCTTCCAGGGCCACGTCAACATGTCAGCTGACATGCCCATCAGCACTGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAACGATTTACGATATTTTGACTGGTTATGTGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCCCAG	EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWISWVRQMPGKGLEWMGRIDPAGSYSYYSPSFQGHVNMSADMPISTAYLQWSSLKASDTAMYYCARTIYDILTGYVYYFDYWGQGTLVTVSP	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GYSFTSYW	IDPAGSYS	ARTIYDILTGYVYYFDY	MN008292.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	315-06-05M_1A09	GAGGGGCAGCTGGCCCATTCGGGAGAAGAGGTAAAAAACCCCGGGGAGTTTTTGAGGTTTCCCTGTAAGGTTTCGGGATACAGCTTTCCCAGCTACGGGTTCAGCGGGGTGCCCCAGATCCCCGGAAAAGCCCGGGAGGGGATGGGGAGGATTGATCCTAGTGGTTTTTATCCCAATTACAGCCCGTCCTTCCAAGGCCACGTCACCATTTCAGCTGACAAGTCCATCAGCACTGCCTACCTGCAATGGAGCAGCCTGGAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAACCTATTACGATATTTTGACTGGTTATATATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EGQLAHSGEEVKNPGEFLRFPCKVSGYSFPSYGFSGVPQIPGKAREGMGRIDPSGFYPNYSPSFQGHVTISADKSISTAYLQWSSLEASDTAMYYCARTYYDILTGYIYYFDYWGQGTLVTVSS	nan	nan	IGHV5-10-1*01,IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GYSFPSYG	IDPSGFYP	ARTYYDILTGYIYYFDY	MN008280.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	20A-618-30_2C09	GAGGTGCAGCTGGTGCAGTCCGGAGCAGAGGTGAGAAAGCCCGGAGAGTCTCTGAAGATCTCCTGTAAGGCTTCTGGATACAGCTTTGCCAGCTTCTGGATCAGCTGGGTGCGCCAGATGCCCGGGAGAGGCCTGGAGTGGATGGGGAGGATTGATCGTAATGACTCTTATACCAACTACAGCCCGTCCTTCCAAGGCCACGTCACCATCTCTGCTGACGAGTCCATCAGCACTGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATATATTACTGTGCGAGAACCTATTACGATGTTTTGACTGGTTATATTTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVQSGAEVRKPGESLKISCKASGYSFASFWISWVRQMPGRGLEWMGRIDRNDSYTNYSPSFQGHVTISADESISTAYLQWSSLKASDTAIYYCARTYYDVLTGYIYYFDYWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GYSFASFW	IDRNDSYT	ARTYYDVLTGYIYYFDY	MN007842.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
13	20A-609-30_1G11	GAGGTGCAGCTGGTGCAGTCCGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCATCTGGGTGCGCCAGATGCCCGGGAAAGGCCTAGAGTGGATGGGGAGGATTGATCCTAGTGAGTCTTATACCGACTACAGCCCGTCCTTCCAAGGCCACGTCACCATCTCAGTTGACAAGTCCATCAGCACTGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGGTATATTACGATATTTTGACTGGTTATTATATCTACTTTGACTACTGGGGCCAGGGGACCCTGGTCACCGTCTCCTCAG	EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWIIWVRQMPGKGLEWMGRIDPSESYTDYSPSFQGHVTISVDKSISTAYLQWSSLKASDTAMYYCARVYYDILTGYYIYFDYWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02,IGHJ4*03	IGHD3-9*01	nan	nan	nan	nan	nan	GYSFTSYW	IDPSESYT	ARVYYDILTGYYIYFDY	MN008294.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
13	20A-618-30_2G12	GAGGTGCAGCTGGTGCAGTCCGGGGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAAATCTCCTGTAAGGGTTCTGGAGACAGCTTTACCAGCTACTGGATCAGTTGTGTGCGCCAGATGCCCGGGAAGGGCCAGGAAGTGATGGGGAGGATTGCTCCCATTGACTCTTATACCAATTACAGTCCGTCCTTCCAAGGCCACGTCACCATATCTGCTGACAAGTCCATCAGCACTGCCTACCTGCAGTGGAGTAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGACCACCTATTACGATGTTTTGACTGGTTATTATATCTACCTTCACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVQSGAEVKKPGESLKISCKGSGDSFTSYWISCVRQMPGKGQEVMGRIAPIDSYTNYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCATTYYDVLTGYYIYLHYWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GDSFTSYW	IAPIDSYT	ATTYYDVLTGYYIYLHY	MN007843.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
13	315B_02Mem_1A06	GAGGTGCAGCTGGTGCAGTCCGAAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCAGCTGGGTGCCCCAGATTCCCGGGAAAGGCCTGGAGTGGATGGGGAGGGTTGATCCTAGTGACTCTTATACCAACTACAGCCCGTCCTTCCAAGGCCACGTCTACTTCTCAGCTGACAAGTCCATCAGCACTGCCTACCTGCAGTGGAACAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGACGACGTATTACGATGTTTTGACTGGATATTATTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVQSEAEVKKPGESLRISCKGSGYSFTSYWISWVPQIPGKGLEWMGRVDPSDSYTNYSPSFQGHVYFSADKSISTAYLQWNSLKASDTAMYYCATTYYDVLTGYYYYFDYWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GYSFTSYW	VDPSDSYT	ATTYYDVLTGYYYYFDY	MN007525.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
14	mbc_T2-4C	nan	nan	nan	nan	IGHV1-69*01or1-69D*01	IGHJ6*03	IGHD2-2*02	IGKV3-20*01	IGKJ1*01	nan	nan	QQYGTSPQTF	nan	nan	AKGPTYYNSYMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	Group 1	HA:Stem	Donor_H	B-cells;Influenza Human Vaccinee	nan	35.0
14	T1-3B	GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAGGAAGCCTGGGTCTTCGGTGAAGGTCTCCTGCAAGCCTTCTGGCGGCATCTTCAACAAATATGCTGTCACCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGCATCATCGCTGTCTTCAGAACAACAAACTACGCACACAAGTTCCAGGGCAGAGTCACGATTAGCGCGGACGAGTCCATGAACACAGTGTACCTGGAGCTGAGAAGCCTGAGATCTGACGACACGGCCGTTTATTACTGTGCGAGAGGCCCCAATTACTATAACTCGTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVQSGAEVRKPGSSVKVSCKPSGGIFNKYAVTWVRQAPGQGLEWMGGIIAVFRTTNYAHKFQGRVTISADESMNTVYLELRSLRSDDTAVYYCARGPNYYNSYMDVWGKGTTVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGTCAGTCAGAGTCTTACCAACCGTGACTTAGCCTGGTATCAGCAACAACCTGGCCAGGCTCCCAGACTCCTCATCCATGGTGCATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTCTATTACTGTCAGCAGTATGGGACCTCACCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC	EIVLTQSPGTLSLSPGERATLSCRVSQSLTNRDLAWYQQQPGQAPRLLIHGASTRATGIPDRFSGSGSGTEFTLTISRLEPEDFAVYYCQQYGTSPQTFGQGTKVEIK	IGHV1-69*01,IGHV1-69D*01	IGHJ6*03	IGHD3-10*01,IGHD3-10*02,IGHD3-22*01	IGKV3-20*01	IGKJ1*01	QSLTNRD	GAS	QQYGTSPQT	GGIFNKYA	IIAVFRTT	ARGPNYYNSYMDV	KP231622.1	KP231643.1	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	Group 1	HA:Stem	Donor_H	B-cells;Influenza Human Vaccinee	nan	35.0
14	T2-5A	GAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCTTCGGTGAAGGTCTCCTGCAGGACTTCTGGCGGCATCTTCAACAGTTATGGAATCACCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGCATCCTCGCAATCTTTCGCACAACAAAATATGCACAGAGGTTCCAGGGCAGAGTCACGATTAGTGCGGACGAATCCATGAACACAGTGTACATGGAGTTGAGCGGCCTGAGATCTGACGACACGGCCGTTTATTACTGTGCGAGAGGCCCCACCTACTATAACTCCTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGAEVKKPGSSVKVSCRTSGGIFNSYGITWVRQAPGQGLEWMGGILAIFRTTKYAQRFQGRVTISADESMNTVYMELSGLRSDDTAVYYCARGPTYYNSYMDVWGKGTTVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGTAGGGTCAGTCAGAGTCTTAGCAGCAATAACTTAGCCTGGTACCAGAAGAAACCTGGCCAGGCTCCCAGACTCCTCATCCATGGTGCATTCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCAGCATCAGCAGACTGGAGGCTGAAGATTTTGCAGTGTATTACTGTCAGCAATATGGTAGCTCACCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC	EIVLTQSPGTLSLSPGERATLSCRVSQSLSSNNLAWYQKKPGQAPRLLIHGAFTRATGIPDRFSGSGSGTEFTLSISRLEAEDFAVYYCQQYGSSPQTFGQGTKVEIK	IGHV1-69*01,IGHV1-69D*01	IGHJ6*03	nan	IGKV3-20*01	IGKJ1*01	QSLSSNN	GAF	QQYGSSPQT	GGIFNSYG	ILAIFRTT	ARGPTYYNSYMDV	KP231620.1	KP231641.1	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	Group 1	HA:Stem	Donor_H	B-cells;Influenza Human Vaccinee	nan	35.0
14	T2-5C	GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCTTCGGTGAAGGTCTCCTGCAAGTCTTCTGGCGGCATCTTCAACAGTTTTGGTATCTCCTGGGTGCGGCAGGCCCCTGGACAAGGACTTGAGTGGATGGGAGGCATCCTCGCTATCTTTAGAACAACAAAATACGCACAGAAGTTCCAGGGCAGAGTCACGATAAGCGCGGACGAATCCATGAACACCGTGTACTTGGAGTTGAGCGGCCTGAGATCTGACGACACGGCCGTTTATTTCTGTGCGAGAGGCCCCACCTACTATAACTCCTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVQSGAEVKKPGSSVKVSCKSSGGIFNSFGISWVRQAPGQGLEWMGGILAIFRTTKYAQKFQGRVTISADESMNTVYLELSGLRSDDTAVYFCARGPTYYNSYMDVWGKGTTVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGTCAGTCAGAGTGTTAGAAGCAATAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGATGCATCCTCCAGGGCCACTGCCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATGGTACTTCACCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC	EIVLTQSPGTLSLSPGERATLSCRVSQSVRSNNLAWYQQKPGQAPRLLIYDASSRATAIPDRFSGSGSGTEFTLTISRLEPEDFAVYYCQQYGTSPQTFGQGTKVEIK	IGHV1-69*01,IGHV1-69D*01	IGHJ6*03	nan	IGKV3-20*01	IGKJ1*01	QSVRSNN	DAS	QQYGTSPQT	GGIFNSFG	ILAIFRTT	ARGPTYYNSYMDV	KP231621.1	KP231642.1	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	Group 1	HA:Stem	Donor_H	B-cells;Influenza Human Vaccinee	nan	35.0
14	T3-1B	GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCTTCGGTGAAGGTCTCCTGCAAGGCCTCTGGCGGCATCTTCAACAGCTACGGTATTTCTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGCATCATCGCTATCTTTGCAACAACAACCTACGCACAGAAGTTCCAGGGCAGAGTCACGATCAGCGCGGACAAATCCACGACCACAGTGTACATGGAGTTGAGCAGCCTAAAATCTGACGACACGGCCGTGTATTACTGTGCGAGAGGCCCCACCTACTATAACTCCTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVQSGAEVKKPGSSVKVSCKASGGIFNSYGISWVRQAPGQGLEWMGGIIAIFATTTYAQKFQGRVTISADKSTTTVYMELSSLKSDDTAVYYCARGPTYYNSYMDVWGKGTTVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGTCAGTCAGAGTGTTCGCAGCAGTAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGTCTCCTCATCCATGGTGCATCCAACAGGGCCACTGGCGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTTCCTCACCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC	EIVLTQSPGTLSLSPGERATLSCRVSQSVRSSNLAWYQQKPGQAPSLLIHGASNRATGVPDRFSGSGSGTEFTLTISRLEPEDFAVYYCQQYGSSPQTFGQGTKVEIK	IGHV1-69*06	IGHJ6*03	nan	IGKV3-20*01	IGKJ1*01	QSVRSSN	GAS	QQYGSSPQT	GGIFNSYG	IIAIFATT	ARGPTYYNSYMDV	KP231624.1	KP231645.1	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	Group 1	HA:Stem	Donor_H	B-cells;Influenza Human Vaccinee	nan	35.0
14	CR6334	GAGGTGCAGCTGGTGGAGACTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCCCCTGCAAATCTTCTGGAAGCCCCTTCAGGAGTAATGCTGTCAGCTGGGTGCGACAGGCCCCCGGACAAGGGCTTGAGTGGGTGGGAGGAATCCTCGGTGTCTTTGGTTCACCAAGCTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACCAACACAGTCCACATGGAGCTGAGAGGTTTGAGATCTGAGGACACGGCCGTGTATTATTGTGCGAGAGGTCCTACCTACTACTACTCCTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCGAGTGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGCGCCTTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTCATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCCGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGAGCGTGCTCACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTGAGCAACAAGGCCCTGCCTGCCCCCATCGAGAAGACCATCAGCAAGGCCAAGGGCCAGCCCCGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTCACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTCACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGAGCCCCGGCAAG	EVQLVETGAEVKKPGSSVKVPCKSSGSPFRSNAVSWVRQAPGQGLEWVGGILGVFGSPSYAQKFQGRVTITADESTNTVHMELRGLRSEDTAVYYCARGPTYYYSYMDVWGKGTTVTVS	TCCTATGTGCTGACTCAGCCACCCTCGGAGTCAGTGGCCCCAGGACAGACGGCCAGGATTACCTGTGGGGGAAATAACATTGGAAGAAATAGTGTGCACTGGTATCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTGTATGATGATAGCGACCGGCCCTCAGGGATCCCTGAGCGATTTTCTGGCTCCAAGTCTGGGAACACGGCCACCCTGATTATCAGCAGGGTCGAAGTCGGGGATGAGGCCGACTACTACTGTCAGGTGTGGCATAGTAGTAGTGATCATTATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAGGTGCGGCCGCAGGCCAGCCCAAGGCCGCTCCCAGCGTGACCCTGTTCCCCCCCTCCTCCGAGGAGCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTCATCAGCGACTTCTACCCTGGCGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTCACCCCCGAGCAGTGGAAGAGCCACCGGAGCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAGAAGACCGTGGCCCCCACCGAGTGCAG	SYVLTQPPSESVAPGQTARITCGGNNIGRNSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSKSGNTATLIISRVEVGDEADYYCQVWHSSSDHYVFGTGTKVTVL	IGHV1-69*01,IGHV1-69D*01	IGHJ6*03	nan	IGLV3-21*02	IGLJ1*01	NIGRNS	DDS	QVWHSSSDHYV	GSPFRSNA	ILGVFGSP	ARGPTYYYSYMDV	nan	nan	19079604	Throsby et al. PLoS One 3:e3942 (2008); Patent: WO2012112489A2	H5	HA:Stem	Crucell_donors	Healthy donors 	nan	nan
14	CR6332	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTAAAGGTCTCCTGCAAGGCTTCTGGAGGCCCCTTCCGCAATTTTGCTATCAACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCGCTGTCTTTGGGACGACAAAGTACGCACATAAGTTCCAGGGCAGAGTCACCATCACCGCGGACGACTCCACAAATACAGCTTACATGGAGCTGGGCAGCCTGAAATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGGTCCCCACTACTACTCCTCCTACATGGACGTCTGGGGCGAAGGGACCACGGTCACCGTCTCGAGTGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGCGCCTTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTCATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCCGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGAGCGTGCTCACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTGAGCAACAAGGCCCTGCCTGCCCCCATCGAGAAGACCATCAGCAAGGCCAAGGGCCAGCCCCGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTCACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTCACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGAGCCCCGGCAAG	QVQLVQSGAEVKKPGSSVKVSCKASGGPFRNFAINWVRQAPGQGLEWMGGIIAVFGTTKYAHKFQGRVTITADDSTNTAYMELGSLKSEDTAVYYCARGPHYYSSYMDVWGEGTTVTVS	GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCGAGTCAGGGCATTAGCACTTATTTAGCCTGGTATCAGCAGAAACCCGGGAAAGTTCCTAAACTCCTGATCTATGCTGCATCCACTTTGCAATCAGGGGTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAAAAGTATAACAGTGCCCCTTCTTTCGGCCCTGGGACCAAAGTGGATATCAAACGTGCGGCCGCACCCAGCGTGTTCATCTTCCCCCCCTCCGACGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGCCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTCACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAGGTGACCCACCAGGGCCTGAGCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT	DIQLTQSPSSLSASVGDRVTITCRASQGISTYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPSFGPGTKVDIK	IGHV1-69*01,IGHV1-69D*01	IGHJ6*03	nan	IGKV1-27*01	IGKJ3*01	QGISTY	AAS	QKYNSAPS	GGPFRNFA	IIAVFGTT	ARGPHYYSSYMDV	nan	nan	19079604	Throsby et al. PLoS One 3:e3942 (2008); Patent: WO2012112489A2	H5	HA:Stem	Crucell_donors	Healthy donors 	nan	148.0
14	V3-3D2	ATGGACTGGACCTGGAGGGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGCTGGTCCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGTAAGGCTCCTGGAGTCATCTTCAATGCCTATGCTATGAGCTGGGTGCGACAGGCCCCCGGACAAGGGCTTGAGTGGATGGGAGGGATCACCGGTGTCTTTCACACAGCAACCTACGCACCGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGCGAGGACCCAAGTACTACCACTCCTACATGGACGTCTGGGGCGAAGGGACCACGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKAPGVIFNAYAMSWVRQAPGQGLEWMGGITGVFHTATYAPKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARGPKYYHSYMDVWGEGTTVTVSS	ATGGACATGAGAGCCCTCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGTTTCCCAGGTGCCAGATGTGACATCCAGATGACCCAGTCTCCATCTTCACTGTCTGCATCTGTAGGAGATAGAGTCACCATCACTTGTCGGGCGAGTCAGGACATTAGCAATTATGTAGCCTGGTTTCAACAGAAACCAGGGAAAACCCCTAAGTCCCTGATGTATGCTACATCCAAATTGCAAAATGGGGTCCCTTCAAGATTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAACTTATTACTGCCAACAGTATAGTCGTTATCCTCCCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC	DIQMTQSPSSLSASVGDRVTITCRASQDISNYVAWFQQKPGKTPKSLMYATSKLQNGVPSRFSGSGSGTDFTLTISSLQSEDFATYYCQQYSRYPPTFGGGTKVEIK	IGHV1-69*01,IGHV1-69D*01	IGHJ6*03	nan	IGKV1-16*01	IGKJ4*01	QDISNY	ATS	QQYSRYPPT	GVIFNAYA	ITGVFHTA	ARGPKYYHSYMDV	nan	nan	22586427	Thomson et al. Front Immunol 3:87 (2012)	Group 1	HA:Stem	Canada_patients	convalescent patients with confirmed infections with pdmH1N1	nan	nan
14	CR6262	CAGGTACAGCTGCAGCAGTCAGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGTTTCCGGAGTCATTTTCAGCGGCAGTGCGATCAGCTGGGTGCGACAGGCCCCTGGACAAGGCCTTGAGTGGATGGGAGGGATCAGCCCTCTCTTTGGCACAACAAATTACGCACAAAAGTTCCAGGGCAGAGTCACGATTACCGCGGACCAATCCACGAACACAACCTACATGGAGGTGAACAGCCTGAGATATGAGGACACGGCCGTGTATTTCTGTGCGCGAGGTCCAAAATATTACAGTGAGTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCGAGTGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGCGCCTTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTCATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCCGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGAGCGTGCTCACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTGAGCAACAAGGCCCTGCCTGCCCCATCGAGAAGACCATCAGCAAGGCCAAGGGCCAGCCCCGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTCACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTCACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGAGCCCCGGCAAG	QVQLQQSGAEVKKPGSSVKVSCKVSGVIFSGSAISWVRQAPGQGLEWMGGISPLFGTTNYAQKFQGRVTITADQSTNTTYMEVNSLRYEDTAVYFCARGPKYYSEYMDVWGKGTTVTVS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCGAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAGAAGCCAGGGAAAGTTCCTACACTCCTGATCTATGATGCATCCACTTTGCGATCAGGGGTCCCATCTCGCTTCAGTGGCAGTGGATCTGCGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAAAGGTATAACAGTGCCCCCCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGTGCGGCCGCACCCAGCGTGTTCATCTTCCCCCCCTCCGACGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGCCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTCACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAGGTGACCCACCAGGGCCTGAGCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT	DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKVPTLLIYDASTLRSGVPSRFSGSGSATDFTLTISSLQPEDVATYYCQRYNSAPPITFGQGTRLEIK	IGHV1-69*01,IGHV1-69*06,IGHV1-69*12	IGHJ6*03	IGHD2/OR15-2a*01,IGHD2/OR15-2b*01,IGHD3-10*01	IGKV1-27*01	IGKJ5*01	QGISSY	DAS	QRYNSAPPIT	GVIFSGSA	ISPLFGTT	ARGPKYYSEYMDV	nan	nan	19079604	Throsby et al. PLoS One 3:e3942 (2008); Patent: WO2012112489A2	H5	HA:Stem	Crucell_donors	Healthy donors 	nan	148.0
14	mbc_T3-8A	nan	nan	nan	nan	IGHV1-69*01or1-69D*01	IGHJ6*03	IGHD2-2*01	IGKV2-28*01or2D-28*01	IGKJ1*01	nan	nan	MQALQTPRAC	nan	nan	ARGPTYHYNYMDV	nan	nan	26011643	Huang et al. J Clin Invest 125:2631-2645 (2015)	Group 1	HA:Stem	Donor_H	B-cells;Influenza Human Vaccinee	nan	nan
15	315-05-08_1E07	CAGCTGTACCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGAAGTAGCAATTACCACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGAGCGCCTCCTACTACCAGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACACGTCCCAGAATCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTATTGTGCGAGACGGCTCGGTGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	QLYLQESGPGLVKPSETLSLTCTVSGGSIRSSNYHWGWIRQPPGKGLEWIGSIYYSGSASYYQSLKSRVTISVDTSQNQFSLKLSSVTAADTAVYYCARRLGAFDIWGQGTMVTVSS	nan	nan	IGHV4-39*01	IGHJ3*02	IGHD6-6*01	nan	nan	nan	nan	nan	GGSIRSSNYH	IYYSGSA	ARRLGAFDI	MN007684.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
15	20A-618-30_1A04	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCGTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGGAGTAGCAATTACTATTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATGTATTATGGTGGGAGCGCGCACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCGGTGGAGGCGTCCAAGAACCAGTTCTCCCTGAAACTGACCTCTGTGACCGCCACAGACACGGCTGTATATTATTGTGCGAGACGATTGGGTGCCTACGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAC	QVQLQESGPGLVKPSETVSLTCTVSGGSIRSSNYYWGWIRQPPGKGLEWIGSMYYGGSAHYNPSLKSRVTISVEASKNQFSLKLTSVTATDTAVYYCARRLGAYDIWGQGTMVTVSS	nan	nan	IGHV4-39*01	IGHJ3*02	IGHD2-21*01,IGHD3-16*01,IGHD3-16*02	nan	nan	nan	nan	nan	GGSIRSSNYY	MYYGGSA	ARRLGAYDI	MN007685.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
15	20A-618-30_1A01	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGTCTTCGGAGACCCTGTCCCTCACCTGCAGTGTCTCTCGTGGCTCCATCAGCAGTAGTAATTATCACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAATGGATTGGGAGTATGTACTATAGTGGGAGCACCTACTACAGCCCGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGTTGAGGTCTGTGACCGCCGCAGACACGGCTGTCTATTACTGTGCGAGACGTCTGGGACCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	QVQLQESGPGLVKSSETLSLTCSVSRGSISSSNYHWGWIRQPPGKGLEWIGSMYYSGSTYYSPSLKSRVTISVDTSKNQFSLKLRSVTAADTAVYYCARRLGPFDIWGQGTMVTVSS	nan	nan	IGHV4-39*01	IGHJ3*02	IGHD1-26*01,IGHD7-27*01	nan	nan	nan	nan	nan	RGSISSSNYH	MYYSGST	ARRLGPFDI	MN007686.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
15	20A-618-30_1B07	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTCGTGGCTCCATCAGCAGTAGTAATTACTACTGGGGCTGGATCCGCCAGCCCCCACGGAAGGGGCTGGAGTGGATTGGGACTATCTATTATAGTGGGACCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACAGGTCCAAGAACCAATTCTCATTGAGGCTGACCTCTGTGACCGCCGCAGACACGGCTATGTATTACTGTGCGAGACGCCTGGGACCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	QVQLQESGPGLVKPSETLSLTCTVSRGSISSSNYYWGWIRQPPRKGLEWIGTIYYSGTTYYNPSLKSRVTISVDRSKNQFSLRLTSVTAADTAMYYCARRLGPFDIWGQGTMVTVSS	nan	nan	IGHV4-39*01	IGHJ3*02	IGHD1-26*01,IGHD7-27*01	nan	nan	nan	nan	nan	RGSISSSNYY	IYYSGTT	ARRLGPFDI	MN007687.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
15	20A-618-30_2F05	CAGGTGCAGCTGCAAGAGTCGGGCCCAGGACTGGTGAAGTCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGGAGTAGTAATTATCATTGGGGCTGGATCCGCCAGCCCCCAGGAAAGGCACTGGAGTGGATTGGGAGTCTCTATTATAGTGGGAGCAACTCCTATAACCCGTCCCTCAAGAGTCGAGTCAGCATATCCGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGATCTGTGACCGCCGCAGACACGGCTGTGTATTATTGTGCGAGACGGCTCGGTCCTTTTGACATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	QVQLQESGPGLVKSSETLSLTCTVSGGSIRSSNYHWGWIRQPPGKALEWIGSLYYSGSNSYNPSLKSRVSISVDTSKNQFSLKLRSVTAADTAVYYCARRLGPFDIWGQGTMVTVSS	nan	nan	IGHV4-39*01	IGHJ3*02	IGHD6-6*01	nan	nan	nan	nan	nan	GGSIRSSNYH	LYYSGSN	ARRLGPFDI	MN007683.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
15	315-06-06_1C04	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAATTATTATTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAGGTCCAAGAACCAGTTCTCCCTGAAACTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTTCTGTGCGAGGCGGCTGGGTCCGTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	QVQLQESGPGLVKPSETLSLTCTVSGGSISSSNYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDRSKNQFSLKLSSVTAADTAVYFCARRLGPFDIWGQGTMVTVSS	nan	nan	IGHV4-39*07	IGHJ3*02	IGHD6-19*01,IGHD6-25*01	nan	nan	nan	nan	nan	GGSISSSNYY	IYYSGST	ARRLGPFDI	MN008063.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
15	315-06-06_1E06	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAATTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGACTATCTATTATACTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAGGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCATGTATTACTGTGCGAGGCGGCTGGGTCCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	QVQLQESGPGLVKPSETLSLTCTVSGGSISSSNYYWGWIRQPPGKGLEWIGTIYYTGSTYYNPSLKSRVTISVDRSKNQFSLKLSSVTAADTAMYYCARRLGPFDIWGQGTMVTVSS	nan	nan	IGHV4-39*07	IGHJ3*02	IGHD6-19*01,IGHD6-25*01	nan	nan	nan	nan	nan	GGSISSSNYY	IYYTGST	ARRLGPFDI	MN008064.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
15	315-06-06_1F05	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGGAGTACTAATTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATGTTTTATAGTGGGAGCACCCACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCGAAGAACCAGTTCTCCCTGAAGGTGAACTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCCCGCCGCCTCGGTCCTTTTGATATCTGGGGCCAAGGGACAACGGTCACCGTCTCTTCAG	QVQLQESGPGLVKPSETLSLTCTVSGGSIRSTNYYWGWIRQPPGKGLEWIGSMFYSGSTHYNPSLKSRVTISVDTSKNQFSLKVNSVTAADTAVYYCARRLGPFDIWGQGTTVTVSS	nan	nan	IGHV4-39*07	IGHJ3*02	nan	nan	nan	nan	nan	nan	GGSIRSTNYY	MFYSGST	ARRLGPFDI	MN008065.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
15	315-06-08_1F01	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGGAGTACTAATTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATGTTTTATAGTGGGAGCACCCACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCGAAGAACCAGTTCTCCCTGAAGGTGAACTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCCCGCCGCCTCGGTCCTTTTGATATCTGGGGCCAAGGGACAACGGTCACCGTCTCTTCAG	QVQLQESGPGLVKPSETLSLTCTVSGGSIRSTNYYWGWIRQPPGKGLEWIGSMFYSGSTHYNPSLKSRVTISVDTSKNQFSLKVNSVTAADTAVYYCARRLGPFDIWGQGTTVTVSS	nan	nan	IGHV4-39*07	IGHJ3*02	nan	nan	nan	nan	nan	nan	GGSIRSTNYY	MFYSGST	ARRLGPFDI	MN008066.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
16	SFV015_2A06	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTAAAGAAGCCTGGGACCTCAGTGAAAGTCTCCTGCAAGGCTTCTGGATACATCTTCTCCGGCTCCTATATCCAGTGGGTACGACAGGCCCCTGGGCAAGGGCTTGAGTGGATGGGAAGGATCAACCCTAAGACTGGTAATACAAATTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACATGTCCATCAGCACAGCCTACATGGAGCTGACTAGGCTGAGCTCTGACGACACGGCCGTGTATTACTGTGCGAGAGACTTTGATTACGGTGACTACCGCGGCTCTGCTTTTGATATCTGGGGCCAAGGGGCAATGGTCACCGTCTCTTCA	QVQLVQSGAEVKKPGTSVKVSCKASGYIFSGSYIQWVRQAPGQGLEWMGRINPKTGNTNYAQKFQGRVTMTRDMSISTAYMELTRLSSDDTAVYYCARDFDYGDYRGSAFDIWGQGAMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGTGACAGAGTCACCATCACTTGCCAGCCGAGTCAGGACTTTAGCAACTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACGATACATCCAATTTGGAAACAGGGGTCCCATCAAGATTCAGTGGAAGTGGGGCTGGGACACATTTTACTCTCACCATCAACAGCCTGCAGCCTGAAGACATTGCAACATATTACTGTCAACAGTTAAATACCTTCGGCCCTGGGACCAAAGTGGATATCAAA	DIQMTQSPSSLSASVGDRVTITCQPSQDFSNYLNWYQQKPGKAPKLLIYDTSNLETGVPSRFSGSGAGTHFTLTINSLQPEDIATYYCQQLNTFGPGTKVDIK	IGHV1-2*02,IGHV1-2*06	IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ3*01	QDFSNY	DTS	QQLNT	GYIFSGSY	INPKTGNT	ARDFDYGDYRGSAFDI	MW857999.1	MW858038.1	34078743	Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV015	B-cells;Influenza Human Vaccinee	nan	54.0
16	SFV015_2F04	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTAAAGAAGCCTGGGACCTCAGTGAAAGTCTCCTGCAAGGCTTCTGGATACATCTTCTCCGGCTCCTATATTCAATGGGTACGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCAACCCTAAGACTGGTGGCACAAATTATCCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACATGTCCATCAGCACAGCCTATATGGAGCTGAGTAGGCTGATCTCTGACGACACGGCCGTGTATTACTGTGCGAGAGACTTCGATTACGGTGACTACCGCGGCTCTGCTTTTGATATCTGGGGCCAAGGGGCAATGGTCACCGTCTCTTCA	QVQLVQSGAEVKKPGTSVKVSCKASGYIFSGSYIQWVRQAPGQGLEWMGRINPKTGGTNYPQKFQGRVTMTRDMSISTAYMELSRLISDDTAVYYCARDFDYGDYRGSAFDIWGQGAMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGTGACAGAGTCACCATCACTTGCCAGACGAGTCAGGACTTTAGCAATTATTTAAATTGGTATCAGCAGAAACCAGGAAAAGCCCCTAAACTCCTGATCCACGATACATCCAAGTTGGAAACAGGGGTCCCATCAAGATTCAGTGGAGGTGGGGCCGGGACATATTTTACTCTCACCATCAACGGCCTGCAGCCTGAAGACATTGCAACATATTGGTGTCAACAGTTGAATACCTTCGGTCCTGGGACCAAAGTGGATATCAAA	DIQMTQSPSSLSASVGDRVTITCQTSQDFSNYLNWYQQKPGKAPKLLIHDTSKLETGVPSRFSGGGAGTYFTLTINGLQPEDIATYWCQQLNTFGPGTKVDIK	IGHV1-2*02,IGHV1-2*06	IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ3*01	QDFSNY	DTS	QQLNT	GYIFSGSY	INPKTGGT	ARDFDYGDYRGSAFDI	MW858006.1	MW858043.1	34078743	Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV015	B-cells;Influenza Human Vaccinee	nan	54.0
16	SFV015_2G04	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTAAAGAAGCCTGGGACCTCAGTGAAAGTCTCCTGCAAGGCTTCTGGATACGTCTTCTCCGACTCCTATATTCAATGGGTACGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCAACCCTAAGACTGGTGGCACAAATTTTGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACATGTCCATCAGCACAGCCTATATGGACCTGAGTAGGCTGATCTCTGACGACACGGCCGTATATTACTGTGCGAGAGACTTCGATTACGGTGACTACCGCGGCTCTGCTTTTGATATCTGGGGCCAAGGGGCAATGGTCACCGTCTCTTCA	QVQLVQSGAEVKKPGTSVKVSCKASGYVFSDSYIQWVRQAPGQGLEWMGRINPKTGGTNFAQKFQGRVTMTRDMSISTAYMDLSRLISDDTAVYYCARDFDYGDYRGSAFDIWGQGAMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGTGACAGAGTCACCATCACTTGCCAGACGAGTCAGGACTTTAGCAATTATTTAAATTGGTATCAGCAGAAACCAGGAAAAGCCCCTAAACTCCTGATCCACGATACATCCAAGTTGGAAACAGGGGTCCCATCAAGATTCAGTGGAGGTGGGGCCGGGACATATTTTACTCTCACCATCAACGGCCTGCAGCCTGAAGACATTGCAACATATTGGTGTCAACAGTTGAATACCTTCGGCCCTGGGACCAAAGTGGATATCAAA	DIQMTQSPSSLSASVGDRVTITCQTSQDFSNYLNWYQQKPGKAPKLLIHDTSKLETGVPSRFSGGGAGTYFTLTINGLQPEDIATYWCQQLNTFGPGTKVDIK	IGHV1-2*02,IGHV1-2*06	IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ3*01	QDFSNY	DTS	QQLNT	GYVFSDSY	INPKTGGT	ARDFDYGDYRGSAFDI	MW858003.1	MW858045.1	34078743	Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV015	B-cells;Influenza Human Vaccinee	nan	54.0
16	SFV019_4D05	GAGGTGCAGCTGGTGGAGTCCGGGGGAAAGGTAGTTCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGGCTCTGGATTCACCTTCAGTAGTTCCTGGATGCACTGGGTCCGCCAAGTTCCAGGGAAGGGGCTGGCGTGGGTCTCACGTATTAATAGCGCTGGGACTAGCAAAAGCTACGCGGACTCCGTGAAGGGCCGATTCGCCATCTCCAGAGACAACGGCAGGAACACTCTGTTTCTGCAAATGAATAGTCTGAGAGACGAGGACACGGCTCTGTATTATTGTGCAAGAGACCATGACTACGGTGACTACAGAGGGAACGCTTTTGATCTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA	EVQLVESGGKVVQPGGSLRLSCAGSGFTFSSSWMHWVRQVPGKGLAWVSRINSAGTSKSYADSVKGRFAISRDNGRNTLFLQMNSLRDEDTALYYCARDHDYGDYRGNAFDLWGQGTMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGTATCTGTGGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGATATTAGCAATTATTTAAATTGGTATCAGCAGAAAGCAGGGAAAGCCCCTAAGCTCCTGATCTACGATTCATCCAAGTTGGAAGCAGGGGTCCCATCAAGGTTCAGTGGAAGGCAATCTGGGACAGATTATACTTTCACCATCACCAGCCTGCAGCCTGAGGACATTGCAACATATTTCTGTCAACAACTTAATACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA	DIQMTQSPSSLSVSVGDRVTITCQASQDISNYLNWYQQKAGKAPKLLIYDSSKLEAGVPSRFSGRQSGTDYTFTITSLQPEDIATYFCQQLNTFGGGTKVEIK	IGHV3-74*01	IGHJ3*01,IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ4*01,IGKJ4*02	QDISNY	DSS	nan	GFTFSSSW	INSAGTSK	ARDHDYGDYRGNAFDL	MW858016.1	MW858061.1	34078743	Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV019	B-cells;Influenza Human Vaccinee	nan	30.0
16	SFV019_1B04	GAGGTGCAGCTGGTGGAGTCCGGGGGAAAGGTCGTTCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTCCTGGATGCACTGGGTCCGCCAAGCTCCAGGGCAGGGGCTGGTGTGGGTCTCACGTATTAACAGTGCTGGGAGTAGCAAAAGCTACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAGAGGCGAGGACACGGCTGTGTATTACTGTGCAAGAGATCATGACTACGGTGACTACAGAGGGAACGCTTTTGATATGTGGGGCCTAGGGACAATGGTCACCGTCTCTTCA	EVQLVESGGKVVQPGGSLRLSCAASGFTFSSSWMHWVRQAPGQGLVWVSRINSAGSSKSYADSVKGRFTISRDNAKNTLYLQMNSLRGEDTAVYYCARDHDYGDYRGNAFDMWGLGTMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACGATGCATCCAAATTGGAAACAGGGGTCCCATCAAGGTTCAGTGGAAGACAATCTGGGACAGATTATACTTTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACATATTTCTGTCAACAGCTTCATACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASKLETGVPSRFSGRQSGTDYTFTISSLQPEDFATYFCQQLHTFGGGTKVEIK	IGHV3-74*01	IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ4*01,IGKJ4*02	QDISNY	DAS	nan	GFTFSSSW	INSAGSSK	ARDHDYGDYRGNAFDM	MW857988.1	MW858063.1	34078743	Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV019	B-cells;Influenza Human Vaccinee	nan	30.0
16	SFV019_4G05	GAGGTGCAGCTGGTGGAGTCGGGGGGAGACTTAGTTCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGGCTCTGGATTCACCTTCAGTAGTTCCTGGATGCACTGGGTCCGCCAAGCTCCAGGGAAGGGGCTGGTGTGGGTCTCACGTATTAATAGTGGTGGGAATTTCAAAAAATACGCGGACTCCGTGAGGGGCCGATTCACCATCTCCAGAGACAACACCAGGAACACCCTATATCTGCATATGAGCAGTCTGAGACACGAGGACACGGCTCTTTATTACTGTGCAAGAGATCATGACTACGGTGACTACAGAGGGAACGCGTATGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	EVQLVESGGDLVQPGGSLRLSCAGSGFTFSSSWMHWVRQAPGKGLVWVSRINSGGNFKKYADSVRGRFTISRDNTRNTLYLHMSSLRHEDTALYYCARDHDYGDYRGNAYDIWGQGTMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATTAGCAACTATTTCAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTAATCTTCGATACATCCAAGTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGAAGACAATCTGGGACAGATTATACTTTCACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTTCTGTCAGCAGCTTGATAGTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC	DIQMTQSPSSLSASVGDRVTITCQASQDISNYFNWYQQKPGKAPKLLIFDTSKLETGVPSRFSGRQSGTDYTFTISSLQPEDIATYFCQQLDSFGGGTKVEIK	IGHV3-74*01,IGHV3-74*03	IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ4*01,IGKJ4*02	QDISNY	DTS	nan	GFTFSSSW	INSGGNFK	ARDHDYGDYRGNAYDI	JX027457.1	JX027451.1	22615367, 34078743	Li  et al. PNAS 109:9047-9052 (2012); Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV019	B-cells;Influenza Human Vaccinee	nan	30.0
16	SFV019_1C05	GAGGTGCAGCTGGTGGAGTCCGGGGGAAAGGTAGTTCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGGCTCTGGATTCACCTTCAGTAGTTCCTGGATGCACTGGGTCCGCCAAGTTCCAGGGAAGGGGCTGGCGTGGGTCTCACGCATTAATAGTGGTGGGACTATGAAAGGGTACGCGGACTCCGTGAAGGGCCGATTCGCCATCTCCAGAGACAACGGCAGGAACACTCTGTATCTGCAAATGAATAGTCTGAGAGACGAGGACACGGCTCTATATTATTGTGCAAGAGACTATGACTACGGTGACTACAGAGGGAACGCTTTTGATCTCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA	EVQLVESGGKVVQPGGSLRLSCAGSGFTFSSSWMHWVRQVPGKGLAWVSRINSGGTMKGYADSVKGRFAISRDNGRNTLYLQMNSLRDEDTALYYCARDYDYGDYRGNAFDLWGQGTMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGATGTTAGTAATTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTTCGATTCATCCAATTTGGAAGCAGGGGTCCCATCAAGGTTCAGTGGAAGGCAATCTGGGACAGATTATACTTTGACCATCAACAGCCTGCAGCCTGAGGACATTGCAACATATTTCTGTCAACAACTTAATACTTTCGGCGGAGGGACCAAGGTGGAAATCAAA	DIQMTQSPSSLSASVGDRVTITCQASQDVSNYLNWYQQKPGKAPKLLIFDSSNLEAGVPSRFSGRQSGTDYTLTINSLQPEDIATYFCQQLNTFGGGTKVEIK	IGHV3-74*01,IGHV3-74*03	IGHJ3*01,IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ4*01,IGKJ4*02	QDVSNY	DSS	nan	GFTFSSSW	INSGGTMK	ARDYDYGDYRGNAFDL	MW858021.1	MW858064.1	34078743	Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV019	B-cells;Influenza Human Vaccinee	nan	30.0
16	SFV019_2A02	CAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAGGCCTGGGGCCTCACTGAAGGTCTCCTGCAAGGCCTCTGGTTACAGCTTTACCACCTACGGGATCACCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCACTTACAATGGTTACACAAACTATGCACAGAGACTCCAGGGCAGAGTCACCATGACCACAGACACATCCACTGGGACAGCCTACTTGGAGCTGAGGAGCCTGACATATGACGACACGGCCGTCTATTATTGTGCGAGACGTGGGGACTACGGTGACTACCGGGGTGATGCATTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG	QVQLVQSGAEVKRPGASLKVSCKASGYSFTTYGITWVRQAPGQGLEWMGWISTYNGYTNYAQRLQGRVTMTTDTSTGTAYLELRSLTYDDTAVYYCARRGDYGDYRGDAFDIWGQGTMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGCGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACGTTAGCAACTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTACGATACATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGAACTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACATATTTCTGTCAACAGGTTTTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAC	DIQMTQSPSSLSASVGDRVTITCQASQDVSNYLNWYQQKPGKAPKLLIYDTSNLETGVPSRFSGTGSGTDFTFTISSLQPEDVATYFCQQVFTFGPGTKVDIK	IGHV1-18*04	IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ3*01	QDVSNY	DTS	QQVFT	GYSFTTYG	ISTYNGYT	ARRGDYGDYRGDAFDI	JX027455.1	JX027462.1	22615367, 34078743	Li  et al. PNAS 109:9047-9052 (2012); Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV019	B-cells;Influenza Human Vaccinee	nan	nan
16	SFV019_2A06	GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGTTTCTGGATGCACTGGGTCCGCCAAGTTCCAGGGAAGGGACTGCTGTGGGTCGCACGTATTAACAACGATGGGACTTTCACAACCTACGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAATACGCTGAATCTGCACATGAGCAATCTCAGAGTCGAGGATTCGGCTCTGTATTTCTGTGTAAGAGATAATGACTACGGCGACTACAGAGGGAACGCTTTTGATATTTGGGGCCAGGGGACAATGGTCACCGTCTCTTCAG	EVQLVESGGGLVQPGGSLRLSCAASGFSFSSFWMHWVRQVPGKGLLWVARINNDGTFTTYADSVKGRFTISRDNAKNTLNLHMSNLRVEDSALYFCVRDNDYGDYRGNAFDIWGQGTMVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATGAGCAACTATTTAAATTGGTATCAGCAAAAATCAGGGAAAGCCCCTAAGCTCCTGATTTACGATACTTCCAAATTGGAAGCAGGGGTCCCATCAAGGTTCAGTGGCAGTGGATTTGGGACACATTATGTTTTAAGCATCACCAGTCTACAGCCTGAAGATATTGCAACATATTACTGTGAACAGCTTCATACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC	DIQMTQSPSSLSASVGDRVTITCQASQDMSNYLNWYQQKSGKAPKLLIYDTSKLEAGVPSRFSGSGFGTHYVLSITSLQPEDIATYYCEQLHTFGGGTKVEIK	IGHV3-74*01,IGHV3-74*03	IGHJ3*02	IGHD4-17*01	IGKV1-33*01,IGKV1D-33*01	IGKJ4*01,IGKJ4*02	QDMSNY	DTS	nan	GFSFSSFW	INNDGTFT	VRDNDYGDYRGNAFDI	JX027459.1	JX027452.1	22615367, 34078743	Li  et al. PNAS 109:9047-9052 (2012); Guthmiller et al. Sci Transl Med 13:eabg4535 (2021)	Group 1	HA:Head	PCWilson_donor_SFV019	B-cells;Influenza Human Vaccinee	nan	30.0
17	315-02-06_6D03	CTGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCGCTATCTCTGGTGGCACCATCAGCAGTGGTGCTTACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGCTACATCCATTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGACTCACGATGTCAGTAGACACGTCTAACAACCAGTTCTCCCTGAAACTGAGCTCTGTGACTGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGGAGCCACGTATTACTATGACAGTAGTGGTAATTACGGTCGCTACTTTGACTACTGGGGCCAGGGATCCCTGGTCACCGTCTCCTCAG	LVQLQESGPGLVKPSQTLSLTCAISGGTISSGAYYWSWIRQHPGKGLEWIGYIHYSGSTYYNPSLKSRLTMSVDTSNNQFSLKLSSVTAADTAVYYCARGATYYYDSSGNYGRYFDYWGQGSLVTVSS	nan	nan	IGHV4-31*11	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGTISSGAYY	IHYSGST	ARGATYYYDSSGNYGRYFDY	MN007256.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
17	315-02-06_6B08	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGGCCGTGTATTATTGTGCGAGAGGAGCCACGTATTACTATGATAGTAGTGGTTCTTACGGTCGGTTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGATYYYDSSGSYGRFFDYWGQGTLVTVSS	nan	nan	IGHV4-31*03	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGSISSGGYY	IYYSGST	ARGATYYYDSSGSYGRFFDY	MN007258.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
17	315-02-06_6E06	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTGCTTACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGCAGTGGATTGGGTACATCCATTACAGTGGGAGCACCTACTACAACCCGTCCCTGAAGACTCGAGTTACCATATCAGTAGACACGTCTGAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGGCCGTGTATTATTGTGCGAGAGGAGCCACGTATTACTATGATAGTAGTGGTTCTTATGGTCGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGAYYWSWIRQHPGKGLQWIGYIHYSGSTYYNPSLKTRVTISVDTSENQFSLKLSSVTAADTAVYYCARGATYYYDSSGSYGRYFDYWGQGTLVTVSS	nan	nan	IGHV4-31*03	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGSISSGAYY	IHYSGST	ARGATYYYDSSGSYGRYFDY	MN007257.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
17	315-21-05M_1G07	CAGGTGCAGCTGCAGGAGTCGGCCCCAGGACTGGTGAACCTTTCGGGGACCCTGTCCCTCACTTGCGCTGTTTCTGGTGGTTCCATCACCAGTAGTAACTGGTGGAGTTGGGTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCTATCATAGTGGGAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAAGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGGGGCAACGTATTACTATGATAGTAGTGGTTATTACACACGAGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESAPGLVNLSGTLSLTCAVSGGSITSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGATYYYDSSGYYTRAFDYWGQGTLVTVSS	nan	nan	IGHV4-4*02	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGSITSSNW	IYHSGST	ARGATYYYDSSGYYTRAFDY	MN009190.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
17	315_21Mem_1B06	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTAGTAACTGGTGGAGTTGGGTCCGCCAGTCCCCAGGGAAGGGGCTGGAGTGGGTTGGGCAGATCTATCATAGTGGGAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAAGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGGGACAACTTATTACTATGATACTGGTGGTTATTACACACGAGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQSPGKGLEWVGQIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGTTYYYDTGGYYTRAFDYWGQGTLVTVSS	nan	nan	IGHV4-4*02	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGSISSSNW	IYHSGST	ARGTTYYYDTGGYYTRAFDY	MN009191.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
17	315_21Mem_1C09	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTAGTAACTGGTGGAGTTGGGTCCGCCAGTCCCCAGGGAAGGGGCTGGAGTGGGTTGGGCAGATCTATCATAGTGGGAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAAGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGGGACAACTTATTACTATGATACTGGTGGTTATTACACACGAGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQSPGKGLEWVGQIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGTTYYYDTGGYYTRAFDYWGQGTLVTVSS	nan	nan	IGHV4-4*02	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGSISSSNW	IYHSGST	ARGTTYYYDTGGYYTRAFDY	MN009192.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
17	315-21-05M_1A06	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTAGTAACTGGTGGAGTTGGGTCCGCCAGTCCCCAGGGAAGGGGCTGGAGTGGGTTGGGCAGATCTATCATAGTGGGAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAAGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGGGACAACTTATTACTATGATACTGGTGGTTATTACACACGAGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQSPGKGLEWVGQIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGTTYYYDTGGYYTRAFDYWGQGTLVTVSS	nan	nan	IGHV4-4*02	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GGSISSSNW	IYHSGST	ARGTTYYYDTGGYYTRAFDY	MN009193.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
18	R95-2C03	CAGGTGCGACTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGGCACCTTCAACAGTTACAGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGATACACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCTACGACCACAGTGTACATGGAACTGAGCAGCCTGAGATTGGAGGACTCGGCCATTTATTATTGTGCAAGTGATTCCTCATGTAGATATTACGATATTTTGAATGGACCGTTTCACTACTGGGGCCAGGGAACCATGGTCATCGTCTCGTCAG	QVRLVQSGAEVKRPGSSVKVSCEASGGTFNSYSISWVRQAPGQGLEWMGGIIPIFDTPNYAQKFQGRVTITADKSTTTVYMELSSLRLEDSAIYYCASDSSCRYYDILNGPFHYWGQGTMVIVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GGTFNSYS	IIPIFDTP	ASDSSCRYYDILNGPFHY	MK311753.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
18	K77-1H04	CAGGTGCGACTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGGCACCTTCAACAGTTACAGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGATACACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCTACGACCACTGTGTACATGGAACTGAGCAGCCTGAGATCGGAGGACTCGGCCATTTATTATTGTGCAAGTGATTCCTCATCTAGATATTACGATATTTTGACTGGACCGTTTCACTACTGGGGCCAGGGAACCCTGGTCATCGTCTCGTCAG	QVRLVQSGAEVKRPGSSVKVSCEASGGTFNSYSISWVRQAPGQGLEWMGGIIPIFDTPNYAQKFQGRVTITADKSTTTVYMELSSLRSEDSAIYYCASDSSSRYYDILTGPFHYWGQGTLVIVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTACATAGAAATGGATACAACTATTTGGATTGGTACTTGCAGAGGCCAGGGCAGTCTCCACACCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGTTTTTACACTGAAAATCAGCAGAGTGGAAGTTGAGGATGTTGGGGTCTATTTCTGCATGCAAGCTCTACAAGCTCCTCTCACTTTCGGCGGAGGGACCAGGGTGGAGATCAAAA	DIVMTQSPLSLPVTPGEPASISCRSSQSLLHRNGYNYLDWYLQRPGQSPHLLIYLGSNRASGVPDRFSGSGSGTVFTLKISRVEVEDVGVYFCMQALQAPLTFGGGTRVEIK	IGHV1-69*06	IGHJ4*02	IGHD3-9*01	IGKV2-28*01,IGKV2D-28*01	IGKJ4*01	QSLLHRNGYNY	LGS	MQALQAPLT	GGTFNSYS	IIPIFDTP	ASDSSSRYYDILTGPFHY	MK311384.1	MK311882.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	nan
18	R95-2B10	CAGGTGCGACTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGGCACCTTCAACAGTTACAGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGATACACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCTACGACCACTGTGTACATGGAACTGAGCAGCCTGAGATCGGAGGACTCGGCCATTTATTATTGTGCAAGTGATTCCTCATCTAGATATTACGATATTTTGACTGGACCGTTTCACTACTGGGGCCAGGGAACCCTGGTCATCGTCTCGTCAG	QVRLVQSGAEVKRPGSSVKVSCEASGGTFNSYSISWVRQAPGQGLEWMGGIIPIFDTPNYAQKFQGRVTITADKSTTTVYMELSSLRSEDSAIYYCASDSSSRYYDILTGPFHYWGQGTLVIVSS	CAGTCTGCCCTGACTCAGCCTCGCTCAGTGTCCGGGTCTCCTGGACAGTCAGTCACCATCTCCTGCACTGGAACCAGCAGTGATGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAGCACCCAGGCAAGGCCCCCAAACTCATGATTTATGATGTCAGTAAGCGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGTTGAGGATGAGGCTGATTATTACTGCTGCTCATATGCAGGCAGGTACAGGGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCACTA	QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQVEDEADYYCCSYAGRYRVVFGGGTKLTV	IGHV1-69*06	IGHJ4*02	IGHD3-9*01	IGLV2-11*01	IGLJ2*01,IGLJ3*01	SSDVGGYNY	DVS	CSYAGRYRVV	GGTFNSYS	IIPIFDTP	ASDSSSRYYDILTGPFHY	MK311754.1	MK312106.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
18	R95-2B11	CAGGTGCGACTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGGCACCTTCAACAGTTACAGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGATACACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCTACGACCACTGTGTACATGGAACTGAGCAGCCTGAGATCGGAGGACTCGGCCATTTATTATTGTGCAAGTGATTCCTCATCTAGATATTACGATATTTTGACTGGACCGTTTCACTACTGGGGCCAGGGAACCCTGGTCATCGTCTCGTCAG	QVRLVQSGAEVKRPGSSVKVSCEASGGTFNSYSISWVRQAPGQGLEWMGGIIPIFDTPNYAQKFQGRVTITADKSTTTVYMELSSLRSEDSAIYYCASDSSSRYYDILTGPFHYWGQGTLVIVSS	TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACCTGTGGGGGACACAACATAGGAAGTAAAAGTGTGCACTGGTACCAGCAGAGGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGAAGATAGCGACCGACCCTCAGGGATCCCTGAACGATTCTCTGGCTCCAACTCTGGGGACACGGCCACCCTGACAATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGGGATAGCAGTAGTGATCATGTCGTATTCGGCGGAGGGACCAAGCTGACTGCTACAA	SYELTQPPSVSVAPGQTARITCGGHNIGSKSVHWYQQRPGQAPVLVVYEDSDRPSGIPERFSGSNSGDTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLT	IGHV1-69*06	IGHJ4*02	IGHD3-9*01	IGLV3-21*02	IGLJ2*01,IGLJ3*01	NIGSKS	EDS	QVWDSSSDHVV	GGTFNSYS	IIPIFDTP	ASDSSSRYYDILTGPFHY	MK311755.1	MK312107.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
18	R95-2D06	CAGGTGCGACTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGGCACCTTCAACAGTTACAGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGATACACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCTACGACCACTGTGTACATGGAACTGAGCAGCCTGAGATCGGAGGACTCGGCCATTTATTATTGTGCAAGTGATTCCTCATCTAGATATTACGATATTTTGACTGGACCGTTTCACTACTGGGGCCAGGGAACCCTGGTCATCGTCTCGTCAG	QVRLVQSGAEVKRPGSSVKVSCEASGGTFNSYSISWVRQAPGQGLEWMGGIIPIFDTPNYAQKFQGRVTITADKSTTTVYMELSSLRSEDSAIYYCASDSSSRYYDILTGPFHYWGQGTLVIVSS	CAGTCTGCCCTGACTCAGCCTGCCTCCGAGTCTGGCTCTCCTGGACAGTCGATCACCATCTCCTGCACAGGAACCAGCAGTGATGTTGGGCATTATAACCGTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCCGACTCATGATTTATGAGGACACTGAGCGGCCCTCAAGGCTTTCTAATCGCTTCTCTGCCTCCAAGTCTGGCAGCACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAAGACGAGGCTGATTATTACTGTTGCTCATATGCAACTAGTGGCACTCTTGTCTTCGGCACTGGGACCAGGGTCACCGTCCTAG	QSALTQPASESGSPGQSITISCTGTSSDVGHYNRVSWYQQHPGKAPRLMIYEDTERPSRLSNRFSASKSGSTASLTISGLQAEDEADYYCCSYATSGTLVFGTGTRVTVL	IGHV1-69*06	IGHJ4*02	IGHD3-9*01	IGLV2-23*01,IGLV2-23*02,IGLV2-23*03	IGLJ1*01	SSDVGHYNR	EDT	CSYATSGTLV	GGTFNSYS	IIPIFDTP	ASDSSSRYYDILTGPFHY	MK311756.1	MK312108.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
18	R95-2E05	CAGGTGCGACTGGTGCAGTGTGGGGGTGAGGTGAAGAGGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGTTTCTGGAGGCACCTTCAACAGTTACAGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGATACACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCTACGACCACTGTGTACATGGAACTGAGCAGCCTGAGATCGGAGGACTCGGCCATTTATTATTGTGCAAGTGATTCCTCATCTAGATATTACGATATTTTGACTGGACCGTTTCACTACTGGGGCCAGGGAACCCTGGTCATCGTCTCTCAGC	QVRLVQCGGEVKRPGSSVKVSCEVSGGTFNSYSISWVRQAPGQGLEWMGGIIPIFDTPNYAQKFQGRVTITADKSTTTVYMELSSLRSEDSAIYYCASDSSSRYYDILTGPFHYWGQGTLVIVS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GGTFNSYS	IIPIFDTP	ASDSSSRYYDILTGPFHY	MK311757.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
18	R95-2F05	CAGGTGCGACTGGTGCAGTCTGGGGCTGAGGTGAAGAGGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGGCACCTTCAACAGTTACAGTATCAGTTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGATACACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCTACGACCACTGTGTACATGGAACTGAGCAGCCTGAGATCGGAGGACTCGGCCATTTATTATTGTGCAAGTGATTCCTCATCTAGATATTACGATATTTTGACTGGACCGTTTCACTACTGGGGCCAGGGAACCCTGGTCATCGTCTCGTCAG	QVRLVQSGAEVKRPGSSVKVSCEASGGTFNSYSISWVRQAPGQGLEWMGGIIPIFDTPNYAQKFQGRVTITADKSTTTVYMELSSLRSEDSAIYYCASDSSSRYYDILTGPFHYWGQGTLVIVSS	CAGGCTGTGTTGACCCAGGAGCCCTCACCGACTGTGTCCCCAGGAGGGACACTCACTCTCACCTGTGCTTCCAGCACAGGAGCAGTCACCAGTGGTTACTATCCAAACTGGTTCCAGCAGAAACCTGGACAAGCACCCAGGGCAATGATTTATAGTACAAGCAATAAACACTCCTGGACCCCTGCCCGATTCTCAGGCTCCCTCATTGGGGGCAAAGCTGCCCTGACACTGTCAGGTGTGCAGCCTGAGGACGAGGCTGAGTATTACTGCCTGCTCTACTATGGTGGTGCTCAGGTGAATGTGGTATTCGGCGGAGGGACCAAGCTGACTGTCATCG	QAVLTQEPSPTVSPGGTLTLTCASSTGAVTSGYYPNWFQQKPGQAPRAMIYSTSNKHSWTPARFSGSLIGGKAALTLSGVQPEDEAEYYCLLYYGGAQVNVVFGGGTKLTV	IGHV1-69*06	IGHJ4*02	IGHD3-9*01	IGLV7-43*01	IGLJ2*01,IGLJ3*01	TGAVTSGYY	STS	LLYYGGAQVNVV	GGTFNSYS	IIPIFDTP	ASDSSSRYYDILTGPFHY	MK311758.1	MK312109.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
19	315-24-06_1E04	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGCCTAGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGACTATCTATTATACTGGGAGCACCTACTTCAACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACACGTCCAAGAACCAGTTCTCCCTGAGGCTGAGCTCTGTGACCGCCGCAGATACGGCTGTGTATTACTGTGCGAGATCTCATAACAGTGGCTGGTACGGCTATGACTACTATCACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGTIYYTGSTYFNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARSHNSGWYGYDYYHYGMDVWGQGTTVTVSS	nan	nan	IGHV4-39*01	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GGSISSSSYY	IYYTGST	ARSHNSGWYGYDYYHYGMDV	MN009379.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
19	315-24-04_1B11	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTAGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGACTATCTATTATAGTGGGAGCACCTACTTCAACCCGTCCCTCAAGAGTCGAGTCACCATGTCCGTAGACACGTCCAAGAACCAGTTCTCCCTGAGGCTGAGCTCTGTGACCGCCGCAGATACGGCTGTGTATTACTGTGCGAGATCTCACAACAGTGGCTGGTACGGCTATGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGTIYYSGSTYFNPSLKSRVTMSVDTSKNQFSLRLSSVTAADTAVYYCARSHNSGWYGYDYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV4-39*01	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GGSISSSSYY	IYYSGST	ARSHNSGWYGYDYYYYGMDV	MN009380.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
19	315-24-06_1E10	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGCCTCTGGTGGCTCCATCAGCAGTAGTGATTACTACTGGGACTGGCTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGACTATCTATTATAGTGGGAGCACCTACTATAACCCGTCCCTCAAGAGTCGAGTCACCCTATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGTCGCAGACACGGCTGTGTATTACTGTGCGAGATCTCATAACAGTGGCTGGTACGGCTATGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGGCCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTASGGSISSSDYYWDWLRQPPGKGLEWIGTIYYSGSTYYNPSLKSRVTLSVDTSKNQFSLKLSSVTVADTAVYYCARSHNSGWYGYDYYYYGMDVWGQGATVTVSS	nan	nan	IGHV4-39*01	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GGSISSSDYY	IYYSGST	ARSHNSGWYGYDYYYYGMDV	MN009381.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
19	315-24-06_1H01	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGCCTCTGGTGGCTCCATCAGCAGTAGTGATTACTACTGGGACTGGCTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGACTATCTATTATAGTGGGAGCACCTACTATAACCCGTCCCTCAAGAGTCGAGTCACCCTATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGAGATCTCATAACAGTGGCTGGTACGGCTATGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGGCCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTASGGSISSSDYYWDWLRQPPGKGLEWIGTIYYSGSTYYNPSLKSRVTLSVDTSKNQFSLKLSSVTAADTAVYYCARSHNSGWYGYDYYYYGMDVWGQGATVTVSS	nan	nan	IGHV4-39*01	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GGSISSSDYY	IYYSGST	ARSHNSGWYGYDYYYYGMDV	MN009382.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
19	20A-623-30_1G08	CAGGTGCAGCTGCCGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTTTCTGGTGCCTCCATCAGCAGTACTAATTACTACTGGGACTGGCTCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGGTTGGGACTACCTATTATAATGGGAGCACCTTCTATAATCCGTCCCTCAAGAGTCGAGTCTTCCTATCCGTTGACACGTCCAAGAACCACTTCTCCCTGAAGCTGAGGTCTGTGACCGCCGCAGACACGGCTGTCTATTACTGTGCGAGATCTCATAACACTGGCTGGTACGGCCATGACTACTACGACTACGGTATGGACGTCTGGGGCCAAGGGGCCACGGTCACCGTCTCCTCA	QVQLPESGPGLVKPSETLSLTCTVSGASISSTNYYWDWLRQPPGKGLEWVGTTYYNGSTFYNPSLKSRVFLSVDTSKNHFSLKLRSVTAADTAVYYCARSHNTGWYGHDYYDYGMDVWGQGATVTVSS	nan	nan	IGHV4-39*02	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GASISSTNYY	TYYNGST	ARSHNTGWYGHDYYDYGMDV	MN009383.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
19	315-54-08_1H01	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCGTTCACCTGCTCTGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGACTATCTATTATAGTGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTGCGAGGTCTTATAACAGTGGCTGGTACGGACATGATTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSFTCSVSGGSISSSSYYWGWIRQPPGKGLEWIGTIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARSYNSGWYGHDYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV4-39*01	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GGSISSSSYY	IYYSGST	ARSYNSGWYGHDYYYYGMDV	MN009901.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
20	315-09-08_1D05	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTACTTGGAATAGTGCTGATATAGGCTATGCGGACTCTGTGAAGGGCCGATTCAACATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGACCTGAGGACACGGCCTTGTATTACTGTGCAAAAGATGGAGGGAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVKPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGITWNSADIGYADSVKGRFNISRDNAKNSLYLQMNSLRPEDTALYYCAKDGGNWFDPWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*02	nan	nan	nan	nan	nan	nan	GFTFDDYA	ITWNSADI	AKDGGNWFDP	MN008536.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
20	20A-618-30_2G02	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGTTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCATCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTACTTGGAATAGTGCTGATTTAGACTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCACGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAAGACACGGCCTTGTATTATTGTGCAAAAGATATGGGAAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVQPGRSLRLSCAASGFIFDDYAMHWVRQAPGKGLEWVSGITWNSADLDYADSVKGRFTISRDNATNSLYLQMNSLRAEDTALYYCAKDMGNWFDPWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*02	IGHD1-26*01	nan	nan	nan	nan	nan	GFIFDDYA	ITWNSADL	AKDMGNWFDP	MN007727.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
20	20A-678-41_1G05	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCACTGAGACTCTCCTGTGTTGCGTCTGGATTCATCTTTGATGATTATGCCATTCACTGGGTCCGACAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTACTTGGAATAGTGCTGATACAGGCTATGCGGATTCTGTGAAGGGCCGATTTAACATCTCCAGAGACAACTCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTATATTACTGTGCAAAAGATATGGGAAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVQPGRSLRLSCVASGFIFDDYAIHWVRQAPGKGLEWVSGITWNSADTGYADSVKGRFNISRDNSKNSLYLQMNSLRAEDTALYYCAKDMGNWFDPWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*02	IGHD1-26*01	nan	nan	nan	nan	nan	GFIFDDYA	ITWNSADT	AKDMGNWFDP	MN009636.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
20	20A-618-30_1E05	GAGGTGCAGCTGGTGGAGTTTGGGGGAGGCTTGGTACAACCTGGCAGGTCCCTGAGACTCTCCTGTGTAGCCTCTGGATTCACGTTTGATGACTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGCATTACTTGGAATAGTGCTGACATAGGCTATGCGGACTCTGTGAAGGGCCGATTCAACATCTCCAGAGACAACGCCAAGAACTCCGTCTTTCTGCAAATGAATAATCTGCGAGCTGAGGACACGGCCTTGTATTACTGTACAAAAGATGGTGGGAACTGGTTCGACCCCTGGGGCCAAGGAACCCTGGTCACCGTCTCCTCAG	EVQLVEFGGGLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGITWNSADIGYADSVKGRFNISRDNAKNSVFLQMNNLRAEDTALYYCTKDGGNWFDPWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*01,IGHJ5*02	IGHD1-26*01,IGHD2-15*01,IGHD2-21*01	nan	nan	nan	nan	nan	GFTFDDYA	ITWNSADI	TKDGGNWFDP	MN007728.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
20	20A-618-30_1F01	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTACTTGGAATAATGTTAGTATAGGATATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATTTGCAGATGGACAGTCTGAGACCTGAGGACACGGCCTTGTATTACTGTACAAAAGATGGGGGAAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACGGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGITWNNVSIGYVDSVKGRFTISRDNAKNSLYLQMDSLRPEDTALYYCTKDGGNWFDPWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*02	IGHD3-16*01,IGHD3-16*02	nan	nan	nan	nan	nan	GFTFDDYA	ITWNNVSI	TKDGGNWFDP	MN007729.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
20	315-05-04_1B12	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTGTTAGTTGGAATAGTGCTAGCATAGACTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAAGTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGTACAAAAGATATGGGAAACTGGTTCGACCCCTGGGGCCAGGGAACCCTTGTCACCGTCTCTTCAG	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSASIDYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCTKDMGNWFDPWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*02	IGHD1-26*01	nan	nan	nan	nan	nan	GFTFDDYA	VSWNSASI	TKDMGNWFDP	MN007720.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
21	315-09-04_1B11	CAGGTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTCCTGGAGCTGGATCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATCATAGTGCGAGCACCTATTACAATCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAGGTCCAAGAATCAATTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTCTATTACTGTGCCAGATTTAGTGGGAGCTACTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYHSASTYYNPSLKSRVTISVDRSKNQFSLKLSSVTAADTAVYYCARFSGSYFDYWGQGTLVTVSS	nan	nan	IGHV4-30-2*01	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSGGYS	IYHSAST	ARFSGSYFDY	MN008470.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
21	315-09-05M_1B10	CAGGTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGTAGTGGTGGTTACTCCTGGAGCTGGATCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATCATAGTGCGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATTTCAGTAGACAGGTCCAAGAACCAATTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTCTATTACTGTGCCAGATTTAGTGGGAGCTACTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYHSASTYYNPSLKSRVTISVDRSKNQFSLKLSSVTAADTAVYYCARFSGSYFDYWGQGTLVTVSS	nan	nan	IGHV4-30-2*01	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSGGYS	IYHSAST	ARFSGSYFDY	MN008471.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
21	315-09-06_1E12	CAGGTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTCCTGGAGCTGGATCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTCCATCTATCATATTGGGAGCACCTACTCCAACCCGTCCCTCAAGAGTCGAGTCAGCATATCACTAGACAGGTCCAAGAACCAGTTCTCCCTGAGGCTGAGCTCTGTGACCGCCGCGGACACGGGCGTCTATTACTGTGCCAGATTTAGTGGGAGCTACTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGSIYHIGSTYSNPSLKSRVSISLDRSKNQFSLRLSSVTAADTGVYYCARFSGSYFDYWGQGTLVTVSS	nan	nan	IGHV4-30-2*01	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSGGYS	IYHIGST	ARFSGSYFDY	MN008474.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
21	315-09-08_1A06	CAGGTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTCCTGGAGCTGGATCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATCATAGTGCGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAGGTCCAAGAACCAATTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTCTATTACTGTGCCAGATTTAGTGGGAGCTACTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYHSASTYYNPSLKSRVTISVDRSKNQFSLKLSSVTAADTAVYYCARFSGSYFDYWGQGTLVTVSS	nan	nan	IGHV4-30-2*01	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSGGYS	IYHSAST	ARFSGSYFDY	MN008476.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
21	315-09-08_1E07	CAGGTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTCCTGGAGCTGGATCCGGCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTCCATCTATCATATTGGGAGCACCTACTCCAACCCGTCCCTCAAGAGTCGAGTCAGCATATCACTAGACAGGTCCAAGAACCAGTTCTCCCTGAGGCTGAGCTCTGTGACCGCCGCGGACACGGGCGTCTATTACTGTGCCAGATTTAGTGGGAGCTACTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGSIYHIGSTYSNPSLKSRVSISLDRSKNQFSLRLSSVTAADTGVYYCARFSGSYFDYWGQGTLVTVSS	nan	nan	IGHV4-30-2*01	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSGGYS	IYHIGST	ARFSGSYFDY	MN008477.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
21	315-54-06_4F10	CAGGTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTCCTGGAGCTGGATCCGGCAGCCACCAGGGAGGGGCCTGGAGTGGATTGGGTACATCTATCATATTGGGAGCACCTACTACAACCCGTCCTTCAAGAGTCGAGTCACCATGTCAGTAGACAACTCCAAGAACCAGCTCTCCCTGAACCTGACCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCCAGGTATAGTGGGAGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGRGLEWIGYIYHIGSTYYNPSFKSRVTMSVDNSKNQLSLNLTSVTAADTAVYYCARYSGSYFDYWGQGTLVTVSS	nan	nan	IGHV4-30-2*01	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSISSGGYS	IYHIGST	ARYSGSYFDY	MN009869.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
22	315-54-06_4A11	CAGGTTCAGTTGGTGCAGTCTGGAGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGACTTCTGGTTATACCTTTACCAGTTTTGGTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCCTACAATGGTGACACCAAGAATGCACAGAAACTCCAGGGCAGAGTCTCCATGACCACAGACAAGTCCACGAACACAGCCTACATGGAGCTGAGGACCCTCACATCTGACGACACGGCCGTATATTACTGTGCGAGAGGCCCTCCGTTATTTTTCAGCAGTTGGCCTATTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGASVKVSCKTSGYTFTSFGVSWVRQAPGQGLEWMGWISAYNGDTKNAQKLQGRVSMTTDKSTNTAYMELRTLTSDDTAVYYCARGPPLFFSSWPIDYWGQGTQVTVSS	nan	nan	IGHV1-18*01	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GYTFTSFG	ISAYNGDT	ARGPPLFFSSWPIDY	MN010119.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
22	315-54-05M_1A05	CAGGTTCAGGTGGCGCTGTGGGGAGGTGAAGTGAAGACGCCGGGGGCCTCAGTGAAGGTCTCCCGCAAGATTTCTGGTTACACCTTTACCAGTTTTGGTGTCAGCGGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCCTACAATGGTGACACCAAGAATGCACAGAAATTCCAGGGCAGAGTCACCATGACCACAGACAAATCCACGAACACAGCCTACATGGAGCTGTGGACCCTCACATCTGACGACACGGCCGTATATTACTGTGCGAGAGGCCCTCCCTTATATAGCAGCAGCTGGCCTATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAT	QVQVALWGGEVKTPGASVKVSRKISGYTFTSFGVSGVRQAPGQGLEWMGWISAYNGDTKNAQKFQGRVTMTTDKSTNTAYMELWTLTSDDTAVYYCARGPPLYSSSWPIDYWGQGTLVTVSS	nan	nan	IGHV1-18*01	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GYTFTSFG	ISAYNGDT	ARGPPLYSSSWPIDY	MN010118.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
22	315-54-06_4F06	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAAGTGAAGAACCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGACTTCTGGCTACACCTTTACCAGTTTTGGTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCCTACAATGGTGACAGCAAGAATGCACAGAAACTCCAGGGCAGAGTCACCATGACCACAGACAAATCCACAAACACAGCCTACATGGAGCTGAGGACCCTCACACCTGACGACACGGCCTTATATTACTGTGCGAGAGGCCCTCCCCTATATAGCAGCAGCTGGCCTATTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCCTCAG	QVQLVQSGAEVKNPGASVRVSCKTSGYTFTSFGVSWVRQAPGQGLEWMGWISAYNGDSKNAQKLQGRVTMTTDKSTNTAYMELRTLTPDDTALYYCARGPPLYSSSWPIDYWGQGTQVTVSS	nan	nan	IGHV1-18*01	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GYTFTSFG	ISAYNGDS	ARGPPLYSSSWPIDY	MN010120.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
22	315-54-06_4H04	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAAGTGAAGAACCCTGGGGCCTCAGTGAGGGTCTCCTGCAAGACTTCTGGCTACACCTTTACCAGTTTTGGTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCCTACAATGGTGACAGCAAGAATGCACAGAAATTCCAGGGCAGAGTCACCATGACCACAGACAAATCCACGAACACAGCCTACATGGAGCTGAGGACCCTCACACCTGACGACACGGCCTTATATTACTGTGCGAGAGGCCCTCCCCTATATAGCAGCAGCTGGCCTATTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCCTCAG	QVQLVQSGAEVKNPGASVRVSCKTSGYTFTSFGVSWVRQAPGQGLEWMGWISAYNGDSKNAQKFQGRVTMTTDKSTNTAYMELRTLTPDDTALYYCARGPPLYSSSWPIDYWGQGTQVTVSS	nan	nan	IGHV1-18*01	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GYTFTSFG	ISAYNGDS	ARGPPLYSSSWPIDY	MN010121.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
22	315-54-06_4A12	CAGGTTCAACTGGTGCAGTCTGGAGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGACTTCTGGTTACACCTTTACCAGTTTTGGTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCCTACAACGGTGACACCAAGAATGCACAGAAACTCCAGGGCAGAGTCACCATGACCACAGACAAATCCACGAACACAGCCTACATGGAACTGAGGACCCTCACATCTGACGACACGGCCGTATATTACTGTGCGAGAGGCCCTCCCTTATATTATAGCAGTTGGCCTATTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGASVKVSCKTSGYTFTSFGVSWVRQAPGQGLEWMGWISAYNGDTKNAQKLQGRVTMTTDKSTNTAYMELRTLTSDDTAVYYCARGPPLYYSSWPIDYWGQGTQVTVSS	nan	nan	IGHV1-18*01	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GYTFTSFG	ISAYNGDT	ARGPPLYYSSWPIDY	MN010122.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
22	315-02-06_6F12	CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTCACCAGCTTCGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCTCTTACAATGGCAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAACACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTTTACTACTGTGCGAGATCCCCCCCTCTTTATAGCAGCAGCTGGTTTATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSFGISWVRQAPGQGLEWMGWISSYNGNTNYAQKLQGRVTMTTDTSTNTAYMELRSLRSDDTAVYYCARSPPLYSSSWFIDYWGQGTLVTVSS	nan	nan	IGHV1-18*04	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GYTFTSFG	ISSYNGNT	ARSPPLYSSSWFIDY	MN007479.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
23	315-06-06_1A07	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTGCTTACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGGTTGGGTACATCTATTACAGTGGGAGCACCTACAACAACCCGTCCCTCAAGAGTCGAATTAGTCTATCAGTAGACACGTCTAAGAACCAGTTGTCCCTGAAACTGGGCTCTGTGACTGCCGCGGACACGGCCGTGTATTATTGTGCGGGGGGTGCGGCCGGTGACCGCGACTACTACTACTACGGTCTGGACGTCTGGGGCCAAGGGACCCCGGTCACCGTCTCTTCA	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGAYYWSWIRQHPGKGLEWVGYIYYSGSTYNNPSLKSRISLSVDTSKNQLSLKLGSVTAADTAVYYCAGGAAGDRDYYYYGLDVWGQGTPVTVSS	nan	nan	IGHV4-31*03	IGHJ6*02	IGHD4-17*01	nan	nan	nan	nan	nan	GGSISSGAYY	IYYSGST	AGGAAGDRDYYYYGLDV	MN008034.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
23	315-06-06_4B01	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGTGGTGGGAACTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATGTATTATAGTGGGAGCACCGACCACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGGCCGTGTATTACTGTGCGAAAGGCGACGCTGGTGACCGCCACTACTACTACTACGGTCTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGNYWSWIRQHPGKGLEWIGYMYYSGSTDHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAKGDAGDRHYYYYGLDVWGQGTTVTVSS	nan	nan	IGHV4-31*03	IGHJ6*02	IGHD2-21*02	nan	nan	nan	nan	nan	GGSISSGGNY	MYYSGST	AKGDAGDRHYYYYGLDV	MN008033.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
23	315-06-06_1A03	CAGGTGCAGCTGGTGCAGTCTGGGGTTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGACACCTTCAACACCTATACTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAACAAATTACGCACAGAAGTTCCAGGGCAGAGTCACAATTACCGCGGACGAATCCACGAGCACCGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGTGGTTTGGCTGGTGATAGGCACTACTACTACTATGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGVEVKKPGSSVKVSCEASGDTFNTYTISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCASGLAGDRHYYYYGLDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GDTFNTYT	IIPIFGTT	ASGLAGDRHYYYYGLDV	MN008281.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
23	315-06-06_1B02	CAGGTGCAGCTGGTGCAGTCTGGGGTTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCGAGGCTTCTGGAGACACCTTCAACACCTATACTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAACAAATTACGCACAGAAGTTCCAGGGCAGAGTCACAATTACCGCGGACGAATCCACGAGCACCGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGTGGTTTGGCTGGTGATAGGCACTACTACTACTATGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGVEVKKPGSSVKVSCEASGDTFNTYTISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCASGLAGDRHYYYYGLDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	IGHD6-19*01	nan	nan	nan	nan	nan	GDTFNTYT	IIPIFGTT	ASGLAGDRHYYYYGLDV	MN008282.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
23	20A-604-30_1C06	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGACTCCGTCAGCAGTGGTAGTAACTATTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTACTTCAGTGGGAACACCAGATACAACCCCTCCCTCAAGAGTCGAGTCACCATATCACTAGACACGTCCGAGGACCAGTTCTCCCTGAAGCTGACCTCTATGACCGCTGCGGACACGGCCGTGTATTATTGTGCGAGTGGGTCGGCTGGGGATAGGCACTACTACTACTACGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCCCA	QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGSNYWSWIRQPPGKGLEWIGYIYFSGNTRYNPSLKSRVTISLDTSEDQFSLKLTSMTAADTAVYYCASGSAGDRHYYYYGLDVWGQGTTVTVS	nan	nan	IGHV4-61*01	IGHJ6*02	IGHD7-27*01	nan	nan	nan	nan	nan	GDSVSSGSNY	IYFSGNT	ASGSAGDRHYYYYGLDV	MN009893.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
24	LPAF-a.03	CAGGTCACCTTGAGGGAGTCTGGTCCTGCGCTGGTGAAACCCACACAGACCCTCACACTGACCTGCTCCTTCTCTGGTTTCTCACTCACCACTAGTGGAATGTGTGTGAGCTGGATCCGTCAGCCCCCAGGGAGGGCCCTGGAGTGGCTTGCACTCATTGATTGGAATGATGCTAAATACTACAACACATCCCTGAAGACCAGGCTCACCATCTCCAGGGACACCTCCAAAAAGCAGGTGGTCCTTATAATGTCCAACATGGACCCTTTGGACACAGCCACTTATTACTGTGCACGGATTCTCTATGGTGACTTCGTTGGCTACCTCGACCCCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAG	QVTLRESGPALVKPTQTLTLTCSFSGFSLTTSGMCVSWIRQPPGRALEWLALIDWNDAKYYNTSLKTRLTISRDTSKKQVVLIMSNMDPLDTATYYCARILYGDFVGYLDPWGQGTLVTVSS	TATGAGCTGACTCAGCCACTCTCAGTGTCAGTGGCCCTGGGACAGACGGCCAGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAATGTGCACTGGTACCAGCGGAAGCCAGGCCAGGCCCCTGTCCTGGTCATTTATACGGACATCAACCGGCCCTCTGGGATCCCTGAGCGATTCTCTGGCTCCAACTCGGGGAACACGGCCACCCTGACCATCAGCAGAGCCCAAGCCGGGGATGAGGCTGACTATTTCTGTCAGGTGTGGGACACCAACACCGTGCTATTCGGCGGAGGGACCAAGCTGACCGTCCTAG	YELTQPLSVSVALGQTARITCGGNNIGSKNVHWYQRKPGQAPVLVIYTDINRPSGIPERFSGSNSGNTATLTISRAQAGDEADYFCQVWDTNTVLFGGGTKLTVL	IGHV2-70*01	IGHJ5*02	IGHD4-17*01	IGLV3-9*01	IGLJ2*01,IGLJ3*01	NIGSKN	TDI	QVWDTNTVL	GFSLTTSGMC	IDWNDAK	ARILYGDFVGYLDP	MT755770.1	MT755798.1	32877670	Cheung et al. Cell Rep 32:108088 (2020)	Group 1	HA:Head	Lanzavecchia_donor_LPAF	human vaccinees	nan	42.0
24	LPAF-a.05	CAGGTCACCTTGAGGGAGTCTGGTCCTGCGCTGGTGAAACCCACACAGACCCTCACACTGACCTGCACCTTCTCGGGGTTCTCATTCACCACTAGTGGAATGTGTGTGAGCTGGGTCCGTCAGCCCCCAGGGAAGGCCCTGGAGTGGCTTGCCCTCATTGATTGGCGTGATAATAAATTCTACAGCACATCTCTGAGGACCAGGCTCACCATCTCCAAGGACACCTCCAGAAACCAGGTTGTCCTTACAATGACCGACATGGACCCTGTGGACACAGCCACATATTCCTGTGCGCGGATGCTCTACGGTGACTTCGCTGGGTACCTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVTLRESGPALVKPTQTLTLTCTFSGFSFTTSGMCVSWVRQPPGKALEWLALIDWRDNKFYSTSLRTRLTISKDTSRNQVVLTMTDMDPVDTATYSCARMLYGDFAGYLDPWGQGTLVTVSS	TCCTATGAGCTGACTCAGGCACTCTCAGTGTCAGTGGCCCTGGGACAGACGGCCAGGATTACCTGTGGGGGAAACAACATCGGATATAAAAATGTGCACTGGTACCAGTATAAGCCAGGCCAGGCCCCTGTGCTGGTCATCTATAGGGATACCAACCGGCCCTCTGGGATCCCTGAGCGCTTCTCTGGCTCCAACTCGGGGAACACGGCCACCCTGACCATCAGCGGAGCCCAAGGCGGGGATGAGGCTGACTATTATTGTCAGGTGTGGGACAGCAGTTCCGTGGCATTCGGCGGAGGGACCAAGCTGACCGTCCTAG	SYELTQALSVSVALGQTARITCGGNNIGYKNVHWYQYKPGQAPVLVIYRDTNRPSGIPERFSGSNSGNTATLTISGAQGGDEADYYCQVWDSSSVAFGGGTKLTVL	IGHV2-70*20	IGHJ5*02	IGHD4-17*01	IGLV3-9*01	IGLJ2*01,IGLJ3*01	NIGYKN	RDT	QVWDSSSVA	GFSFTTSGMC	IDWRDNK	ARMLYGDFAGYLDP	MT755772.1	MT755800.1	32877670	Cheung et al. Cell Rep 32:108088 (2020)	Group 1	HA:Head	Lanzavecchia_donor_LPAF	human vaccinees	nan	42.0
24	LPAF-a.02	CAGGTCACCTTGAGGGAGTCTGGTCCTGCGCTGGTGAAACCCACACAGACCCTCACACTGACCTGCTCCTTCTCTGGGTTCTCACTCACCACTAGTGGAATGTGTGTGAGCTGGATCCGTCAGCCCCCAGGGAGGGCCCTGGAGTGGCTTGCACTCATTGATTGGAATGATGTTAAATACTACAGCACATCTCTGAAGACCAGGCTCACCATCTCCAGGGACACCTCCAAAAAGCAGGTGGTCCTTACAATGTCCAACATGGACCCTTTGGACACAGCCACTTATTACTGTGCACGGATGCTCTACGGTGACTTCGGTGGGTACCTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVTLRESGPALVKPTQTLTLTCSFSGFSLTTSGMCVSWIRQPPGRALEWLALIDWNDVKYYSTSLKTRLTISRDTSKKQVVLTMSNMDPLDTATYYCARMLYGDFGGYLDPWGQGTLVTVSS	CTGACTCAGCCACTCTCAGTGTCAGTGGCCCTGGGACAGACGGCCGGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAATGTGCACTGGTACCAGCGGAAGCCAGGCCAGGCCCCTGTCCTGGTCATCTATACGGACATCAACCGGCCCTCTGGGATCCCTGAGCGATTCTCTGGCTCCAACTCGGGGAACACGGCCACCCTGACCATCAGCAGAGCCCAAGCCGGGGATGAGGCTGACTATTTCTGTCAGGTGTGGGACAGCAACACCGTGCTATTCGGCGGAGGGACCAAGCTGACCGTCCTAG	LTQPLSVSVALGQTAGITCGGNNIGSKNVHWYQRKPGQAPVLVIYTDINRPSGIPERFSGSNSGNTATLTISRAQAGDEADYFCQVWDSNTVLFGGGTKLTVL	IGHV2-70*01	IGHJ5*02	IGHD4-17*01	IGLV3-9*01	IGLJ2*01,IGLJ3*01	NIGSKN	TDI	QVWDSNTVL	GFSLTTSGMC	IDWNDVK	ARMLYGDFGGYLDP	MT755769.1	MT755797.1	32877670	Cheung et al. Cell Rep 32:108088 (2020)	Group 1	HA:Head	Lanzavecchia_donor_LPAF	human vaccinees	nan	42.0
24	FISW-f.01	CAGGTCACCTTGAGGGAGTCTGGTCCTGCGCTGGTGAAACCCACACAGACCCTCACACTGACCTGCACCTTCTCTGGGTTCTCACTCAGCACTAGTGGAATGTGTGTGAGCTGGATCCGTCAGCCCCCAGGGAAGGCCCTGGAGTGGCTTGCACTCATTAATTGGAATGATGATAAATACTACAGCGGACCTCTGAAGACCAGGCTCACCATCTCCAAGGACACCTCCAAAAACCAGGTGGTCCTTATAATGACCAACATGGACCCTGTGGACACAGCCACATATTACTGTGCACGGATGTTGTACGGTGACTTCGGTCGCTACTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMCVSWIRQPPGKALEWLALINWNDDKYYSGPLKTRLTISKDTSKNQVVLIMTNMDPVDTATYYCARMLYGDFGRYFDPWGQGTLVTVSS	TCGTCTGTGCTGACTCAGCCACCCTCAGTGTCAGTGGCCCCAGGAAAGACGGCCAGGATTTCCTGTGGGGGAATCAACATTGGAAGTAAAGGTGTGCACTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCATCTATTATGATAGCGGCCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGAAACACGGCCACCCTGACCATCCGCGGGGTCGAGGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGCGATACTAGTGGTTATCATGGGGTATTCGGCGGAGGGACCAGACTGACCGTCCTAG	SSVLTQPPSVSVAPGKTARISCGGINIGSKGVHWYQQKPGQAPVLVIYYDSGRPSGIPERFSGSNSGNTATLTIRGVEAGDEADYYCQVCDTSGYHGVFGGGTRLTVL	IGHV2-70*01	IGHJ5*02	IGHD4-17*01	IGLV3-21*04	IGLJ2*01,IGLJ3*01	NIGSKG	YDS	QVCDTSGYHGV	GFSLSTSGMC	INWNDDK	ARMLYGDFGRYFDP	MT755755.1	MT755783.1	32877670	Cheung et al. Cell Rep 32:108088 (2020)	Group 1	HA:Head	Lanzavecchia_donor_FISW	human vaccinees	nan	nan
24	LPAF-a.06	GTGCAGCTGGTGGAGTCTGGTCCTGCGCTGGTGAAACCCACACAGACCCTAACACTGACCTGCACCTTCTCTGGATTCTCACTCACCACTAGTGGGATGTGTGTGAGCTGGATCCGTCAGCCCCCAGGGAAGGCCCTGGAGTGGCTTGCACTCATTGATTGGGATGATAATAAATATTATGGAACATCTCTGAGGACCCGGCTCACCATCTCCAAGGACACCTCCAAAAAGCAGGTGGTCCTTAAAATGACCAACATGGACCCTGTGGACACAGGCACGTATTATTGTGCACGGATGCTGTACGGTGATATCGGTGGGTGGCTCGACCCCTTGGGCCAGGGAACCCAGGTCACCGTCTCTTCAG	VQLVESGPALVKPTQTLTLTCTFSGFSLTTSGMCVSWIRQPPGKALEWLALIDWDDNKYYGTSLRTRLTISKDTSKKQVVLKMTNMDPVDTGTYYCARMLYGDIGGWLDPLGQGTQVTVSS	TCCTATGAACTGACTCAGCCACTCTCAGTGTCAGTGGCCCTGGGACAGACGGCCAGGATTACCTGTGACGGAAACAACATTGGAAGTAAGAATCTTCATTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTTCTGGTCATGTATACGGATATCAATCGGCCCTCTGGGATCCCTGAGCGATTGTCTGGCTCCAACTCGGGGAACACGGCCACCCTGACCATCAGCAGAGCCCAAGCCGGGGATGAGGCTGACTATTACTGTCAGGTGTGGGACAGCAGCACCGTTGTCTTCGGCGGAGGGACCAAGCTGACCGTCCTAG	SYELTQPLSVSVALGQTARITCDGNNIGSKNLHWYQQKPGQAPVLVMYTDINRPSGIPERLSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTVVFGGGTKLTVL	IGHV2-70*13	IGHJ5*02	IGHD4-17*01	IGLV3-9*01	IGLJ2*01,IGLJ3*01,IGLJ3*02	NIGSKN	TDI	QVWDSSTVV	GFSLTTSGMC	IDWDDNK	ARMLYGDIGGWLDP	MT755773.1	MT755801.1	32877670	Cheung et al. Cell Rep 32:108088 (2020)	Group 1	HA:Head	Lanzavecchia_donor_LPAF	human vaccinees	nan	42.0
25	315-54-05M_1A09	GAGGTGCAGTTGGTGGAGTCTGGGGGAGCCTTGGTACAGCCTGGCAGGTCCCTGAGACTTTCCTGTGCAGCCTCCGGATTCAACTTTGATGATTTTGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAATTGGAACGGTGATAAAATAGCTTACGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACGACGCCGAGAACTCCCTGTATCTGCAAATGAACAGTTTGAAACCTGAGGACACGGCCTTGTATTACTGTGCAAAAGAGGGGCTGCTATATTACTTTGAGTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGALVQPGRSLRLSCAASGFNFDDFAMHWVRQAPGKGLEWVSGINWNGDKIAYADSVKGRFTISRDDAENSLYLQMNSLKPEDTALYYCAKEGLLYYFEYWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ4*02	IGHD2-2*02	nan	nan	nan	nan	nan	GFNFDDFA	INWNGDKI	AKEGLLYYFEY	MN010036.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
25	315-21-06_1G04	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGAATCACCTTCAGTGACTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCTTTTATATTATATGATGGAACTAAGACACACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAGGAACACGCTGCATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGAGGGTCTCCTGTACTATTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAVSGITFSDYAMHWVRQAPGKGLEWVAFILYDGTKTHYADSVKGRFTISRDNSRNTLHLQMNSLRAEDTAVYYCAREGLLYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*04,IGHV3-30-3*03	IGHJ4*02	nan	nan	nan	nan	nan	nan	GITFSDYA	ILYDGTKT	AREGLLYYFDY	MN008860.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
25	315-21-05M_1H04	CAGGTGCAGCTGGTCCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCTTCAGTGAAGGTTTCCTGCAAGGCATCTGCATACAGCTTCACCAGCTACCATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAATCCTAGTGGTGGTAGCACAACCTACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGAAGGTGGTTATTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGASVKVSCKASAYSFTSYHMHWVRQAPGQGLEWMGIINPSGGSTTYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGGYYYFDYWGQGTLVTVSS	nan	nan	IGHV1-46*01	IGHJ4*02	IGHD3-22*01,IGHD3-3*01,IGHD3-3*02	nan	nan	nan	nan	nan	AYSFTSYH	INPSGGST	AREGGYYYFDY	MN008863.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
25	20A-678-41_1C04	GAGGTGCAGCTGGTGGAGTCTGGGGGACGTGTGGTGCGGCCGGGGGGGTCCCTGAGACTCTCTTGTGCAGCCTCTGGATTCAGCCTTGACGATCATGGCATGAGCTGGGTCCGCCAGGCCCCAGGGAAGGGGCTGGAGTGGGTCGCTGGTATTACCTGGAATGGTGATAAAATAGGTTATGCAGACTCTGTGAGGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATTTGGAAATGAACAGTCTGCGAGCCGAGGATTCGGCCTTCTATTACTGTGCGAGAGAAGGGATCCTCTACTACTTTGACTACTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCAG	EVQLVESGGRVVRPGGSLRLSCAASGFSLDDHGMSWVRQAPGKGLEWVAGITWNGDKIGYADSVRGRFTISRDNAKNSLYLEMNSLRAEDSAFYYCAREGILYYFDYWGQGALVTVSS	nan	nan	IGHV3-20*04	IGHJ4*02	nan	nan	nan	nan	nan	nan	GFSLDDHG	ITWNGDKI	AREGILYYFDY	MN009641.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
25	315-05-08_1E08	CAGGTGCAGCTGGTGGAATCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAACTATGCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGCGATAAATCCTCCGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTATATCTGCAAATGAACAGCCTGAGAGCTGACGACACGGCTGTGTATTACTGTGCGAGAGGCGGTGGCCTCTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMHWVRQAPGKGLEWVAVISYDGSDKSSADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCARGGGLYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30-3*01	IGHJ4*02	IGHD4-23*01	nan	nan	nan	nan	nan	GFTFSNYA	ISYDGSDK	ARGGGLYYFDY	MN007733.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
26	315-24-06_1A01	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGTGTGGTACGGCCTGGGGGGTCCCTAAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATGATGGCATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCTAGTATTAATTGGAATGGTGGTAGCACAGGTTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAGGAACTCCCTGTATCTGCAAATGAGCAGTCTGAGAGCCGCGGACACGGCCTTCTACTTCTGTGCGAGAGAAAGCATTGGCTGGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVRPGGSLRLSCAASGFTFDDDGMSWVRQAPGKGLEWVSSINWNGGSTGYADSVKGRFTISRDNARNSLYLQMSSLRAADTAFYFCARESIGWYYFDYWGQGTLVTVSS	nan	nan	IGHV3-20*04	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFTFDDDG	INWNGGST	ARESIGWYYFDY	MN009292.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
26	315-24-06_1C06	GAGGTGCAGCTGGTAGAGTCTGGGGGAGGTGTGGTTCGGCCTGGGGGGTCCCTAAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATGATGGCATGAGTTGTGTCCGCCAAGCTCCAGGGAAGGGGCTGGAGTGGGTCTCCAGTATTCATTGGAATGGTGGTAGCACAGGTTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCCTTCTACTACTGTGCGAGAGAAAGCATTGGCTGGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVRPGGSLRLSCAASGFTFDDDGMSCVRQAPGKGLEWVSSIHWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAFYYCARESIGWYYFDYWGQGTLVTVSS	nan	nan	IGHV3-20*04	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFTFDDDG	IHWNGGST	ARESIGWYYFDY	MN009293.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
26	315-24-06_1G02	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGTGTGGTACGGCCTGGGGGGTCCCTAAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATGATGGCATGAGTTGGGTCCGCCAAGCTCCAGGGAAGGGGCTGGAGTGGGTCTCTGGTATTAATTGGAATGGTGGTAGCACAGGTTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCCTTCTACTACTGTGCGAGAGAAAGCATTGGCTGGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVRPGGSLRLSCAASGFTFDDDGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAFYYCARESIGWYYFDYWGQGTLVTVSS	nan	nan	IGHV3-20*04	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFTFDDDG	INWNGGST	ARESIGWYYFDY	MN009294.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-24	H7N9 Human Vaccinee	nan	nan
26	315-54-08_1C03	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGTGTGGTCCGGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCCCCTTTGATGAATCTGCCATGAGCTGGGTCCGCCAAGCTCCAGGGAAGGGGCTGGAGTGGGTCTCTGGTATTAGTTGGGATGGTGGTAGCACAGGTTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGTCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCCTTGTATCACTGTGCGAGGGGGAGCATTGGCTGGTACTTTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVRPGGSLRLSCAASGFPFDESAMSWVRQAPGKGLEWVSGISWDGGSTGYADSVKGRFTISRDNVKNSLYLQMNSLRAEDTALYHCARGSIGWYFFDYWGQGTLVTVSS	nan	nan	IGHV3-20*01	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFPFDESA	ISWDGGST	ARGSIGWYFFDY	MN010060.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
27	315-06-08_1E09	GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGAGAGTCTCTGAAGATCTCCTGTAAGGCTTCTGGATACAGCTTTACCACCTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGCTCATCTATCCTGATGACTCTGATACCAGATACAGTCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAACACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGATTCCCCCTTGGCTCAGACTACTACTATTATGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVQSGAEVKKPGESLKISCKASGYSFTTYWIGWVRQMPGKGLEWMGLIYPDDSDTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAMYYCARFPLGSDYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV5-51*01	IGHJ6*02	IGHD5-12*01,IGHD5-24*01,IGHD6-19*01	nan	nan	nan	nan	nan	GYSFTTYW	IYPDDSDT	ARFPLGSDYYYYGMDV	MN008236.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
27	315-05-08_1D09	GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCCTGGTCAGGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTTTAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATCCATTAGTAGAAGTGCCACTTACACAGACTACGCAGACTCAATGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGTCACGTCGGGTAGTGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGGLVRPGGSLRLSCAASGFTFSSFSMNWVRQAPGKGLEWVSSISRSATYTDYADSMKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTSGSDYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-21*01	IGHJ6*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GFTFSSFS	ISRSATYT	ARVTSGSDYYYYGMDV	MN007803.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
27	20A-618-30_2A03	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTTTTCTATGAACTGGGTCCGCCAGACTCCAGGCACGGGGCTGGAGTGGGTGGCAGTTATTTCATATGATGGAAGTAATAAGTACTACGCAGACTCCGTGAGGGGCCGATTCACCATCTCCAGGGACAATTCCAAGAACACGTTGCATCTGCAAATGAACAGCTTGAGAGCGGAGGACGCGGCTGTATATTATTGTGCGAGAGTAACTAGTGGGAACTACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCGTCA	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSFSMNWVRQTPGTGLEWVAVISYDGSNKYYADSVRGRFTISRDNSKNTLHLQMNSLRAEDAAVYYCARVTSGNYYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-30*04,IGHV3-30-3*03	IGHJ6*02	IGHD1-26*01	nan	nan	nan	nan	nan	GFTFSSFS	ISYDGSNK	ARVTSGNYYYYYGMDV	MN007811.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
27	20A-618-30_2E01	GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCACTCTCTTTAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATCCATTAGTAGTGATTATCGTCACATGTATTACGCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAGCTCACTGTTTCTGCAAATGAACAGCCTGAGAGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGTAACTAGTGGGAGCCACGACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCTCGGTCACCGTCTCCTCA	EVQLVESGGGLVKPGGSLRLSCAASGFTFTLFSMNWVRQAPGKGLEWVSSISSDYRHMYYADSVKGRFTISRDNAKSSLFLQMNSLRVEDTAVYYCARVTSGSHDYYYGMDVWGQGTSVTVSS	nan	nan	IGHV3-21*01	IGHJ6*02	IGHD1-26*01	nan	nan	nan	nan	nan	GFTFTLFS	ISSDYRHM	ARVTSGSHDYYYGMDV	MN007806.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
28	K77-2E02	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCCTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCAGCAGTAGTTACTACTGGAGTTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATGACAATGGGAAAACCAACCACAACCCCACCCTCACGAGTCGAGTCACCATATCAGCAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACGGCCGCAGACACGGCCGTCTATTACTGCGCGAGCGCGAAACGATATTGTAGTAGTACCAGCTGCTATGGCTTAGAGTACTTATTCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTVSGGSSSSYYWSWIRQPPGKGLEWIGYIYDNGKTNHNPTLTSRVTISADTSKNQFSLKLSSVTAADTAVYYCASAKRYCSSTSCYGLEYLFGMDVWGQGTTVTVSS	TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGGAGAATCATTGCCAAAACAATATGGTTATTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTGATATATAAAGACATTGAGAGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAGCTCAGGGCCAACAGTCACGTTGACCATCAGTAGAGTCCAGGCGGAAGACGAGGCTGACTATTACTGTCAATCAGCAGACAACAGTACTACTTACCTGGTGTTCGGCGGAGGGACCAAGCTGACTGCTACAA	SYELTQPPSVSVSPGQTARITCSGESLPKQYGYWYQQKPGQAPVLVIYKDIERPSGIPERFSGSSSGPTVTLTISRVQAEDEADYYCQSADNSTTYLVFGGGTKLT	IGHV4-59*08	IGHJ6*02	IGHD2-2*01,IGHD2-2*03	IGLV3-25*03	IGLJ3*02	SLPKQY	KDI	QSADNSTTYLV	GGSSSSYY	IYDNGKT	ASAKRYCSSTSCYGLEYLFGMDV	MK311486.1	MK312041.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Head	Melbourne_donor_K77	2015 IIV3 vaccination	nan	114.0
28	K77-1H06	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTCACTACTGGAGTTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATGACAGTGGGAAAACCAACCACAACCCCACCCTCAAGAGTCGAGTCACCATATCAGCAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACGGCCGCAGACACGGCCGTCTATTACTGTGCGAGCGCAAGACGATATTGTAGTAGTACCAGCTGCTATGGCTTAGAGTACTACTTCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQPPGKGLEWIGYIYDSGKTNHNPTLKSRVTISADTSKNQFSLKLSSVTAADTAVYYCASARRYCSSTSCYGLEYYFGMDVWGQGTTVTVSS	nan	nan	IGHV4-59*08	IGHJ6*02	IGHD2-2*01,IGHD2-2*03	nan	nan	nan	nan	nan	GGSISSHY	IYDSGKT	ASARRYCSSTSCYGLEYYFGMDV	MK311487.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	nan
28	K77-1H07	CTGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTCACTACTGGAGTTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATGACAGTGGCAAAACCAACCACAACCCCACCCTCAAGAGTCGAGTCACCATATCAGCAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACGGCCGCAGACACGGCCGTCTATTACTGTGCGAGCGCAAGACGATATTGTAGTAGTACCAGCTGCTATGGCTTAGAGTACTACTTCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	LVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQPPGKGLEWIGYIYDSGKTNHNPTLKSRVTISADTSKNQFSLKLSSVTAADTAVYYCASARRYCSSTSCYGLEYYFGMDVWGQGTTVTVSS	TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGTCCCCAGGACAGACGGCCAGGATCACCTGCTCTGGAGAATCATTGCCAAAGCAATATGGTTATTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTGATATATAAAGACATTGAGAGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAGCTCAGGGACAACAGTCACGTTGACCATCAGTAGAGTCCAGGCAGAAGACGAGGCTGACTATTACTGTCAATCAGCAGACAGCAATACTACTTACCTGATATTCGGCGGAGGGACCAAGCTGACCGTCACTA	SYELTQPPSVSVSPGQTARITCSGESLPKQYGYWYQQKPGQAPVLVIYKDIERPSGIPERFSGSSSGTTVTLTISRVQAEDEADYYCQSADSNTTYLIFGGGTKLTV	IGHV4-59*08	IGHJ6*02	IGHD2-2*01,IGHD2-2*03	IGLV3-25*03	IGLJ2*01,IGLJ3*01	SLPKQY	KDI	QSADSNTTYLI	GGSISSHY	IYDSGKT	ASARRYCSSTSCYGLEYYFGMDV	MK311488.1	MK312042.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	114.0
28	R95-2F01	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTCACTACTGGAGTTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATGACAGTGGCAAAACCAACCACAACCCCACCCTCAAGAGTCGAGTCACCATATCAGCAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACGGCCGCAGACACGGCCGTCTATTACTGTGCGAGCGCAAGACGATATTGTAGTAGTACCAGCTGCTATGGCTTAGAGTACTACTTCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQPPGKGLEWIGYIYDSGKTNHNPTLKSRVTISADTSKNQFSLKLSSVTAADTAVYYCASARRYCSSTSCYGLEYYFGMDVWGQGTTVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCGTGCATAGTAATGGACACAATTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAACTCCTGATCTATTTGAGTTCTAGTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAGATTAACAGAGTGGAGGCTGAGGATGTTGGGGTTTATTTCTGCATGCAAGCTCTACAAGCTCCGTACACTTTTGGCCAGGGGACCAGGCTGGAGATCAAAC	DIVMTQSPLSLPVTPGEPASISCRSSQSLVHSNGHNYLDWYLQKPGQSPQLLIYLSSSRASGVPDRFSGSGSGTDFTLKINRVEAEDVGVYFCMQALQAPYTFGQGTRLEIK	IGHV4-59*08	IGHJ6*02	IGHD2-2*01,IGHD2-2*03	IGKV2-28*01,IGKV2D-28*01	IGKJ2*01	QSLVHSNGHNY	LSS	MQALQAPYT	GGSISSHY	IYDSGKT	ASARRYCSSTSCYGLEYYFGMDV	MK311861.1	MK312003.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
29	315-54-06_1E11	CAGGTGCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGACACCTTCAGCAGCTATGCTATCAACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCCATCTTTGGAACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGTCTACATGGAACTGAACAGCCTGAGATCTGAGGACACGGCCGTGTTTTACTGTGCGAGAGTGGGATTTTGTGGTGGTGACTGCTATTCCCTGTATTACCACTACTACAGTCTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCG	QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYAINWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTVYMELNSLRSEDTAVFYCARVGFCGGDCYSLYYHYYSLDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	IGHD2-21*02	nan	nan	nan	nan	nan	GDTFSSYA	IIPIFGTA	ARVGFCGGDCYSLYYHYYSLDV	MN010291.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
29	315-54-05M_1B11	CAGGTGCACCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGACACCTTCAGTAGCTATGCTATCAACTGGGTGCGACAGGCCCCTGGACAAGGGCCTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAGCTACGCACTGAAGTTCCAGGGCAGAGTCACGATTACCGCTGACGATTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTATATTACTGTGCGAGAGTGGGGTATTGTGGTGGTGACTGCTATTCCCTTTACTACTACTACTACGCTATAGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCC	QVHLVQSGAEVKKPGSSVKVSCKASGDTFSSYAINWVRQAPGQGPEWMGGIIPIFGTASYALKFQGRVTITADDSTSTVYMELSSLRSEDTAVYYCARVGYCGGDCYSLYYYYYAIDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	IGHD2-21*02	nan	nan	nan	nan	nan	GDTFSSYA	IIPIFGTA	ARVGYCGGDCYSLYYYYYAIDV	MN010290.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
29	315-09-04_1B10	CAGGTGCACCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGAAGACACCTTCAGCAGCTATGCTATCAACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGATAGACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATTCACGAGCACAGTCTACATGGACCTGAGTAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGTGGGCTATTGTGGTGGTGATTGCTATTCAGGGTACTACTACTACTACGGTGTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVHLVQSGAEVKKPGSSVKVSCKASEDTFSSYAINWVRQAPGQGLEWMGGIIPIFDRPNYAQKFQGRVTITADEFTSTVYMDLSSLRSEDTAVYYCARVGYCGGDCYSGYYYYYGVDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	IGHD2-21*01	nan	nan	nan	nan	nan	EDTFSSYA	IIPIFDRP	ARVGYCGGDCYSGYYYYYGVDV	MN008747.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
29	315-54-06_1G10	CAGGTGCACCTGGTGCAGTCTGGGCCTGAGGTGAGGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGACACCTTCAGCAGCTATGCTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCCTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACGCACGGAAGTTCCAGGGCAGAGTCACAATTACCGCGGACGAATCCACGAGCACATTATACATGGAGCTGAGCAGCCTGAGATTTGAGGACACGGCCGTGTATTATTGTGTGAGAGTGGGGTATTGTGGTGTTGACTGCTATTCCCTATACTACTCCTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCAGCGTCTCCTCA	QVHLVQSGPEVRKPGSSVKVSCKASGDTFSSYAVSWVRQAPGQGPEWMGGIIPIFGTANYARKFQGRVTITADESTSTLYMELSSLRFEDTAVYYCVRVGYCGVDCYSLYYSYYAMDVWGQGTTVSVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	IGHD2-21*02	nan	nan	nan	nan	nan	GDTFSSYA	IIPIFGTA	VRVGYCGVDCYSLYYSYYAMDV	MN010292.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
30	20A-518-30_1F04	CAGGCGCAGCTGGCGCAGTCTGGGGCTGAGGTTAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCAGGAGACACCTTCAGCAGTCATAGTATCAGCTGGGTTCGACAGGCGCCTGGACAAGGGCTTGAATGGATGGGAGAGATCATCCCTATTCTTGGTACAGTAAAGTACGCAGAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATTCACGACCACAGCCTACATGGAGGTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGGGACAACTTATGGGTGACCGCCACTTCTACTACTATGGGATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QAQLAQSGAEVKKPGSSVKVSCKASGDTFSSHSISWVRQAPGQGLEWMGEIIPILGTVKYAEKFQGRVTITADEFTTTAYMEVSSLRSEDTAVYYCAGQLMGDRHFYYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69*16,IGHV1-69D*01	IGHJ6*02	IGHD2-21*02,IGHD4-17*01	nan	nan	nan	nan	nan	GDTFSSHS	IIPILGTV	AGQLMGDRHFYYYGMDV	MN008669.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
30	20A-618-30_2H03	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGGCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGACACCTTCAGCAGCTATACTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATTCCTATCTTTGGTACAGTCAACTACGCACAGAACTTCCAGGGCAGAGTCACGATTTCCGCGGACGAATCCACGAGCACAGCGTACATGGCGCTGAGCAGCCTGAGATTTGAGGACACGGCCGTGTATTACTGTGCGAGAGCCTTAATCGGAGACCGACACTTCTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKAGSSVKVSCKASGDTFSSYTISWVRQAPGQGLEWMGGIIPIFGTVNYAQNFQGRVTISADESTSTAYMALSSLRFEDTAVYYCARALIGDRHFYYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	nan	nan	nan	nan	nan	nan	GDTFSSYT	IIPIFGTV	ARALIGDRHFYYYGMDV	MN007846.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
30	315-09-08_1E10	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCAGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGACACCTTCAGCAGCTATGGTATCTCCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATCCCTATCTTTGGTACAACAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGGACCTGAGCAGCCTGAGATCTGAGGACACGGCCATCTATTACTGTGCGAGACACCTTATAGGTGACCGCCATTTCTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYGISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMDLSSLRSEDTAIYYCARHLIGDRHFYYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-69*01,IGHV1-69D*01	IGHJ6*02	IGHD2-21*02	nan	nan	nan	nan	nan	GDTFSSYG	IIPIFGTT	ARHLIGDRHFYYYGMDV	MN008667.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
31	AG13-3F04	GTGCAGCTGGTGCAGTCTGGGGCTGAAATGCAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTCACCGGGTTCTATTTGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCTCAATAGTGGTGACACAGACACTGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGTGACACGTCCATCAGCACAGCCTACATGGACCTGAGCAGCCTGAAATCTGACGACACGGCCGTCTATTACTGTGCGACTTGGTATATCAGTGGCTGGTACGACGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	VQLVQSGAEMQKPGASVKVSCKASGFTFTGFYLHWVRQAPGQGLEWMGWINLNSGDTDTAQKFQGRVTMTSDTSISTAYMDLSSLKSDDTAVYYCATWYISGWYDGMDVWGQGTTVTVSS	GATATTGTGATGACTCAGTCGCCACTCTCCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTAAATACTAATGGATACACCTATTTGGATTGGTTCCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTTTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACATATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCCCGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAA	DIVMTQSPLSLPVTPGEAASISCRSSQSLLNTNGYTYLDWFLQKPGQSPQLLIYLGFNRASGVPDRFSGSGSGTYFTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKVEIK	IGHV1-2*02	IGHJ6*02	IGHD6-19*01	IGKV2-28*01,IGKV2D-28*01	IGKJ1*01	QSLLNTNGYTY	LGF	MQALQTPRT	GFTFTGFY	INLNSGDT	ATWYISGWYDGMDV	MH205394.1	MH205570.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Unk	PCWilson_donor_AG13	B-cells;Influenza natural infection or vaccination	nan	56.0
31	AG13-3G03	GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTCACCGGCTTCTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCAAACAGTGGTGACACAGATTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGTGACACGTCCATCAGCACAGCCTACATGGACCTGACCAGGCTGAGATATGACGACACGGCCGTCTATTACTGTGCGACTTGGTATATCAGTGGCTGGTACGACGGCATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	VQLVQSGAEVKKPGASVKVSCKASGFTFTGFYMHWVRQAPGQGLEWMGWINPNSGDTDYAQKFQGRVTMTSDTSISTAYMDLTRLRYDDTAVYYCATWYISGWYDGMDVWGQGTTVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGGCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTAAATACTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCGGTCTCCACAGCTCCTGATCTATTTGGGTTCTATTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAAGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCCCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA	DIVMTQSPLSLPVTPGEAASISCRSSQSLLNTNGYNYLDWYLQKPGRSPQLLIYLGSIRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKVEIK	IGHV1-2*02	IGHJ6*02	IGHD6-19*01	IGKV2-28*01,IGKV2D-28*01	IGKJ1*01	QSLLNTNGYNY	LGS	MQALQTPRT	GFTFTGFY	INPNSGDT	ATWYISGWYDGMDV	MH205391.1	MH205578.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Unk	PCWilson_donor_AG13	B-cells;Influenza natural infection or vaccination	nan	56.0
31	AG5-E04	GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAGGGCTTCTGGATTCACCTTCACCGGCTTCTATGTCCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGGTGGGATGGATCAACCCTAACAGTGGTGACACAAAGTATACACAGAAGTTTCAGGACAGGGTCACCATGACCGGGGACACGTCCATTAGTACCGCATACATGGAGCTGACCAGGCTGAGATCCGACGACACGGCCGTCTATTACTGTGCGACCTGGTATGTCAGTGGCTGGTACGACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	VQLVQSGAEVKKPGASVKVSCRASGFTFTGFYVHWVRQAPGQGLEWVGWINPNSGDTKYTQKFQDRVTMTGDTSISTAYMELTRLRSDDTAVYYCATWYVSGWYDGMDVWGQGTTVTVSS	GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCTCCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTACATAGTAATGGATACACCTATTTGGATTGGTACCTGCAGAAGCCAGGACAGTCTCCACAGCTCCTGATCTATTTGCGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAGAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTCTACAAACTCCTCGAACATTCGGCCAAGGGACCAAGGTGGAAATCAAA	DIVMTQSPLSLPVSPGEPASISCRSSQSLLHSNGYTYLDWYLQKPGQSPQLLIYLRSNRASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQGLQTPRTFGQGTKVEIK	IGHV1-2*02	IGHJ6*02	IGHD6-19*01	IGKV2-28*01,IGKV2D-28*01	IGKJ1*01	QSLLHSNGYTY	LRS	MQGLQTPRT	GFTFTGFY	INPNSGDT	ATWYVSGWYDGMDV	MH205319.1	MH205580.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Unk	PCWilson_donor_AG5	B-cells;Influenza natural infection or vaccination	nan	56.0
32	20A-620-30_1H05	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTTTCAACTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGAAGGATCATCCCTGTCCTTGGTATAGAAAAATACGCACAGAGATTCCAGGGCAGAATCACGCTTACCGCGGACAAATCCACGAGCACAGCCTACATGCAGCTGAGCAACCTCAGATCTGACGACACGGCCGTTTATTACTGTGCGAGAGCGTCCGGTGGTAACTCCCCCCTCGACTACTGGGGCCTGGGAGTCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAFNWVRQAPGQGLEWMGRIIPVLGIEKYAQRFQGRITLTADKSTSTAYMQLSNLRSDDTAVYYCARASGGNSPLDYWGLGVLVTVSS	nan	nan	IGHV1-69*09	IGHJ4*02	IGHD4-23*01	nan	nan	nan	nan	nan	GGTFSSYA	IIPVLGIE	ARASGGNSPLDY	MN008869.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
32	315-06-06_1C05	CTGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGGTGGGAGGGATCATCCCTATCTTTGGAACTATAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTATCGCGGACAAATCCACGACCACAGCCTACATGGAGCTGAACAGCCTGAGATCTGACGACACGGCCGTCTATTACTGTGCGAGAGCTAGCGGAAAAAGGTCGCCCCTTGACTACTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCAG	LVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAFSWVRQAPGQGLEWVGGIIPIFGTINYAQKFQGRVTIIADKSTTTAYMELNSLRSDDTAVYYCARASGKRSPLDYWGQGALVTVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD1-14*01,IGHD6-25*01	nan	nan	nan	nan	nan	GGTFSSYA	IIPIFGTI	ARASGKRSPLDY	MN008176.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
32	20A-609-30_1E03	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCCGGGTCCTCGGTGAGGATCTCCTGCAAGGCTTCTGGAGGCAGCTTCAGCAGCTATGCCTTCAACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCACCCCCATCCTTGGGACGGCGACCTACGCCCGGAAATTCCAGGCCAGAGCCACGATCACCGCGGACAAATCCACGGGCACAGTGTCCATGGATCTGACCAGCCTGACATCTGAGGACACGGCCCTTTATTACTGTGCGCGAGCTAGCGGGAGACGGTCTCCCCTTGACTACTGGGGCCAGGGAACCCTGGTCGCCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVRISCKASGGSFSSYAFNWVRQAPGQGLEWMGGITPILGTATYARKFQARATITADKSTGTVSMDLTSLTSEDTALYYCARASGRRSPLDYWGQGTLVAVSS	nan	nan	IGHV1-69*06	IGHJ4*02	IGHD1-26*01	nan	nan	nan	nan	nan	GGSFSSYA	ITPILGTA	ARASGRRSPLDY	MN008181.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
33	315-06-06_1F12	CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCTGAGACCCTGTCCCTCACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGCAGTGGATTGGGGAAATCAAGCATAGTGGAAGCACCAACTACAACCCGTCCCTCAAGAGTCGAGTCAGCATATCAGTGGACACGTCCAAGAGCCAGTTCTCCCTGATTCTGAGGTCTGTGACCGCCGCGGACACGGCTGTCTATTACTGTGCGAGAGGTCCGAGCAGCTGGTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLQWIGEIKHSGSTNYNPSLKSRVSISVDTSKSQFSLILRSVTAADTAVYYCARGPSSWYFDYWGQGTLVTVSS	nan	nan	IGHV4-34*01	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GGSFSGYY	IKHSGST	ARGPSSWYFDY	MN008085.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
33	315-02-06_6B02	CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCCTCGGAGACCCTGTCCCTCATGTGTGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAATCACCAACTACAACCCGTCCCTCGAGAGTCGAGTTACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTTTATTACTGTGCGAGAGGCCCCAGCAGCTGGTACCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQQWGAGLLKPSETLSLMCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGITNYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGPSSWYLDYWGQGTLVTVSS	nan	nan	IGHV4-34*01	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GGSFSGYY	INHSGIT	ARGPSSWYLDY	MN007281.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
33	315B_02Mem_1E12	CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCGGTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGTCCCCAGGGACGGGGCTGGAGTGGATTGGGGAAATCAGTCATAGAGGAACCACCGACTACAACCCGTCCCTCACGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAATCTGAGTTCTGTGACCGCCGCGGACACGGCTGTCTATTACTGTGCGAGAGGCCCCAGCAGCTGGTACCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLQQWGAGLLKPSETLSLTCGVYGGSFSGYYWSWIRQSPGTGLEWIGEISHRGTTDYNPSLTSRVTISVDTSKNQFSLNLSSVTAADTAVYYCARGPSSWYLDYWGQGTLVTVSS	nan	nan	IGHV4-34*01	IGHJ4*02	IGHD6-13*01	nan	nan	nan	nan	nan	GGSFSGYY	ISHRGTT	ARGPSSWYLDY	MN007279.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
34	315-54-04_1C04	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCGGCCTCTGGATTCACTTTCAGTAACTATAACATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATATATTAGTAGCGATAGTACTACCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCACGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGACGAGGACACGGCTGTATATTACTGTGCGAGAGATAAATGGCTACAGTTGGAAGGCCTTGACTACTGGGGCCAGGGAACCCTGATCACCGTCTCCTCAG	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYNMNWVRQAPGKGLEWVSYISSDSTTIYYADSVKGRFTISRDNATNSLYLQMNSLRDEDTAVYYCARDKWLQLEGLDYWGQGTLITVSS	nan	nan	IGHV3-48*02	IGHJ4*02	IGHD5-24*01	nan	nan	nan	nan	nan	GFTFSNYN	ISSDSTTI	ARDKWLQLEGLDY	MN010075.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
34	315-54-08_1B12	CAAGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAGCTTCAATAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCACTTCTATGGTATGATGGAAATAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCACGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTATATTACTGTGCGAGAGATAAGTGGCTACGCTTAGAGGGTTTTGACTACTGGGGCCAGGGAACCCTGGTCTCCGTCTTCTCAG	QVHLVESGGGVVQPGRSLRLSCAASGFSFNNYGMHWVRQAPGKGLEWVALLWYDGNNKYYADSVKGRFTISRDNSTNTLYLQMNSLRAEDTAVYYCARDKWLRLEGFDYWGQGTLVSVFS	nan	nan	IGHV3-33*01	IGHJ4*02	IGHD5-12*01	nan	nan	nan	nan	nan	GFSFNNYG	LWYDGNNK	ARDKWLRLEGFDY	MN010080.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
34	315-06-04_1B07	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAATTATGAAATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAATGGTAGTACCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACACCGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTTTATTACTGTGCGAGAGATCGGTGGCTACGATTAGAGGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYEMNWVRQAPGKGLEWVSYISSNGSTIYYADSVKGRFTISRDTAKNSLYLQMNSLRAEDTAVYYCARDRWLRLEGFDYWGQGTLVTVSS	nan	nan	IGHV3-48*03	IGHJ4*02	IGHD5-12*01	nan	nan	nan	nan	nan	GFTFSNYE	ISSNGSTI	ARDRWLRLEGFDY	MN008186.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
35	315-21-06_1A08	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGTACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGCGTGGCAGTTATATCATATGATGGAGGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACTCTGTTTCTGCAAATGAGCAGCCTGAGACCTGAGGACACGGCTATGTATTACTGTGCGAAAGTGGAGAGGCAGTGGCTGGCCTCCTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMYWVRQAPGKGLECVAVISYDGGNKYYADSVKGRFTISRDNSKNTLFLQMSSLRPEDTAMYYCAKVERQWLASYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFTFSSYG	ISYDGGNK	AKVERQWLASYYFDY	MN008942.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
35	315-21-06_1E09	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGTACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACTCTGTTTCTGCAAATGAGCAGCCTGAGACCTGAGGACACGGCTGTGTATTATTGTGCGAAAGTGGAGAGGCAGTGGCTGGCCTCGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLFLQMSSLRPEDTAVYYCAKVERQWLASYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFTFSSYG	ISYDGSNK	AKVERQWLASYYFDY	MN008946.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
35	315-06-06_5H03	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCATTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAGGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCCTCTCCAGAGACAATTCCAAGAACACCTTGTCTCTGCAAATGAACAGCCTGAGACCTGAGGACACGTCTGTCTATTACTGTGCGAAAGTAGAAAGGCAGTGGCTGGACTACTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGGNKYYADSVKGRFTLSRDNSKNTLSLQMNSLRPEDTSVYYCAKVERQWLDYYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD6-19*01	nan	nan	nan	nan	nan	GFTFSSYG	ISYDGGNK	AKVERQWLDYYYFDY	MN008212.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
36	R95-1D10	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATCTACACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGCATTAATCAACCCTAGTGGTGGTGGCACAAGTTACGCACAGATGTTCCAAGGCAGAGTCACCCTGACCAGCGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCTAGAACCCTCTCTTGTGGTGGTGACTGCTATTACTTTGACTTCTGGGGCCAGGGAACCCCGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYLHWVRQAPGQGLEWMALINPSGGGTSYAQMFQGRVTLTSDTSTSTVYMELSSLRSDDTAVYYCARTLSCGGDCYYFDFWGQGTPVTVSS	TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACCTGTGGGGGAATCAACATTGGAAGTAAAAGTGTGCACTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGATGATAGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTTTTACTGTCAACTATGGGATGGTGGCAGTGATCTTTGGTTGTTCGGCGGAGGGACCAAGCTGAACGTCCTAC	SYELTQPPSVSVAPGQTARITCGGINIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADFYCQLWDGGSDLWLFGGGTKLNVL	IGHV1-46*03	IGHJ4*02	IGHD2-21*02	IGLV3-21*02	IGLJ3*02	NIGSKS	DDS	QLWDGGSDLWL	GYTFTSYY	INPSGGGT	ARTLSCGGDCYYFDF	MK311740.1	MK312102.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Head	Melbourne_donor_R95	2015 IIV3 vaccination	nan	117.0
36	R95-1B05	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATCTGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGCATTAATCAACCCTAGTGGTGGTGGCACAAGTTACGCACAGATGTTCCAAGGCAGAGTCACCCTGACCAGCGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCTAGAACCCTGTCTTGTGGTGGAGACTGCTATTACTTTGACTACTGGGGCCAGGGAACCCCGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYLHWVRQAPGQGLEWMALINPSGGGTSYAQMFQGRVTLTSDTSTSTVYMELSSLRSDDTAVYYCARTLSCGGDCYYFDYWGQGTPVTVSS	nan	nan	IGHV1-46*03	IGHJ4*02	IGHD2-21*02	nan	nan	nan	nan	nan	GYTFTSYY	INPSGGGT	ARTLSCGGDCYYFDY	MK311741.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
36	W85-1D10	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGACTAATCAACCCTAGTGGTGGTCACACAAACTACGCACAGAAGTTCCAGGGCAGAGTCTCCATGACCAGGGACATGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAACCCGAAATTGTGGTGGTGACTGCTACTACTTTGACTACTGGGGCCAGGGAACCCAGGTCACCGTCTCGTCAG	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGLINPSGGHTNYAQKFQGRVSMTRDMSTSTVYMELSSLRSEDTAVYYCARTRNCGGDCYYFDYWGQGTQVTVSS	TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAGTGTGCACTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGATGATAGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGGTATAGTAGTAGTGATCATTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG	SYELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWYSSSDHWVFGGGTKLTVL	IGHV1-46*01	IGHJ4*02	IGHD2-21*02	IGLV3-21*02	IGLJ3*02	NIGSKS	DDS	QVWYSSSDHWV	GYTFTSYY	INPSGGHT	ARTRNCGGDCYYFDY	MK311511.1	MK312046.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_W85	2015 IIV3 vaccination	nan	117.0
37	20A-609-30_1F07	CAAGTGCAGCTGGTGCAGTCTGGGCCTGAGGTGAAGAAGCCTGGGACCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATTCACCTTTATTACCTCTACTGTGCAGTGGGTGCGACAGGCTCGTGGACAACGCCTTGAGTGGATAGGATGGATCGTCGTTGGCAGTGGTAACACAAAGTACGCACAGAAGTTCCAGGAAAGAGTCACCATTGCCAGGGACATGTCCACAAGCACAGCCTACATGGAGCTGAGCAGCCTGCGATCCGAAGACACGGCCCTTTATTACTGTGCGTCAAGTGGCTACGACGATTTCTACTACTACGGTCTGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGPEVKKPGTSVKVSCKASGFTFITSTVQWVRQARGQRLEWIGWIVVGSGNTKYAQKFQERVTIARDMSTSTAYMELSSLRSEDTALYYCASSGYDDFYYYGLDVWGQGTTVTVSS	nan	nan	IGHV1-58*01	IGHJ6*02	IGHD5-12*01	nan	nan	nan	nan	nan	GFTFITST	IVVGSGNT	ASSGYDDFYYYGLDV	MN008216.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
37	315-05-06_1E08	CAGGTGCAGCTGGTGCAATCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAGGGCCTCTGGATACACCTTCAGCAGTCATGATATCAACTGGATGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAATCCTAACAGTGGTAACACAGGCTATGCACATAAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGTACAGCTTACATGGAATTGAGCAGCCTGAGATCTGAGGACACGGCCGTATATTACTGTGCGAGCAGTGGCTACGATGACTATTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGAEVKKPGASVKVSCRASGYTFSSHDINWMRQATGQGLEWMGWMNPNSGNTGYAHKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCASSGYDDYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV1-8*01	IGHJ6*02	IGHD5-12*01	nan	nan	nan	nan	nan	GYTFSSHD	MNPNSGNT	ASSGYDDYYYYGMDV	MN007793.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
37	315-21-08_1H04	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGAATTCACCTTCACTAGCTATACTATGCACTGGGTCCGCCGGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTTCGTCCAGTAACTACGATGACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVESGGGVVQPGRSLRLSCAASEFTFTSYTMHWVRRAPGKGLEWVAFISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCSSSNYDDYYYYGMDVWGQGTTVTVSS	nan	nan	IGHV3-30*04,IGHV3-30-3*03	IGHJ6*02	IGHD4-11*01,IGHD4-4*01	nan	nan	nan	nan	nan	EFTFTSYT	ISYDGSNK	SSSNYDDYYYYGMDV	MN008949.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-21	H7N9 Human Vaccinee	nan	nan
38	315-06-08_1F12	GAGGTGCAGCTGGTGCAGTCCGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAGGATCTCCTGTAAGGCTTCGGGATACACCTTTACCAGCTTCTGGATCATCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGAGGATTGATCCTAGTGGCTCTTATACCGTCTTCAGCCCGTCCTTCCAAGGCCACGTCAACATCTCAGTTGACAACTCCATCACCACTGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGGAATATTACGATGTTATGACTGGTTATCCAATCTACTTTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVQSGAEVKKPGESLRISCKASGYTFTSFWIIWVRQMPGKGLEWMGRIDPSGSYTVFSPSFQGHVNISVDNSITTAYLQWSSLKASDTAMYYCAREYYDVMTGYPIYFDFWGQGTLVTVSS	nan	nan	IGHV5-10-1*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GYTFTSFW	IDPSGSYT	AREYYDVMTGYPIYFDF	MN008283.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
38	20A-618-30_2B12	CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGCAGACCCTGTCCCTCACCTGCAGTGTCTCTGGTGCCTCCATCCCCACTGGTGGTTTCTATTGGAACTGGATCCGTCAGCACCCAGGGAAGGGCCTGGAATGGATTGGGTACATCTATTACAGTGGGATCACCTACTACAACCCGCCCCTCAAGAGTCGAGTTAACATATCAGTCGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTCACTGCCGCGGACACGGCCGTATATTACTGTGTCAGGGAATATTACGATGTTTTGACAGGTTATCCGATCTATTTTGACTATTGGGGCCAGGGAATCCTGGTCACCGTCTCCTCAG	QVQLQESGPGLVKPSQTLSLTCSVSGASIPTGGFYWNWIRQHPGKGLEWIGYIYYSGITYYNPPLKSRVNISVDTSKNQFSLKLSSVTAADTAVYYCVREYYDVLTGYPIYFDYWGQGILVTVSS	nan	nan	IGHV4-31*03	IGHJ4*02	IGHD3-9*01	nan	nan	nan	nan	nan	GASIPTGGFY	IYYSGIT	VREYYDVLTGYPIYFDY	MN007659.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
39	310-18B4	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCCCCTTCAGAAGCCATGCCGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGAATCATGGCTGTTTTTGGCACAGCAAATTACGCACAGAAGTTTCAGGGCAGAGTCACCATTACCGCGGACGAGTCTACGAGCACAGTCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTATTGTGCGAGAAGTGGCAATTACTATGGTTCGGGTAGTGGGGGGTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGPFRSHAVSWVRQAPGQGLEWMGGIMAVFGTANYAQKFQGRVTITADESTSTVYMELRSLRSDDTAVYYCARSGNYYGSGSGGWFDPWGQGTLVTVSS	TCACCCTGTCTTTGTCTCCAGGGGAAAGAGTCACCCTCTCCTGCAGGGCCAGCCAGACTGTTAGCAACAACTACTTAGCCTGGTACCGTCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCCGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCACACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTACCCTACCGATCACCTTCGGCCAAGGGACACGACTGGAGACTAAAC	TLSLSPGERVTLSCRASQTVSNNYLAWYRQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISTLEPEDFAVYYCQQYGTLPITFGQGTRLETK	IGHV1-69*01,IGHV1-69D*01	IGHJ5*02	IGHD3-10*01	IGKV3-20*01	IGKJ5*01	QTVSNNY	GAS	QQYGTLPIT	GGPFRSHA	IMAVFGTA	ARSGNYYGSGSGGWFDP	KJ149383.1	KJ149317.1	24501410	Whittle et al. J Virol 88:4047-4057 (2014)	Group 1	HA:Unk	VRC_310_cohort	Vaccinated	nan	nan
39	315-53-06_1F06	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACATCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGACTTGAGTGGATGGGATGGATCAACCCTAACACTGGTGGCACAAAGTATGCACAAAACTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATAAGTACAGCCTACATGGAGTTGAGCGGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGTGCCGTATTATTATGGTTCGGGGAGTGGGGGTTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGASVKVSCKASGYIFTGYYMHWVRQAPGQGLEWMGWINPNTGGTKYAQNFQGRVTMTRDTSISTAYMELSGLRSDDTAVYYCARVPYYYGSGSGGWFDPWGQGTLVTVSS	nan	nan	IGHV1-2*02,IGHV1-2*07	IGHJ5*02	IGHD3-10*01	nan	nan	nan	nan	nan	GYIFTGYY	INPNTGGT	ARVPYYYGSGSGGWFDP	MN009746.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-53	H7N9 Human Vaccinee	nan	nan
40	K77-2F10	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGAGGTCCAGCCGGGGGGGTCCCTGAGACTCTCCTGTGCAGCCGCTGGATTTACCTTCAGTTCTTACTCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCACTTATATCATATGATGGAAGAAACAAAGACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAAATCCAAGAACACTCTGTATCTGCAAGTGAACAGCCTGAGAACTGAGGACACGGCTGTGTATTATTGTGCGAGAGATGAGGACAGTTATGGCCGACTCGGCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGEVQPGGSLRLSCAAAGFTFSSYSMHWVRQAPGKGLEWVALISYDGRNKDYADSVKGRFTISRDKSKNTLYLQVNSLRTEDTAVYYCARDEDSYGRLGYWGQGTLVTVSS	nan	nan	IGHV3-30*04,IGHV3-30-3*01,IGHV3-30-3*03	IGHJ4*02	IGHD5-18*01,IGHD5-5*01	nan	nan	nan	nan	nan	GFTFSSYS	ISYDGRNK	ARDEDSYGRLGY	MK311421.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_K77	2015 IIV3 vaccination	nan	nan
40	R95-2F03	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAATTCCTATGGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGACTGGAGTGGGTCTCATCCATTGGTACTAGTGGTAATTACATATACTACGCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGACACAGCTGTATATTTCTGTGCGAGAGATTCGGACAGTTATGGCCGTAATGGCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVKPGGSLRLSCAASGFTFNSYGMNWVRQAPGKGLEWVSSIGTSGNYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYFCARDSDSYGRNGYWGQGTLVTVSS	nan	nan	IGHV3-21*03	IGHJ4*02	IGHD3-10*01,IGHD3-10*02	nan	nan	nan	nan	nan	GFTFNSYG	IGTSGNYI	ARDSDSYGRNGY	MK311772.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
41	315-06-05M_1C12	CAGGTGCAGCTGCAGGAGTCGGGCCCCGGGATGGGGAACCCTTTGGGAGCCCTTTCCCTTCCCTCCACTGTTTTGGGGCCCTCCACCGGTAGTTATTACGGGAGCGGGTTCCGGCAGCCCCCAGGGAAGGGACGGGAGTGGATGGGGTATTTTTTTGCCAGTGGAAGCACCACCTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCTGCGGACACGTCCAAGAACCAGAGCTCCCTGAGGCTGAGTTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAAAGAGGGCCCCTACTACCACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	QVQLQESGPGMGNPLGALSLPSTVLGPSTGSYYGSGFRQPPGKGREWMGYFFASGSTTYNPSLKSRVTISADTSKNQSSLRLSSVTAADTAVYYCAKEGPYYHMDVWGKGTTVTVSS	nan	nan	IGHV4-59*01	IGHJ6*03	nan	nan	nan	nan	nan	nan	GPSTGSYY	FFASGST	AKEGPYYHMDV	MN008084.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-06	H7N9 Human Vaccinee	nan	nan
41	315-02-06_6C09	GAGGTGCAGCTGGTGGAGTCTGGGGGAGTCGTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTAACCTTTGAAGATTATACCATGCACTGGGTCCGTCAAGCTCCGGGGAAGGGTCTGGAGTGGGTCTCTCATATTACTTGGGATGGTGGTAGGACATCCTATGCAGACTCTGTGAGGGGCCGATTCACCATCTCCAGAGACAACAGCAAAAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACCGCCTTATATTACTGTGCAAAAGAAGGCAGCTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA	EVQLVESGGVVVQPGGSLRLSCAASGLTFEDYTMHWVRQAPGKGLEWVSHITWDGGRTSYADSVRGRFTISRDNSKNSLYLQMNSLRAEDTALYYCAKEGSYYYMDVWGKGTTVTVSS	nan	nan	IGHV3-43*01	IGHJ6*03	nan	nan	nan	nan	nan	nan	GLTFEDYT	ITWDGGRT	AKEGSYYYMDV	MN007395.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-02	H7N9 Human Vaccinee	nan	nan
42	D8	nan	KKPGSSVKVSCKASGGTFSAYAFTWVRQAPGQGLEWMGGIIGMFGTANYAQKFQGRVTITADELTSTAYMELSSLTSEDTALYYCGLYYYESSFDYWGQGTL	nan	QSVLTQPPSASGSPGQSVTISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVTKRPSGVPDRFSASKSGNTASLTVSGLQAEDEADYFCCSYAGHSAYVFGTGTKVTVL	IGHV1-69*01	nan	nan	IGLV2-11	nan	SSDVGGYNS	EVT	CSYAGHSAYV	GGTFSAYA	IIGMFGTA	ARGLYYYESSFDY	nan	nan	19234466	Sui et al. Nat Struct Mol Biol 16:265-273 (2009)	Group 1	HA:Stem	Marasco_donors	non-immune human antibody	nan	nan
42	CR6331	TGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCGGTATGTTCGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATTTACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGGAAATTATTACTATGAGAGTAGTCTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGTGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGAGCTGGAACAGCGGCGCCTTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAACGCGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTCATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCCGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGAGCGTGCTCACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTGAGCAACAAGGCCCTGCCTGCCCCCATCGAGAAGACCATCAGCAAGGCCAAGGGCCAGCCCCGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTCACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTCACCGTGGACAAGAGCCGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGAGCCCCGGCAAG	VESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIGMFGTANYAQKFQGRVTITADEFTSTAYMELSSLRSEDTAVYYCARGNYYYESSLDYWGQGTLVTVS	CAGTCTGTCGTGACGCAGCCGCCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACCTGTGGGGGAAACAACATTGGAAGTAAAAGTGTGCACTGGTACCAGCAGAAGCCAGGCCAGGCCCCTGTGCTGGTCGTCTATGATGATAGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGGGATAGTAGTAGTGATCATTATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAGGTGCGGCCGCAGGCCAGCCCAAGGCCGCTCCCAGCGTGACCCTGTTCCCCCCCTCCTCCGAGGAGCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTCATCAGCGACTTCTACCCTGGCGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTCACCCCCGAGCAGTGGAAGAGCCACCGGAGCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAGAAGACCGTGGCCCCCACCGAGTGCAG	QSVVTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL	IGHV1-69*01,IGHV1-69*12,IGHV1-69D*01	IGHJ4*02	IGHD3-22*01	IGLV3-21*02	IGLJ1*01	NIGSKS	DDS	QVWDSSSDHYV	GGTFSSYA	IIGMFGTA	ARGNYYYESSLDY	nan	nan	19079604	Throsby et al. PLoS One 3:e3942 (2008); Patent: WO2012112489A2	H5	HA:Stem	Crucell_donors	Healthy donors 	nan	nan
43	20A-618-30_2A09	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCATGGTACAGCCTGGCAAGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCATCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGTTCCAGGGAAGGGCCCAGAATGGGTCTCAGGTATTAGTTGGAACAGTGTTAGCGCAGACTATGTGGACTCTGTGAAGGGCCGATTCAACATCTCCAGAGACAATGCCAAGAAGTCCCTGTATCTGCAAATGGACAGTCTGAGACCTGAGGACACGGCCTTTTATTACTGTGTTAGAGATCAGGGCAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	EVQLVESGGGMVQPGKSLRLSCAASGFIFDDYAMHWVRQVPGKGPEWVSGISWNSVSADYVDSVKGRFNISRDNAKKSLYLQMDSLRPEDTAFYYCVRDQGNWFDPWGQGTLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*02	nan	nan	nan	nan	nan	nan	GFIFDDYA	ISWNSVSA	VRDQGNWFDP	MN007730.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-05	H7N9 Human Vaccinee	nan	nan
43	315-54-06_5C04	GAAGTGCAGCTGGTGGAGTCCGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGTAGCCTCTGAATTCACGTTTGATGACTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAGTTGGAATAGTGCTAGTATAGGCTATGCGGACTCTGTGAAGGGCCGATTCAACATCTCCAGAGACAACGCCAAGAACTCCCTGTATTTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGTGTCCGTGACAGGGGGAACTGGTTCGACCCCTGGGGCCAGGGAAGTCTGGTCACCGTCTCCTCAG	EVQLVESGGGLVQPGRSLRLSCVASEFTFDDYAMHWVRQAPGKGLEWVSGISWNSASIGYADSVKGRFNISRDNAKNSLYLQMNSLRAEDTALYYCVRDRGNWFDPWGQGSLVTVSS	nan	nan	IGHV3-9*01	IGHJ5*02	IGHD2-21*02,IGHD3-16*01,IGHD3-16*02	nan	nan	nan	nan	nan	EFTFDDYA	ISWNSASI	VRDRGNWFDP	MN010031.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
44	V3-2C3	ATGGACTGGACCTGGAGGGTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCTTCAACAACTATGCTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACGCACATAAGTTCCAGGGCAGAGTCACGATTACCGTGGACGAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCATGTATTACTGTGCGAGAGTTTGTAGTTTCTATGGTTCGGGGAGTTATTATAACGTGTTCTGCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGTFNNYAVSWVRQAPGQGLEWMGGIIPIFGTANYAHKFQGRVTITVDESTSTAYMELSSLRSEDTAMYYCARVCSFYGSGSYYNVFCYWGQGTLVTVSS	ATGGACATGAGAGTCCCCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGCTCCCAGGTGCCAAATGTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGCAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCGGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCTAGTTTAGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACACTATAATAGTTATTCTCAGACTTTTGGCCAGGGGACCAAAGTGGAGATCAAAC	DIQMTQSPSTLSASAGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNSYSQTFGQGTKVEIK	IGHV1-69*01,IGHV1-69D*01	IGHJ4*02	IGHD3-10*01	IGKV1-5*03	IGKJ2*01,IGKJ2*02	QSISSW	KAS	QHYNSYSQT	GGTFNNYA	IIPIFGTA	ARVCSFYGSGSYYNVFCY	nan	nan	22586427	Thomson et al. Front Immunol 3:87 (2012)	Group 1	HA:Stem	Canada_patients	convalescent patients with confirmed infections with pdmH1N1	nan	93.0
44	AG7-3C01	GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACTTTCAACAGCTATTCTGTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTGTTTTTGGAACTGCGAGGTACCCACAGAAATTCCAGGGCAGAATTACGATTACCGCGGACGAGTCCAGGACCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTTTATTACTGTGCGAGAGTCGGAAGTTTTTATGGTTCGGGGAATTATTATAATGTTTTCGCCTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	VQLVQSGAEVKKPGSSVKVSCKASGGTFNSYSVSWVRQAPGQGLEWMGGIIPVFGTARYPQKFQGRITITADESRTTAYMELSSLRSEDTAVYYCARVGSFYGSGNYYNVFAYWGQGTLVTVSS	GACATCCAGATGACCCAGTCTCCTTACACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTGCACTCCTGATCTATAAGGCGTCTACTTTAGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACACTATAATACTTATTCGGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA	DIQMTQSPYTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPALLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNTYSVTFGQGTKVEIK	IGHV1-69*01,IGHV1-69D*01	IGHJ4*02	IGHD3-10*01	IGKV1-5*03	IGKJ1*01	QSISSW	KAS	QHYNTYSVT	GGTFNSYS	IIPVFGTA	ARVGSFYGSGNYYNVFAY	MH205329.1	MH205603.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	H1	HA:Unk	PCWilson_donor_AG7	B-cells;Influenza natural infection or vaccination	nan	93.0
45	AG3-D06	CAGCTGCAGCTGCAGGAGTCGGGTCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAGTGTCTCTGGTGGCTCCATCAGCGAGACTATTTATTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATAGGGACTATCTATTCTGATGGGAACACCTACTACAACCCGTCCCTCAAGAGTCGAGTCAACATGTTTGTAGACACGTCCGACAACCAGTTCTCCCTGAAGATGAAATCTTTGAGCGCCGCCGACACGGCTGTCTATTACTGTGCGAGACTGAGGGATGGCTACAAGTATTATTACGGAATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QLQLQESGPGLVKPSETLSLTCSVSGGSISETIYYWGWIRQPPGKGLEWIGTIYSDGNTYYNPSLKSRVNMFVDTSDNQFSLKMKSLSAADTAVYYCARLRDGYKYYYGMDVWGQGTTVTVSS	GACATCCAGATGACCCAGTCTCCGTCCTCCCTATCTGCATCTGTAGGAGACAGAGTCACCATTCCTTGCCGGGCAAGTCAGACAATTAGCACCTATTTGAATTGGTATCAGCAGAGACCAGGGAAAGCCCCCAAACTCCTGATCTACTCTGCATCCATTTTAGAAAGGGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTTCAACCTGAAGATTTTGCAACTTACTACTGTCAGTGGGGTTCCGCTATTTCCGTCACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA	DIQMTQSPSSLSASVGDRVTIPCRASQTISTYLNWYQQRPGKAPKLLIYSASILERGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQWGSAISVTFGQGTKLEIK	IGHV4-39*01	IGHJ6*02	IGHD5-24*01	IGKV1-39*02	IGKJ2*01,IGKJ2*02	QTISTY	SAS	QWGSAISVT	GGSISETIYY	IYSDGNT	ARLRDGYKYYYGMDV	MH205313.1	MH205518.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Unk	PCWilson_donor_AG3	B-cells;Influenza natural infection or vaccination	nan	nan
45	C1-2B06	GTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCAGTGTGTCTGGGGACTCCATCAGTGAAACTATTTATTACTGGGGCTGGATCCGCCAGTCCCAAGGGAAGGGACTCGAGTGGATTGGGAATGTCTATTATGATGCGAGCACCTATTATAACCCGTCCCTCAAGAGTCGAGTCACCATGTCAATAGATACGTCCAAGAATCAGTTCTCCCTGAAGGTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTATTACTGTGCGAGAGTCCCTGATGGATACAAGTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	VQLQESGPGLVKPSETLSLTCSVSGDSISETIYYWGWIRQSQGKGLEWIGNVYYDASTYYNPSLKSRVTMSIDTSKNQFSLKVSSVTAADTAVYYCARVPDGYKYYYGMDVWGQGTTVTVSS	GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGTCACCCTCTCCTGCAGGGCCAGTCAGGGTGTTAGCAGCAAGTTAGCCTGGTATCAGCAGAAACGTGGCCAGGCTCCCAGGCTCCTTATATATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAATTTATTACTGTCAGCAGTATTATAACTGGACTCCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAA	EIVMTQSPATLSVSPGERVTLSCRASQGVSSKLAWYQQKRGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCQQYYNWTPITFGQGTRLEIK	IGHV4-39*07	IGHJ6*02	IGHD5-24*01	IGKV3-15*01	IGKJ5*01	QGVSSK	GAS	QQYYNWTPIT	GDSISETIYY	VYYDAST	ARVPDGYKYYYGMDV	MH205264.1	MH205468.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Unk	PCWilson_donor_C1	B-cells;Influenza natural infection or vaccination	nan	nan
46	024-10128_3E01	GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGACTTCTGGATACACCTTCACAATTTATGAGATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGAACAATGAACCCTAACAGTGCTACCACAGGCTCTGCACAGAAGTTCCAGGGCAGACTCACCATGACCGGGAATACCTCCTTGAGGACAACCTACATGGAGCTGAGCAGCCTGACATCTGAGGACACGGCCGTATATTACTGTGCGAGACTAGTGTCTTGTGGTGGTGACTGCTATTACTTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA	VQLVQSGAEVKKPGASVKVSCKTSGYTFTIYEINWVRQATGQGLEWMGTMNPNSATTGSAQKFQGRLTMTGNTSLRTTYMELSSLTSEDTAVYYCARLVSCGGDCYYFDSWGQGTLVTVSS	TCCTATGAGCTGACACAGGCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTCCCTGTGGGGGAAACAACATTGGAACTAAAAGTGTGCACTGGTACCAGCAGAGGCCAGGCCAGGCCCCTGTGTTGGTCGTCTATGATGATAGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGGGATAGTAGTGGTGATCAATTCGGCGGAGGGACCAAGCTGACCGTCCTA	SYELTQAPSVSVAPGQTARIPCGGNNIGTKSVHWYQQRPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSGDQFGGGTKLTVL	IGHV1-8*01	IGHJ4*02	IGHD2-21*02	IGLV3-21*02	IGLJ2*01,IGLJ3*01	NIGTKS	DDS	QVWDSSGDQ	GYTFTIYE	MNPNSATT	ARLVSCGGDCYYFDS	MH205232.1	MH205433.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Stem	PCWilson_donor_024	B-cells;Influenza natural infection or vaccination	nan	nan
46	R95-1A08	CTCGTACAACTGGTGCAGTCCGGGGCTGAGGTGAAGAAGCCTGGGGCCTCGGTGAGGCTTTCCTGCAGGGCATCTGGATACACTTTCACCGCAAACTATTTGTCCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGACTAATCAACCCTGGTGGTGGTGGCACAAGTTACGCACAGAAGTTCCAGGACAGAGTCACCATGACCCGGGACACGTCCACGACCACAGTCTACATGGACGTGACCACCCTGAGGTCTGAGGACACGGCCGTCTACTTTTGTGCGAGACTCGTTAGTTGTGGTGGCGACTGCTATTACATGGACTCCTGGGGCCAGGGAACACTGGTCACTGTCTACTCAG	LVQLVQSGAEVKKPGASVRLSCRASGYTFTANYLSWVRQAPGQGLEWMGLINPGGGGTSYAQKFQDRVTMTRDTSTTTVYMDVTTLRSEDTAVYFCARLVSCGGDCYYMDSWGQGTLVTVYS	nan	nan	IGHV1-46*01	IGHJ4*02,IGHJ5*01,IGHJ5*02	IGHD2-21*02	nan	nan	nan	nan	nan	GYTFTANY	INPGGGGT	ARLVSCGGDCYYMDS	MK311739.1	nan	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Unk	Melbourne_donor_R95	2015 IIV3 vaccination	nan	nan
47	315-09-08_1D02	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGGAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGTCAGTTATATCATATGATGGAGATAATGAATACTATGCAGACTCCGTGGAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAATACGCTGTTTCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTATTGTGCGAAAGAATATTTCCATGAAAGTAGTGGTTATTATTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVESGGGVVQPGRSLRLSCGASGFTFSSYGMHWVRQAPGKGLEWVSVISYDGDNEYYADSVEGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCAKEYFHESSGYYYFDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFTFSSYG	ISYDGDNE	AKEYFHESSGYYYFDY	MN008654.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-09	H7N9 Human Vaccinee	nan	nan
47	315-54-05M_1D02	CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGCGGTCCACCCTGGGAGGTCCCTGAGAGTTTCCTGTGCAGCCTCTGGATTTAACTTCAGTGTCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGCTGGCAGTTATATCGTATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCTAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTATATTACTGTGCGAAAGAGTATTACTATGAGAGTAGTGGTTATTACTACCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVESGGGAVHPGRSLRVSCAASGFNFSVYGMHWVRQAPGKGLEWLAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEYYYESSGYYYLDYWGQGTLVTVSS	nan	nan	IGHV3-30*18,IGHV3-30-5*01	IGHJ4*02	IGHD3-22*01	nan	nan	nan	nan	nan	GFNFSVYG	ISYDGSNK	AKEYYYESSGYYYLDY	MN010160.1	nan	31350180	Andrews et al. Immunity 51:398-410 (2019)	Group 2	HA:Unk	VRC_315-54	H7N9 Human Vaccinee	nan	nan
48	018_10_4D03	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAGGGTCTCCTGCAAGGCTTCTGGAGGCATCTTCATCAGTTCTGCAATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCAATCCTCTCTTTGGTACAACAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGGGCACAACCTACATGGACCTGAGCAGCCTGAGATCTGAGGACACGGCCGTCTATTACTGTGCGAGAGACGGTTCGGGGAGTTATCTTCCTCTCAACTGGCTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVRVSCKASGGIFISSAISWVRQAPGQGLEWMGGINPLFGTTNYAQKFQGRVTITADKSTGTTYMDLSSLRSEDTAVYYCARDGSGSYLPLNWLDPWGQGTLVTVSS	GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGGTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTATTGTCAGCAGTATGGTAGCTCACCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAAC	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRVLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPFTFGPGTKVDIK	IGHV1-69*06	IGHJ5*02	IGHD3-10*01	IGKV3-20*01	IGKJ3*01	QSVSSSY	GAS	QQYGSSPFT	GGIFISSA	INPLFGTT	ARDGSGSYLPLNWLDP	KU167171.1	KU167315.1	26631631	Andrews et al. Sci Transl Med 7:316ra192 (2015)	Group 1	HA:Stem	PCWilson_donor_018	B-cells;Influenza Human Vaccinee	nan	75.0
48	310-18C12	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCCCCTTCAGAAGCTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTGGAGTGGATGGGAGGGATCATCCCTATCTTTGGAACAGCCAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAACACAGCCTACATAGAGCTGAGCCGTCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGGGATGGTTCGGGGAGTTATTATCCCTCGAACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG	QVQLVQSGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTNTAYIELSRLRSEDTAVYYCARDGSGSYYPSNWFDPWGQGTLVTVSS	ACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAACAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCGTCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTACTACTGTCAGCAGTATGGGAGTTCACCTCAGACGTTTGGCCAAGGGACCAGGGTGGAAATCAAAC	TLSLSPGERATLSCRASQSVSNSNLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPQTFGQGTRVEIK	IGHV1-69*01,IGHV1-69D*01	IGHJ5*02	IGHD3-10*01	IGKV3-20*01	IGKJ1*01	QSVSNSN	GAS	QQYGSSPQT	GGPFRSYA	IIPIFGTA	ARDGSGSYYPSNWFDP	KJ149389.1	KJ149322.1	24501410	Whittle et al. J Virol 88:4047-4057 (2014)	Group 1	HA:Unk	VRC_310_cohort	Vaccinated	nan	75.0
49	028-10134_4B04	GTGCAGCTGGTGCAGTCTGGAGGTGAGGTGAAGAGGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCCTCTGGTTACACCTTTACCAGCTACGGTGTCACCTGGGTCCGACAGGCCCCTGGACAAGGGCTGGAGTGGGTGGGGTGGATCAGCGGTTATAATGGTAATTTGGAGTATGCCCAGAAAGTCCAGGGCAGAATCACCCTGACCACAGACACATCCACGAGTACAGCCCACATGGAGCTGAGGAGCCTGACATCTGACGACACGGCCATTTATTACTGTGCGCGCGATCATTACTATGGTTCGGGGACATACACACCGGACAATTTGTACAACTACTACTACTACATGGACGTCTGGGGCAGAGGGACCACGGTCACCGTCTCCTCA	VQLVQSGGEVKRPGASVKVSCKASGYTFTSYGVTWVRQAPGQGLEWVGWISGYNGNLEYAQKVQGRITLTTDTSTSTAHMELRSLTSDDTAIYYCARDHYYGSGTYTPDNLYNYYYYMDVWGRGTTVTVSS	GACATCCAGATGACCCAGTCTCCGTCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGGGCAAATCAGAGCATTAGTTACTATTTGAATTGGTATCAGTACAAACCGGGAACAGCCCCTAAGGTCCTGATCTATGCTGCATCCAAGTTGCAGAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACCCTCACCATCAACAGTCTGCAACCTGAAGATTTTGCAACTTATTATTGTCAGCAGAGTTACGATTCCCCTCGGTGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAA	DIQMTQSPSSLSASVGDRVTITCRANQSISYYLNWYQYKPGTAPKVLIYAASKLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYDSPRWTFGQGTKVEIK	IGHV1-18*04	IGHJ6*03	IGHD3-10*01	IGKV1-39*01,IGKV1D-39*01	IGKJ1*01	QSISYY	AAS	QQSYDSPRWT	GYTFTSYG	ISGYNGNL	ARDHYYGSGTYTPDNLYNYYYYMDV	MH205237.1	MH205440.1	30795982	Henry et al. Cell Host Microbe 25:357-366.e6 (2019)	Flu B	HA:Unk	PCWilson_donor_028	B-cells;Influenza natural infection or vaccination	nan	89.0
49	K77-2D11	CAGGTGCAGCTGGTGCAGTCTGGAGCTGACGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTATACTTTTACTAGTTATGGTATCACCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGGTGGGATGGATCAGCGGTTACAACGGCAACACAAAGTATGCACAGAACCTCCAGGGCAGAGTCACCATGACCTCAGACACATCCACGAGCACAGCCTACATGGAATTGAGGAGCCTGAGATCTGACGACTCGGCCGTTTACTACTGTGCGAGAGATTCTTACTATGGTTCGGGGACTTATACTCCAATGAACCTTTACAACTATTATTACCATATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA	QVQLVQSGADVKKPGASVKVSCKASGYTFTSYGITWVRQAPGQGLEWVGWISGYNGNTKYAQNLQGRVTMTSDTSTSTAYMELRSLRSDDSAVYYCARDSYYGSGTYTPMNLYNYYYHMDVWGQGTTVTVSS	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCTTCACTTGCCGGGCAAGTCAGACCATTGACAACTATTTAAATTGGTATCAACAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCTAATTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCGGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCACCTTACTACTGTCAACAGACTTACAGTGCCCCCATGTACACTTTTGGCCAGGGGACCAAGTTGGAGATCAAAG	DIQMTQSPSSLSASVGDRVTFTCRASQTIDNYLNWYQQKPGKAPKLLIYAASNLQSGVPSRFSGGGSGTDFTLTISSLQPEDFAPYYCQQTYSAPMYTFGQGTKLEIK	IGHV1-18*01	IGHJ6*02	IGHD3-10*01	IGKV1-39*01,IGKV1D-39*01	IGKJ2*01	QTIDNY	AAS	QQTYSAPMYT	GYTFTSYG	ISGYNGNT	ARDSYYGSGTYTPMNLYNYYYHMDV	MK311358.1	MK311866.1	30659197	Liu et al. Nat Commun 10:324 (2019)	Flu B	HA:Head	Melbourne_donor_K77	2015 IIV3 vaccination	nan	89.0
